This page has been archived and is no longer being updated.
COVID-19 Dashboard
- Experimental Unapproved Treatments for COVID-19
Drug Description Ritonavir An HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection. Chloroquine An antimalarial drug used to treat susceptible infections with P. vivax, P. malariae, P. ovale, and P. falciparum. It is also used for second line treatment for rheumatoid arthritis. Darunavir A HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies. Lopinavir An HIV-1 protease inhibitor used in combination with ritonavir to treat human immunodeficiency virus (HIV) infection. Galidesivir Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various... Favipiravir An antiviral used to manage influenza, and that has the potential to target other viral infections. Umifenovir A dual direct-acting antiviral/host-targeting agent used in the treatment and prophylaxis of influenza and other respiratory viruses. Human interferon beta A polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS). Triazavirin An antiviral used to treat several strains of influenza. TMC-310911 TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections.... Moderna COVID-19 Vaccine An mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus. Ad5-nCoV Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute... AstraZeneca COVID-19 Vaccine A two-dose replication-deficient adenovirus vector vaccine used to prevent COVID-19 caused by SARS-CoV-2. Fingolimod A sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19. Methylprednisolone A corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases. Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Leronlimab A humanized monoclonal antibody being investigated Azithromycin A macrolide antibiotic used to treat a variety of bacterial infections. N4-Hydroxycytidine A cytidine analog being investigated to treat COVID-19. Molnupiravir An orally bioavailable isopropylester cytidine analog used to treat COVID-19. Elbasvir An antiviral and NS5A inhibitor used to treat hepatitis C infections. Tocilizumab An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). GS-441524 An experimental nucleoside analog antiviral investigated for its use in the treatment of Ebola and SARS-CoV-2 infections. Tridecactide An investigational modified alpha melanocyte stimulating hormone being studied for the treatment of COVID-19. Metenkefalin An investigational endogenous opioid being studied for the treatment of COVID-19. Zavegepant A calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura. Ibuprofen An NSAID and non-selective COX inhibitor used to treat mild-moderate pain, fever, and inflammation. Anti-SARS-CoV-2 REGN-COV2 Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of... Dexamethasone A glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders. COVID-19 convalescent plasma COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. This investigational COVID-19 treatment is... INO-4800 INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that... BNT162b1 SARS-CoV-2 Vaccine BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding... BNT162a1 SARS-CoV-2 Vaccine BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in... BNT162c2 SARS-CoV-2 Vaccine BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in... Colchicine An alkaloid used to treat gout and Familial Mediterranean Fever as well as prevent major cardiovascular events. Bamlanivimab A neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19. AZD7442 AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the... GC-376 free acid GC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound... GC-373 GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that... Ifenprodil N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer... Abivertinib Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). It has been investigated for use in... Etesevimab Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral... Baricitinib A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. Subasumstat Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid... Alunacedase alfa Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities. Zansecimab Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19). Goflikicept Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe... Azvudine Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)). Mosedipimod Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia. Thymoquinone Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial. Efprezimod alfa CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients. Tin protoporphyrin IX Not Available Rexin G Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer.... AT-527 Not Available Meplazumab Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia. Oleic monoethanolamide Not Available MAS825 Not Available Efzofitimod Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of... XPro1595 XPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF. Human Interleukin 8 Interleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes). Sarconeos Sarconeos is an activator of the MAS receptor. Ezurpimtrostat Not Annotated APL-9 APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. It shares the same mechanism... DFV890 DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT06097663 (coronary... Veru-111 VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360. These trials aimed to evaluate its efficacy, safety,... TD-0903 TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants with supplemental oxygenation),... CIGB 300 CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix) CM4620 CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and NCT04661540 (critical... Beta-(1,3)-D glucan Not Available Empasiprubart Empasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated. TJ003234 Not Available TL-895 TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation... LSALT Peptide Not Available MEDI3506 Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. These trials include NCT03096795 (completed; healthy participants, COPD... Pam2csk4 Not Available STC3141 STC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia. Carrimycin Not Available EB05 EB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS. Inbakicept An IL-15 receptor agonist used to treat BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. BDB-001 BDB-001, was under investigation in multiple clinical trials to evaluate its safety, tolerability, and efficacy across various conditions. In NCT05075304 and NCT04449588, BDB-001 was studied in mild to severe COVID-19... Dociparstat sodium Not Available Quisovalimab Not Annotated Novaferon Not Available ODN M362 Not Available EDP1815 EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal behavior, atopic dermatitis, psoriasis,... STI-1499 STI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19. CPI-006 CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal... SAB-185 Not Available SAR443122 SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. NCT04469621 was studied in severe COVID-19 patients, while NCT05588843 is currently recruiting participants with ulcerative colitis. Additionally,... Amubarvimab Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy. Romlusevimab Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics. Acetylcysteine zidrimer Not Available RESP301 RESP301 was under investigation in clinical trials for various conditions. It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults... Vasomera Not Available INM005 INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). Additionally, a retrospective cohort study... TY027 Not Available Enpatoran Enpatoran (M5049) was under investigation in clinical trials for various conditions. It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in... Zunsemetinib ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to... XC221 XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections. BCc1 BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies. Upanovimab Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19 beta-Hydroxybutyric acid Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 diabetes),... AT-301 AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine HLX70 HLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics in healthy adult... KAND567 KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation . Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently... MPT0B640 MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies. PF-07304814 PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the... PLN-74809 Through dual inhibition of integrins αvβ6 and αvβ1, PLN-74809 reduces subsequent activation of TGF-β1, which is actively involved in the growth of fibrotic tissue in lung and bile ducts .... TM5614 TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome[L31673,A228793,A228798], and current studies are exploring downstream... Nirmatrelvir An oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19. Fostamatinib A spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment. Sotrovimab A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization. MM3122 Not Annotated Cilgavimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Tixagevimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Vilobelimab An antibody directed against anti-human complement factor 5a is used to treat COVID-19 in adults for emergency use. - Potential Drug Targets
Start Date Drug Title Purpose Phase Status Identifier 2021-06-15 Acetylsalicylic acid Low Dose Aspirin in Moderate to Severe SARS- CoV-2 Infected Patients : A Pilot Randomized Controlled Trial Treatment Not Available Active Not Recruiting CTRI/2020/08/027503 2021-03-01 Human Umbilical Cord Mesenchymal Stem Cells Phase I, Randomized, Double Blinded, Placebo Control Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 With Moderate to Severe Symptoms Treatment 1 Active Not Recruiting NCT04490486 2021-01-10 Budesonide Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial Treatment 4 Active Not Recruiting NCT04374474 2021-01-01 ChulaCov19 mRNA vaccine A Phase 1 / 2, Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of the ChulaCov19 mRNA Vaccine in Healthy Adults Treatment 1 Active Not Recruiting NCT04566276 2020-12-01 Human Umbilical Cord Mesenchymal Stem Cells A Phase 1 Study of the Safety and Tolerability of BX-U001 for the Treatment of Severe COVID-19 Pneumonia With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS). Treatment 1 Active Not Recruiting NCT04452097 2020-12-01 Anti-SARS-CoV-2 immunoglobulin TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19 : A PHASE I / II STUDY Treatment 1, 2 Active Not Recruiting NCT04573855 2020-12-01 Niclosamide Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms Treatment 2 Active Not Recruiting NCT04436458 2020-12-01 Cholecalciferol Proof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19 Treatment 4 Active Not Recruiting NCT04565392 2020-12-01 Ascorbic acid Proof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19 Treatment 4 Active Not Recruiting NCT04565392 2020-12-01 Famotidine Proof-of-concept Open-label Randomized Dose-response Comparison Study of Famotidine Plus Vitamins C and D3 for Adults With Probable COVID-19 Treatment 4 Active Not Recruiting NCT04565392 2020-12-01 Nitazoxanide A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT) Treatment 2 Active Not Recruiting NCT04563208 2020-12-01 Ribavirin A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT) Treatment 2 Active Not Recruiting NCT04563208 2020-12-01 Sofosbuvir A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2 Prevention 2 Active Not Recruiting NCT04561063 2020-12-01 Nitazoxanide A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2 Prevention 2 Active Not Recruiting NCT04561063 2020-12-01 Daclatasvir A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF / DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2 Prevention 2 Active Not Recruiting NCT04561063 2020-12-01 COVID-19 convalescent plasma Assessment of the Safety and Efficacy of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness Treatment 1, 2 Active Not Recruiting NCT04521036 2020-12-01 Nitric Oxide Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen Treatment 2 Active Not Recruiting NCT04398290 2020-12-01 Artesunate Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19 Treatment 2 Active Not Recruiting NCT04387240 2020-12-01 Artemisinin Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19 Treatment 2 Active Not Recruiting NCT04387240 2020-12-01 Isotretinoin Evaluation of the Safety and Efficacy of Isotretinoin in Treatment of COVID-19 : Clinical Study Treatment 3 Active Not Recruiting NCT04361422 2020-12-01 IN01 Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC) Treatment 1 Active Not Recruiting NCT04537130 2020-12-01 Tranexamic acid Antiviral Effects of Tranexamic Acid (TXA) as a Preventative Treatment Following COVID-19 Exposure Prevention 3 Active Not Recruiting NCT04550338 2020-12-01 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins A Phase I / ?a Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia Treatment 1, 2 Active Not Recruiting NCT04527224 2020-12-01 Fisetin COVID-FIS : A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes Treatment 2 Active Not Recruiting NCT04537299 2020-11-30 RAPA-501-Allo Phase I / Phase II Trial of Off-the-Shelf Allogeneic Hybrid TREG / Th2 Cell (RAPA-501-ALLO) Therapy for Severe, Post-Intubation Stage 3 COVID-19 Disease Treatment 1, 2 Active Not Recruiting NCT04482699 2020-11-19 Rubella virus vaccine Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group Treatment 3 Active Not Recruiting IRCT20200802048266N1 2020-11-19 Mumps virus strain B level jeryl lynn live antigen Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group Treatment 3 Active Not Recruiting IRCT20200802048266N1 2020-11-19 Measles virus vaccine live attenuated Investigating the effectiveness of MMR vaccination The rate of COVID19 in medical staff compared to the control group Treatment 3 Active Not Recruiting IRCT20200802048266N1 2020-11-14 KBP-COVID-19 A Phase I / II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-COVID-19 Vaccine in Healthy Seronegative Adults Aged 18-49 and 50-70 Prevention 1, 2 Active Not Recruiting NCT04473690 2020-11-13 Trefoil Factor 2 Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK / PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients Treatment 0 Active Not Recruiting ChiCTR2000035633 2020-11-13 Interferon Kappa Clinical study of safety, tolerance, and pharmacokinetics of nebulizer (INF-K + anti-inflammatory factor TFF2) in healthy volunteers and exploration of PK / PD fitting modeling in clinical trials of Novel Coronavirus Pneumonia (COVID-19) patients Treatment 0 Active Not Recruiting ChiCTR2000035633 2020-11-01 Angiotensin 1-7 A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients Treatment 1, 2 Active Not Recruiting NCT04570501 2020-11-01 Ravulizumab C5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic Microangiopathy Treatment 3 Active Not Recruiting NCT04570397 2020-11-01 Dexamethasone A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Study Evaluating AVM0703 in Patients With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04366115 2020-11-01 PH94B A Phase 2a Open-label Study of the Efficacy and Safety of PRN PH94B Neuroactive Nasal Spray in the Treatment of Adjustment Disorder With Anxiety (AjDA) Associated With COVID-19 Treatment 2 Active Not Recruiting NCT04404192 2020-11-01 Ulinastatin A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients Treatment 1, 2 Active Not Recruiting NCT04393311 2020-11-01 Bicalutamide A Phase II Trial to Promote Recovery From COVID-19 With Endocrine Therapy Treatment 2 Active Not Recruiting NCT04374279 2020-11-01 Ruxolitinib Safety and Efficacy of Ruxolitinib for COVID-19 Treatment 2, 3 Active Not Recruiting NCT04348071 2020-11-01 Baricitinib Safety and Efficacy of Baricitinib for COVID-19 Treatment 2, 3 Active Not Recruiting NCT04340232 2020-11-01 Quetiapine A Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium Treatment 4 Active Not Recruiting NCT04513314 2020-11-01 Valproic acid A Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium Treatment 4 Active Not Recruiting NCT04513314 2020-11-01 Niclosamide A Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04542434 2020-11-01 Oral Polio Vaccine A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19 Prevention 3 Active Not Recruiting NCT04540185 2020-11-01 Brexanolone A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19 Treatment 3 Active Not Recruiting NCT04537806 2020-11-01 Corn A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC Prevention Not Available Active Not Recruiting NCT04537585 2020-11-01 Cultivated mushroom A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC Prevention Not Available Active Not Recruiting NCT04537585 2020-11-01 Soybean A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC Prevention Not Available Active Not Recruiting NCT04537585 2020-11-01 Isoquercetin An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19) Treatment 2 Active Not Recruiting NCT04536090 2020-11-01 Artesunate Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso Treatment 3 Active Not Recruiting PACTR202009642148520 2020-11-01 Pyronaridine Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso Treatment 3 Active Not Recruiting PACTR202009642148520 2020-11-01 Ritonavir A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year Treatment 2 Active Not Recruiting NCT04455958 2020-11-01 Lopinavir A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year Treatment 2 Active Not Recruiting NCT04455958 2020-10-31 Nitrogen Phase 1b Safety Trial for S-Nitrosylation Therapy to Treat COVID-19 Induced Respiratory Distress Treatment 1 Active Not Recruiting NCT04528771 2020-10-31 Tranexamic acid A Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 Pneumonia Treatment 2 Active Not Recruiting NCT04390217 2020-10-31 Efineptakin alfa A Phase I and Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 Treatment 1 Active Not Recruiting NCT04498325 2020-10-31 Chlorpromazine Evaluation of efficacy and safety of adding Chlorpromazine to Atazanavir / Ritonavir regimen in the treatment of COVID-19 patients, a randomized double-blind clinical trial Treatment 2 Active Not Recruiting IRCT20200913048708N1 2020-10-31 Lanadelumab A Phase 1b, Randomized, Double-blind, Single and Repeat Dosing Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab When Added to Standard-of-Care in Subjects Hospitalized With COVID-19 Pneumonia Treatment 1 Active Not Recruiting NCT04460105 2020-10-30 Virus Specific T-Cell BAT IT : Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19 Treatment 1 Active Not Recruiting NCT04401410 2020-10-30 Linagliptin Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes Treatment 4 Active Not Recruiting NCT04341935 2020-10-30 BGB-DXP593 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19 Treatment 2 Active Not Recruiting NCT04551898 2020-10-30 Human Umbilical Cord Mesenchymal Stem Cells Umbilical cord-derived mesenchymal stromal cells therapy for SARS-CoV-2 infection (COVID-19) related Acute Respiratory Distress Syndrome Treatment 1 Active Not Recruiting JPRN-JapicCTI-205465 2020-10-27 Lenalidomide Double-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 Disease Treatment 4 Active Not Recruiting NCT04361643 2020-10-26 Somatotropin The Impact of Growth Hormone in Obese Cases With Covid-19 Treatment 4 Active Not Recruiting NCT04532554 2020-10-22 V590 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults Prevention 1 Active Not Recruiting NCT04569786 2020-10-22 Transcrocetinate Evaluation of trans sodium crocetinate spray against on mild to moderate ARDS induced by COVID-19 patients : A Randomized Open label Clinical Trial Treatment 2 Active Not Recruiting IRCT20081019001369N7 2020-10-20 Adalimumab Adalimumab in COVID-19 to prevent respiratory failure in community care (AVID-CC) : A randomised controlled trial Treatment 2 Active Not Recruiting ISRCTN33260034 2020-10-20 Anti-SARS-CoV-2 equine immunoglobulin fragments Pilot Study to Evaluate Safety and Efficacy of Anti-SARS-CoV-2 Equine Immunoglobulin F(ab')2 Fragments (INOSARS) in Hospitalized Patients With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04514302 2020-10-19 Tocilizumab Tocilizumab for the treatment of COVID-19 in intensive care patients : effect on days free of ventilatory support. Treatment 1, 2 Active Not Recruiting ACTRN12620000580976 2020-10-15 Alteplase Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS) : A Multicentral Randomized Trial (AtTAC-trial) Treatment 3 Active Not Recruiting NCT04453371 2020-10-15 Atazanavir Randomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection Prevention 2, 3 Active Not Recruiting NCT04452565 2020-10-15 Dexamethasone Randomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection Prevention 2, 3 Active Not Recruiting NCT04452565 2020-10-15 Povidone-iodine A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19 Prevention 4 Active Not Recruiting NCT04517188 2020-10-10 Nitric Oxide Inhaled Nitric Oxide for Treatment of SARS-CoV-2 Infection : An Open-Label, Multicenter, Parallel, Randomized Controlled Trial Treatment 2 Active Not Recruiting RBR-8nfx26 2020-10-09 Eflepedocokin alfa A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22 : IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 Treatment 2 Active Not Recruiting NCT04498377 2020-10-07 Daclatasvir Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOn Treatment 2, 3 Active Not Recruiting NCT04468087 2020-10-07 Atazanavir Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOn Treatment 2, 3 Active Not Recruiting NCT04468087 2020-10-07 Sofosbuvir Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection : a Randomized, Phase 2 / 3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX : REVOLUTIOn Treatment 2, 3 Active Not Recruiting NCT04468087 2020-10-07 Acalabrutinib A 2-Part, Phase I, Open-label, Single-dose, Sequential, Randomized, Crossover Study of Acalabrutinib Tablet Suspension Delivered Via Nasogastric Tube in Healthy Subjects to Evaluate Relative Bioavailability and Proton-pump Inhibitor (Rabeprazole) Effect Treatment 1 Active Not Recruiting NCT04564040 2020-10-07 Dexamethasone Efficacy of Dexamethasone Treatment for Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19) Treatment 4 Active Not Recruiting NCT04545242 2020-10-06 Mosedipimod Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS Treatment 2 Active Not Recruiting NCT04569227 2020-10-06 Piclidenoson Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial Treatment 2 Active Not Recruiting NCT04333472 2020-10-06 Niclosamide Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients Treatment 1 Active Not Recruiting NCT04541485 2020-10-05 Ivermectin A randomized double-blind placebo-controlled trial of oral ivermectin outpatient treatment, to prevent hospitalisation, of those at high risk for hospitalization due to SARS-CoV-2 (COVID-19) Treatment 3 Active Not Recruiting ACTRN12620000982910 2020-10-05 COVID-19 convalescent plasma VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1) Treatment 3 Active Not Recruiting NCT04539275 2020-10-03 Lanadelumab Lanadelumab for Treatment of COVID-19 Disease Treatment 1, 2 Active Not Recruiting NCT04422509 2020-10-01 Hydroxychloroquine The Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomized, placebo-controlled prophylaxis study (COPCOV) Treatment 3 Active Not Recruiting PACTR202009786901147 2020-10-01 MVA-SARS-2-S An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S Prevention 1 Active Not Recruiting NCT04569383 2020-10-01 Tafenoquine A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease Treatment 2 Active Not Recruiting NCT04533347 2020-10-01 Ivermectin Outpatient Use of Ivermectin in COVID-19 Treatment 3 Active Not Recruiting NCT04530474 2020-10-01 Dipyridamole A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection Treatment 3 Active Not Recruiting NCT04410328 2020-10-01 Acetylsalicylic acid A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection Treatment 3 Active Not Recruiting NCT04410328 2020-10-01 Tretinoin Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment Treatment 2 Active Not Recruiting NCT04396067 2020-10-01 Montelukast Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms : The COvid-19 Symptom MOntelukast (COSMO) Trial Treatment 3 Active Not Recruiting NCT04389411 2020-10-01 Heparin InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial) Treatment 4 Active Not Recruiting NCT04406389 2020-10-01 Fondaparinux InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial) Treatment 4 Active Not Recruiting NCT04406389 2020-10-01 Argatroban InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial) Treatment 4 Active Not Recruiting NCT04406389 2020-10-01 Enoxaparin InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial) Treatment 4 Active Not Recruiting NCT04406389 2020-10-01 Hydroxychloroquine PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT) Treatment 2, 3 Active Not Recruiting ISRCTN88057279 2020-10-01 Zinc Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial Treatment 3 Active Not Recruiting NCT04392427 2020-10-01 Nitazoxanide Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial Treatment 3 Active Not Recruiting NCT04392427 2020-10-01 Ribavirin Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial Treatment 3 Active Not Recruiting NCT04392427 2020-10-01 Ivermectin Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical Trial Treatment 3 Active Not Recruiting NCT04392427 2020-10-01 Hydroxychloroquine Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial Treatment 4 Active Not Recruiting NCT04382625 2020-10-01 AstraZeneca COVID-19 Vaccine A phase Ib / II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya (COV004) Treatment 1 Active Not Recruiting PACTR202005681895696 2020-10-01 Remestemcel-L Prospective Phase II Study : MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS Treatment 2 Active Not Recruiting NCT04377334 2020-10-01 Linagliptin Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Treatment 3 Active Not Recruiting NCT04371978 2020-10-01 Ascorbic acid Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI) Treatment 2 Active Not Recruiting NCT04344184 2020-10-01 BacTRL-spike A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults Prevention 1 Active Not Recruiting NCT04334980 2020-10-01 Acetylsalicylic acid Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial Trial Treatment 3 Active Not Recruiting NCT04343001 2020-10-01 Simvastatin Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial Trial Treatment 3 Active Not Recruiting NCT04343001 2020-10-01 Losartan Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial Trial Treatment 3 Active Not Recruiting NCT04343001 2020-10-01 Zinc gluconate Randomized, Double -Blind, Placebo Controlled, Trial to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU Supportive Care Not Available Active Not Recruiting NCT04558424 2020-10-01 Ascorbic acid Randomized, Double -Blind, Placebo Controlled, Trial to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU Supportive Care Not Available Active Not Recruiting NCT04558424 2020-10-01 Edoxaban Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting Treatment 3 Active Not Recruiting NCT04516941 2020-10-01 Colchicine Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting Treatment 3 Active Not Recruiting NCT04516941 2020-10-01 Sirolimus Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS) Treatment 1, 2 Active Not Recruiting NCT04482712 2020-10-01 Ethanol Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin . Treatment 3 Active Not Recruiting NCT04554433 2020-10-01 Acetylsalicylic acid Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin . Treatment 3 Active Not Recruiting NCT04554433 2020-10-01 Camostat A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild COVID-19 Treatment 2 Active Not Recruiting NCT04524663 2020-10-01 Oxygen Multicentre Randomized Controlled Trial of Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients Treatment 2, 3 Active Not Recruiting NCT04500626 2020-10-01 Heparin Can Nebulised HepArin Reduce morTality and Time to Extubation in Patients With COVID-19 Requiring Mechanical Ventilation Meta-Trial (CHARTER-MT) : Protocol for an Investigator-initiated International Meta-trial of Randomised Studies Treatment 2, 3 Active Not Recruiting NCT04545541 2020-10-01 Ethinylestradiol Estrogen Therapy in Non-severe COVID-19 Patients : Proposed Treatment Scheme in a Tertiary Hospital Treatment Not Available Active Not Recruiting NCT04539626 2020-10-01 Norelgestromin Estrogen Therapy in Non-severe COVID-19 Patients : Proposed Treatment Scheme in a Tertiary Hospital Treatment Not Available Active Not Recruiting NCT04539626 2020-10-01 Rivaroxaban Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT) Treatment 2 Active Not Recruiting EUCTR2020-002282-33-DE 2020-10-01 Alvelestat A Phase Ib / II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA) Treatment 1, 2 Active Not Recruiting NCT04539795 2020-10-01 Alprostadil Effectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04536363 2020-10-01 COVID-19 convalescent plasma Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection Treatment 2 Active Not Recruiting NCT04456413 2020-09-30 Epigallocatechin A Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Protect Health Workers Against COVID-19 by Using Previfenon® as Chemoprophylaxis During a SARS-CoV-2 Outbreak. The HERD Study Prevention 2, 3 Active Not Recruiting NCT04446065 2020-09-30 Tranexamic acid Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Inpatients Treatment 2 Active Not Recruiting NCT04338126 2020-09-30 COVID-19 convalescent plasma A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Treatment 2 Active Not Recruiting NCT04377568 2020-09-30 Duvelisib A Pilot Study of Duvelisib to Combat COVID-19 Treatment 2 Active Not Recruiting NCT04372602 2020-09-30 Angiotensin 1-7 Angiotensin-(1,7) Treatment in COVID-19 : the ATCO Trial Treatment 2, 3 Active Not Recruiting NCT04332666 2020-09-30 Bucillamine Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19 Treatment 3 Active Not Recruiting NCT04504734 2020-09-30 CoVac-1 P-pVAC-SARS-CoV-2 : Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults Prevention 1 Active Not Recruiting NCT04546841 2020-09-30 Ifenprodil AN OPEN LABEL PHYSICIAN INITIATED 28 DAY PHASE 2A STUDY OF IFENPRODIL ON LUNG FUNCTION IN CONFIRMED COVID-19 INFECTED PATIENTS WITH SEVERE PNEUMONIA Treatment 2 Active Not Recruiting KCT0005307 2020-09-30 Anti-SARS-CoV-2 immunoglobulin An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19 - Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) Treatment 3 Active Not Recruiting EUCTR2020-002542-16-GB 2020-09-29 NasoVAX Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) Treatment 2 Active Not Recruiting NCT04442230 2020-09-29 Ad5-nCoV A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older Prevention 1 Active Not Recruiting NCT04552366 2020-09-29 CK0802 Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) Treatment 1 Active Not Recruiting NCT04468971 2020-09-28 Citrulline Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness Treatment 2 Active Not Recruiting NCT04570384 2020-09-28 Gam-COVID-Vac ?linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-?oV-2 Infection Prophylactic Treatment in Republic of Belarus Prevention 3 Active Not Recruiting NCT04564716 2020-09-28 Zinc Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic : A Randomized Study Treatment Not Available Active Not Recruiting NCT04551339 2020-09-28 Niclosamide A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19) Treatment 3 Active Not Recruiting NCT04558021 2020-09-28 Inactivated SARS-Cov-2 Vaccine A Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years Prevention 1, 2 Active Not Recruiting NCT04551547 2020-09-26 Ad5-nCoV The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years Prevention 1 Active Not Recruiting NCT04568811 2020-09-25 UB-612 A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers Prevention 1 Active Not Recruiting NCT04545749 2020-09-25 Dapansutrile A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Treatment 2 Active Not Recruiting NCT04540120 2020-09-25 Tenecteplase Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04505592 2020-09-25 Molgramostim Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia - GI-COVID Treatment 2 Active Not Recruiting EUCTR2020-001654-21-DE 2020-09-25 Hydroxychloroquine Evaluation of safety and efficacy of post exposure prophylaxis with hydroxychloroquine aiming at prevention of COVID-19 for medical care workers Treatment 1 Active Not Recruiting JPRN-jRCTs051200060 2020-09-25 Ozone Estudo Multicentrico da prática Integrativa e complementar de Ozonioterapia em pacientes ambulatoriais com Covid- 19 Treatment 1, 2 Active Not Recruiting RBR-97nt6j 2020-09-24 Molgramostim Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID) Treatment 2 Active Not Recruiting NCT04569877 2020-09-24 Ad5-nCoV A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV Prevention 2 Active Not Recruiting NCT04566770 2020-09-24 Lopinavir Favipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 Treatment 2 Active Not Recruiting NCT04499677 2020-09-24 Favipiravir Favipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 Treatment 2 Active Not Recruiting NCT04499677 2020-09-24 Ritonavir Favipiravir, Lopinavir / Ritonavir or Combination Therapy : a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 Treatment 2 Active Not Recruiting NCT04499677 2020-09-23 Acetylcysteine Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease Treatment 4 Active Not Recruiting NCT04419025 2020-09-23 Nuvaxovid A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom Treatment 3 Active Not Recruiting EUCTR2020-004123-16-GB 2020-09-22 Tribulus terrestris The effect of herbal tea (including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii) on improving respiratory symptoms in patients with Covid-19 Treatment 3 Active Not Recruiting IRCT20200806048318N1 2020-09-22 Melilotus officinalis pollen The effect of herbal tea (including mallow flower, chicory seeds, sweet violet flower, Melilotus officinalis and Bindii) on improving respiratory symptoms in patients with Covid-19 Treatment 3 Active Not Recruiting IRCT20200806048318N1 2020-09-22 Noscapine Evaluation and comparison of the effectiveness of two herbal products containing Noscapine (Opiucough and Noscough) on clinical symptoms and para-clinical parameters in adults hospitalized with severe COVID-19 Treatment 2 Active Not Recruiting IRCT20180103038199N3 2020-09-22 COVID-19 convalescent plasma Evaluation of Convalescent Plasma Therapy for COVID-19 Patients Treatment 0 Active Not Recruiting IRCT20200503047281N1 2020-09-22 Celecoxib Evaluation of short-term effects of Celecoxib on clinical improvement of COVID-19 patients : A randomized clinical trial study Treatment 1 Recruiting IRCT20200907048644N1 2020-09-22 Eucalyptus oil Evaluation of therapeutic effects of oral eucalyptus tablets on the treatment process of patients with Covid 19 infection. Treatment 3 Active Not Recruiting IRCT20200913048701N1 2020-09-22 Bromhexine Verification of the efficacy of Bromhexine-hydrochloride in treatment of patients with COVID19 disease Treatment 3 Active Not Recruiting IRCT20200818048444N1 2020-09-21 Atazanavir A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study Treatment 2 Active Not Recruiting PACTR202008855701534 2020-09-21 Nitazoxanide A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study Treatment 2 Active Not Recruiting PACTR202008855701534 2020-09-21 Acetylcysteine A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients Treatment 2, 3 Active Not Recruiting NCT04573153 2020-09-21 Levocarnitine A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients Treatment 2, 3 Active Not Recruiting NCT04573153 2020-09-21 Nicotinamide riboside A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients Treatment 2, 3 Active Not Recruiting NCT04573153 2020-09-21 Serine A Multi Centre, Randomised, Controlled, Open-Label Phase 2 / 3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients Treatment 2, 3 Active Not Recruiting NCT04573153 2020-09-21 Maraviroc Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2 Treatment 1 Active Not Recruiting NCT04435522 2020-09-21 Ritonavir A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study Treatment 2 Active Not Recruiting NCT04459286 2020-09-21 Atazanavir A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study Treatment 2 Active Not Recruiting NCT04459286 2020-09-21 Nitazoxanide A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot Study Treatment 2 Active Not Recruiting NCT04459286 2020-09-21 COVID-19 convalescent plasma A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission : Co-CLARITY Trial Treatment 2, 3 Active Not Recruiting NCT04567173 2020-09-21 COVID-19 convalescent plasma A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Treatment 3 Active Not Recruiting NCT04516811 2020-09-21 Antroquinonol A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19 Treatment 2 Active Not Recruiting NCT04523181 2020-09-21 Biomodulin T Safety and effectiveness of BIOMODULINA T in a long-lived population at high risk of COVID-19 infection. Interventional Study (COVID-19) Treatment Not Available Active Not Recruiting RPCEC00000335 2020-09-20 Anti-SARS-CoV-2 immunoglobulin A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04555148 2020-09-20 Omega-3 fatty acids Impact of Different Treatment Modalities on Immunity Against COVID-19 Treatment 2, 3 Active Not Recruiting NCT04553705 2020-09-20 Quinine Impact of Different Treatment Modalities on Immunity Against COVID-19 Treatment 2, 3 Active Not Recruiting NCT04553705 2020-09-19 QazCovid-in Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-IN®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder Prevention 1, 2 Active Not Recruiting NCT04530357 2020-09-18 Anti-SARS-CoV-2 IgY A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) Prevention 1 Active Not Recruiting NCT04567810 2020-09-18 Leflunomide A Phase 1 / 2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Treatment 1, 2 Active Not Recruiting NCT04532372 2020-09-18 Remdesivir A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting Treatment 3 Active Not Recruiting NCT04501952 2020-09-18 Ascorbic acid The Effect of Melatonin and Vitamin C on COVID-19 Supportive Care Not Available Active Not Recruiting NCT04530539 2020-09-18 Melatonin The Effect of Melatonin and Vitamin C on COVID-19 Supportive Care Not Available Active Not Recruiting NCT04530539 2020-09-18 CVnCoV COVID-19 : A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age Prevention 2 Active Not Recruiting NCT04515147 2020-09-17 Favipiravir An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia - An open-label randomized controlled study - Treatment 3 Active Not Recruiting EUCTR2020-002728-35-HU 2020-09-17 Fluvoxamine A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-19 patients Treatment 2 Active Not Recruiting EUCTR2020-002299-11-HU 2020-09-17 Human immunoglobulin G A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit Treatment 2 Active Not Recruiting NCT04480424 2020-09-17 COVID-19 convalescent plasma Study on the use of Convalescent plasma therapy as a COVID-19 treatment - Study on the use of Convalescent plasma therapy as a COVID-19 treatment Treatment Not Available Active Not Recruiting JPRN-jRCTs031200124 2020-09-16 Tofacitinib A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Treatment 2 Active Not Recruiting NCT04469114 2020-09-16 Inactivated SARS-Cov-2 Vaccine Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years Prevention 3 Active Not Recruiting NCT04560881 2020-09-16 Ozanimod A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial Treatment 2 Active Not Recruiting NCT04405102 2020-09-16 Ivermectin A placebo-controlled, randomized, double-blind study in COvid-19 patients with iveRmectin ; An inVEstigator iniTiaTEd trial - CORVETTE-01 Treatment 2 Active Not Recruiting JPRN-jRCT2031200120 2020-09-15 Conestat alfa Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 : a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US) Treatment 2 Active Not Recruiting NCT04530136 2020-09-15 Citrulline CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome Treatment Not Available Active Not Recruiting NCT04404426 2020-09-15 COVID-19 convalescent plasma Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 Treatment Not Available Active Not Recruiting NCT04338360 2020-09-15 MVC-COV1901 A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Prevention 1 Active Not Recruiting NCT04487210 2020-09-15 Ad5-nCoV A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase ? Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older Prevention 3 Active Not Recruiting NCT04526990 2020-09-15 Prolectin-M Effect of Prolectin-M ; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers : A Proof of Concept, Open Label Randomized Controlled Trial Treatment Not Available Active Not Recruiting NCT04512027 2020-09-15 Human immunoglobulin G Intravenous Immunoglobulins for the Treatment of Covid-19 Patients : a Clinical Trial Treatment 3 Active Not Recruiting NCT04548557 2020-09-15 Hydroxychloroquine Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers ; a Pilot Study Treatment 1 Active Not Recruiting NCT04497519 2020-09-15 Vitamin D A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members Treatment 3 Active Not Recruiting NCT04536298 2020-09-15 Descartes-30 Phase I / IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome Treatment 1, 2 Active Not Recruiting NCT04524962 2020-09-15 Human Amniotic Fluid A Phase I / II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients Treatment 1, 2 Active Not Recruiting NCT04497389 2020-09-15 Remdesivir A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers Treatment 1 Active Not Recruiting NCT04480333 2020-09-14 Favipiravir Glasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients Treatment 2 Active Not Recruiting ISRCTN31062548 2020-09-14 Decitabine Decitabine for COVID-19 Pneumonia-ARDS Treatment : DART Trial Treatment 2 Active Not Recruiting NCT04482621 2020-09-14 Remdesivir A Phase 1b / 2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation Treatment 1, 2 Active Not Recruiting NCT04539262 2020-09-14 Lopinavir A Pilot study platform to investigate the pharmacodynamics on QT-prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteers Treatment 2 Active Not Recruiting EUCTR2020-002314-40-AT 2020-09-14 Ribavirin A Pilot study platform to investigate the pharmacodynamics on QT-prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteers Treatment 2 Active Not Recruiting EUCTR2020-002314-40-AT 2020-09-14 Onion Evaluation of safety and efficacy of T-AYU-HM Premium and Onion Steam vaporisation / nebulization in Covid-19 patients (mild to moderate) Treatment 2 Active Not Recruiting CTRI/2020/08/027477 2020-09-11 Ad5-nCoV Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers Prevention 3 Active Not Recruiting NCT04540419 2020-09-11 Bacillus calmette-guerin substrain danish 1331 live antigen Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial. Prevention 3 Active Not Recruiting NCT04542330 2020-09-11 Biomodulin T Safety and effectiveness of BIOMODULIN T in protective therapy in events of local transmission of COVID-19. Interventional Study (COVID-19) Treatment Not Available Active Not Recruiting RPCEC00000334 2020-09-11 Bacillus calmette-guerin substrain danish 1331 live antigen BCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial - BRACE Treatment 3 Active Not Recruiting EUCTR2020-002503-19-GB 2020-09-11 Remestemcel-L Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients : Randomized, Double-blind, and Placebo-controlled Treatment 1 Active Not Recruiting NCT04535856 2020-09-10 Transcrocetinate Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects Treatment 1, 2 Active Not Recruiting NCT04573322 2020-09-10 Lopinavir Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial Treatment 2, 3 Active Not Recruiting NCT04466241 2020-09-10 Ritonavir Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial Treatment 2, 3 Active Not Recruiting NCT04466241 2020-09-10 Telmisartan Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial Treatment 2, 3 Active Not Recruiting NCT04466241 2020-09-10 Atorvastatin Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial Treatment 2, 3 Active Not Recruiting NCT04466241 2020-09-10 Thymalfasin A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia Treatment 2 Active Not Recruiting NCT04487444 2020-09-10 Dental Mesenchymal Pulp Stem Cells Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia- A Phase 2&3 Clinical Trial Treatment 2, 3 Recruiting IRCT20140911019125N8 2020-09-10 Sofosbuvir A Multicentre, Quadruple-blind, Randomized, Parallel-group Study to Compare the Efficacy of Sofosbuvir and Daclatasvir vs. Placebo in the Outpatient Treatment of COVID-19 in adults Treatment 3 Recruiting IRCT20200831048568N1 2020-09-10 Daclatasvir A Multicentre, Quadruple-blind, Randomized, Parallel-group Study to Compare the Efficacy of Sofosbuvir and Daclatasvir vs. Placebo in the Outpatient Treatment of COVID-19 in adults Treatment 3 Recruiting IRCT20200831048568N1 2020-09-10 Ravulizumab A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome Treatment 3 Recruiting JPRN-jRCT2031200126 2020-09-10 AstraZeneca COVID-19 Vaccine A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY IN ADULTS TO DETERMINE THE SAFETY, EFFICACY, AND IMMUNOGENICITY OF AZD1222, A NON-REPLICATING CHADOX1 VECTOR VACCINE, FOR THE PREVENTION OF COVID-19 Treatment 3 Active Not Recruiting PER-059-20 2020-09-10 CVnCoV COVID-19 : A PHASE 2A, PARTIALLY OBSERVER-BLIND, MULTICENTER, CONTROLLED, DOSE-CONFIRMATION CLINICAL TRIAL TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE INVESTIGATIONAL SARS-COV-2 MRNA VACCINE CVNCOV IN ADULTS >60 YEARS OF AGE AND 18 TO 60 YEARS OF AGE Treatment 2 Active Not Recruiting PER-054-20 2020-09-10 Tocilizumab COVIDOSE-2 : A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation Treatment 2 Active Not Recruiting NCT04479358 2020-09-09 Ascorbic acid Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial : The International ALLIANCE Study Treatment 2 Active Not Recruiting NCT04395768 2020-09-09 Avasopasem manganese A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19) Treatment 2 Active Not Recruiting NCT04555096 2020-09-09 BNT162b3 A Multi-site, Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults Prevention 1, 2 Active Not Recruiting NCT04537949 2020-09-08 Zofin A Phase I / II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo Treatment 1, 2 Active Not Recruiting NCT04384445 2020-09-08 Bardoxolone methyl BARCONA : A Phase II / III, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Treatment 2, 3 Active Not Recruiting NCT04494646 2020-09-08 Tenecteplase Low-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism : A Randomized, Double-Blind, Placebo-Controlled Trial Treatment 4 Active Not Recruiting NCT04558125 2020-09-08 Treamid Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia Treatment 2 Active Not Recruiting NCT04527354 2020-09-08 BGB-DXP593 A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects Basic Science 1 Active Not Recruiting NCT04532294 2020-09-08 Umifenovir Phase 3, Randomized, Double-blind, Placebo control trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients. Treatment 3 Active Not Recruiting CTRI/2020/09/027535 2020-09-07 Ivermectin Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic : A Randomized Clinical Controled Trial Prevention 3 Active Not Recruiting NCT04527211 2020-09-07 Gam-COVID-Vac Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-?oV-2 Infection Prophylactic Treatment Prevention 3 Active Not Recruiting NCT04530396 2020-09-07 Janssen COVID-19 Vaccine A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older Prevention 3 Active Not Recruiting NCT04505722 2020-09-07 COVID-19 convalescent plasma RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF PLASMA FROM CONVALESCENT PATIENTS WITH THE NEW CORONAVIRUS DISEASE (COVID-19) FOR THE EXPERIMENTAL TREATMENT OF PATIENTS HOSPITALIZED IN THE CENTRO MEDICO NAVAL "CIRUJANO MAYOR SANTIAGO TAVARA" Treatment 2 Active Not Recruiting PER-060-20 2020-09-07 Pioglitazone Non-blinded, Randomized and Controlled Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19 Treatment 4 Active Not Recruiting NCT04535700 2020-09-07 Prednisone Randomized, Open, Parallel, Single-center, Non-inferiority Clinical Trial, With an Active Control Group, Comparing Two Oral Prednisone Regimens With the Aim of Optimizing the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Infection Treatment 4 Active Not Recruiting NCT04534478 2020-09-04 Bamlanivimab A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 - Therapeutics for Inpatients with COVID-19 (TICO) Treatment 2 Active Not Recruiting EUCTR2020-003278-37-DK 2020-09-04 Rintatolimod Phase 1 / 2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection Supportive Care 1, 2 Active Not Recruiting NCT04379518 2020-09-04 Interferon alfa-2b Phase 1 / 2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection Supportive Care 1, 2 Active Not Recruiting NCT04379518 2020-09-04 Azadirachta indica leaf Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa Treatment Not Available Active Not Recruiting NCT04357990 2020-09-04 St. John's Wort Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa Treatment Not Available Active Not Recruiting NCT04357990 2020-09-04 Rubella virus vaccine An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers Prevention 3 Active Not Recruiting NCT04333732 2020-09-04 Measles virus vaccine live attenuated An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers Prevention 3 Active Not Recruiting NCT04333732 2020-09-04 Mumps virus strain B level jeryl lynn live antigen An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers Prevention 3 Active Not Recruiting NCT04333732 2020-09-04 Tocilizumab Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study Treatment 3 Active Not Recruiting NCT04361032 2020-09-04 Deferoxamine Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study Treatment 3 Active Not Recruiting NCT04361032 2020-09-04 Dalteparin A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 Treatment 4 Active Not Recruiting NCT04505774 2020-09-04 Heparin A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 Treatment 4 Active Not Recruiting NCT04505774 2020-09-04 Enoxaparin A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 Treatment 4 Active Not Recruiting NCT04505774 2020-09-04 Fondaparinux A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 Treatment 4 Active Not Recruiting NCT04505774 2020-09-04 Tinzaparin A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 Treatment 4 Active Not Recruiting NCT04505774 2020-09-04 Daclatasvir Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19) Treatment 3 Active Not Recruiting NCT04535869 2020-09-04 Sofosbuvir Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19) Treatment 3 Active Not Recruiting NCT04535869 2020-09-04 Sodium chloride Impact of Nasopharyngeal wash on Virion Load in COVID-19 Patients Treatment 1, 2 Active Not Recruiting CTRI/2020/08/027465 2020-09-03 Almitrine Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia : a Randomized Controlled Double-blind Study From the Skip-icu Consortium Treatment 3 Active Not Recruiting NCT04357457 2020-09-03 VidPrevtyn Beta Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older Prevention 1, 2 Active Not Recruiting NCT04537208 2020-09-03 Sofosbuvir Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Treatment 2 Active Not Recruiting NCT04532931 2020-09-03 Daclatasvir Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Treatment 2 Active Not Recruiting NCT04532931 2020-09-03 Nitazoxanide Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Treatment 2 Active Not Recruiting NCT04532931 2020-09-03 Favipiravir Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Treatment 2 Active Not Recruiting NCT04532931 2020-09-03 Amodiaquine Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Treatment 2 Active Not Recruiting NCT04532931 2020-09-03 Artesunate Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Treatment 2 Active Not Recruiting NCT04532931 2020-09-03 Pyronaridine Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Treatment 2 Active Not Recruiting NCT04532931 2020-09-02 Mavrilimumab Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation Treatment 2 Active Not Recruiting NCT04463004 2020-09-02 BNT162b3 A Multi-site, Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of a BNT162 Vaccine Against COVID-19 Treatment 1 Active Not Recruiting EUCTR2020-003267-26-DE 2020-09-02 Janssen COVID-19 Vaccine A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older Treatment 2 Active Not Recruiting EUCTR2020-002584-63-DE 2020-09-02 Azithromycin Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies Treatment 2 Active Not Recruiting NCT04392128 2020-09-02 Hydroxychloroquine Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies Treatment 2 Active Not Recruiting NCT04392128 2020-09-02 Nitric Oxide Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19 Treatment 1 Active Not Recruiting NCT04383002 2020-09-02 Ivermectin Assessment of response of ivermectin on virological clearance in COVID 19 : single centre, open labelled, randomised controlled trial Treatment Not Available Active Not Recruiting CTRI/2020/08/027394 2020-09-01 XAV-19 A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia Treatment 2 Active Not Recruiting NCT04453384 2020-09-01 Favipiravir Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID) Prevention 2 Active Not Recruiting NCT04448119 2020-09-01 Remestemcel-L A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy Treatment 1, 2 Active Not Recruiting NCT04445220 2020-09-01 Nitric Oxide Multi-Center, Double-Blinded, Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Mild COVID-19 Treatment 2 Active Not Recruiting NCT04443868 2020-09-01 Fluoxetine Pilot Randomized Controlled Trial : Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19) Treatment 1 Active Not Recruiting NCT04570449 2020-09-01 Tocilizumab An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease Treatment 3 Active Not Recruiting NCT04424056 2020-09-01 Anakinra An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease Treatment 3 Active Not Recruiting NCT04424056 2020-09-01 Ruxolitinib An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease Treatment 3 Active Not Recruiting NCT04424056 2020-09-01 Tamoxifen Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19 Treatment 2 Active Not Recruiting NCT04568096 2020-09-01 Tretinoin Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19 Treatment 2 Active Not Recruiting NCT04568096 2020-09-01 Losartan Safety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19 Treatment 1 Active Not Recruiting ACTRN12620000731998 2020-09-01 Thymalfasin A Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients Prevention 2 Active Not Recruiting NCT04428008 2020-09-01 Ibudilast A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome Treatment 2 Active Not Recruiting NCT04429555 2020-09-01 VXA-CoV2-1 A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers Prevention 1 Active Not Recruiting NCT04563702 2020-09-01 Demeclocycline Multicenter Study to evaluate efficacy and safety of Demethylchlortetracycline in Patients of COVID-19 (COVID-DMC) Treatment 2 Active Not Recruiting JPRN-jRCTs051200049 2020-09-01 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins An Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19) Treatment 1 Active Not Recruiting JPRN-JapicCTI-205416 2020-09-01 Hydroxychloroquine Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study) Prevention 2, 3 Active Not Recruiting NCT04400019 2020-09-01 Melatonin Selective Estrogen Modulation and Melatonin in Early COVID-19 Treatment 2 Active Not Recruiting NCT04531748 2020-09-01 Toremifene Selective Estrogen Modulation and Melatonin in Early COVID-19 Treatment 2 Active Not Recruiting NCT04531748 2020-09-01 Defibrotide Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS) Treatment 1 Active Not Recruiting NCT04530604 2020-09-01 Methylprednisolone Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design Treatment 3 Active Not Recruiting NCT04528888 2020-09-01 Heparin Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design Treatment 3 Active Not Recruiting NCT04528888 2020-09-01 Enoxaparin Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design Treatment 3 Active Not Recruiting NCT04528888 2020-09-01 Abivertinib A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 Treatment 2 Active Not Recruiting NCT04528667 2020-09-01 Vitamin D High Dose Vitamin-D Substitution in Patients With COVID-19 : a Randomized Controlled, Multi Center Study Treatment Not Available Active Not Recruiting NCT04525820 2020-09-01 Metformin MET-Covid Trial - METformin for Prevention and Outpatient Treatment of COVID-19 Treatment 2, 3 Active Not Recruiting NCT04510194 2020-09-01 Sodium chloride Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19 Health Services Research 1 Active Not Recruiting NCT04419610 2020-09-01 COVID-19 convalescent plasma A Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. Treatment 2, 3 Active Not Recruiting NCT04395170 2020-09-01 Isotretinoin Isotretinoin in Treatment of COVID-19 (Randomized) Treatment 3 Active Not Recruiting NCT04353180 2020-09-01 Hydroxychloroquine IMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORT Basic Science Not Available Active Not Recruiting NCT04347798 2020-09-01 Chloroquine IMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORT Basic Science Not Available Active Not Recruiting NCT04347798 2020-09-01 Virus Specific T-Cell Viral Specific T-cells (VSTs) for Treatment of SARS-CoV-2 / COVID-19 Treatment 2 Active Not Recruiting NCT04406064 2020-09-01 Niclosamide Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19) Treatment 2 Active Not Recruiting NCT04399356 2020-09-01 Oxytocin Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19 Treatment 2 Active Not Recruiting NCT04386447 2020-09-01 Human Umbilical Cord Mesenchymal Stem Cells Safety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19 : A Randomized Controlled Trial Treatment 1, 2 Active Not Recruiting NCT04390152 2020-09-01 Peginterferon lambda-1a A Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical Illness Treatment 2 Active Not Recruiting NCT04388709 2020-09-01 Hydroxychloroquine PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT) : a Basket Trial of Prophylactic Interventions Amongst At-risk Patients Prevention 2, 3 Active Not Recruiting NCT04389359 2020-09-01 Recombinant Bacterial ACE2 Receptors-like Enzyme Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2 Treatment 1 Active Not Recruiting NCT04375046 2020-09-01 Povidone-iodine Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2 Treatment 2 Active Not Recruiting NCT04371965 2020-09-01 Ruxolitinib Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe / Very Severe COVID-19 Illness Treatment Not Available Active Not Recruiting NCT04337359 2020-09-01 Dexamethasone Targeted Steroids for ARDS Due to COVID-19 Pneumonia : A Pilot Randomized Clinical Trial Treatment 2 Active Not Recruiting NCT04360876 2020-09-01 Imatinib A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS. Treatment 2 Active Not Recruiting NCT04357613 2020-09-01 Ribavirin An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 Treatment 1 Active Not Recruiting NCT04356677 2020-09-01 Remestemcel-L An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia Treatment 1 Active Not Recruiting ChiCTR2000030944 2020-09-01 Natural Killer Cell An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia Treatment 1 Active Not Recruiting ChiCTR2000030944 2020-09-01 Acetylcysteine Inflammatory regulation effect of N-acetylcysteine on COVID-19 treatment, pilot, double blinded randomized placebo controlled multicenter clinical trial Treatment 3, 4 Active Not Recruiting ISRCTN60069084 2020-09-01 Lenzilumab COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study Arm 4 : Effect of Lenzilumab in cancer patients with severe COVID-19 infection. Treatment 3 Active Not Recruiting ACTRN12620000844943 2020-09-01 Selinexor COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 3 : Effect of selinexor in cancer patients with moderate COVID-19 infection. Treatment 3 Active Not Recruiting ACTRN12620000841976 2020-09-01 Interferon alfa COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 2 : Effect of daily Interferon-alpha on cancer patients with known positive contact with COVID-19. Treatment 3 Active Not Recruiting ACTRN12620000842965 2020-09-01 Interferon alfa COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART study. Arm 1 : Effect of daily Interferon-alpha on cancer patients without known positive contact with COVID-19. Treatment 3 Active Not Recruiting ACTRN12620000843954 2020-09-01 Varicella zoster vaccine (recombinant) Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents : A Randomized, Doubled-Blinded, Comparative Group Observational Study Basic Science 1 Active Not Recruiting NCT04523246 2020-09-01 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection Treatment 1 Active Not Recruiting NCT04522986 2020-09-01 Stem-cell derived exosome vesicle products Extracellular Vesicle Infusion Treatment for Severe COVID-19 Treatment 2 Active Not Recruiting NCT04493242 2020-09-01 COVID-19 convalescent plasma A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation : the CONFIDENT Trial Treatment 2 Active Not Recruiting NCT04558476 2020-09-01 Colchicine Phase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center Treatment 2, 3 Active Not Recruiting NCT04492358 2020-09-01 Prednisone Phase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center Treatment 2, 3 Active Not Recruiting NCT04492358 2020-09-01 Disulfiram Virologic and Immunologic Response to Disulfiram in Early Symptomatic COVID+ Outpatients Treatment 2 Active Not Recruiting NCT04485130 2020-09-01 Canakinumab Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial Treatment 3 Active Not Recruiting NCT04510493 2020-09-01 Bicalutamide Randomized Trial of Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection Treatment 3 Active Not Recruiting NCT04509999 2020-09-01 Autologous peripheral blood-derived CD34+ cells CLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary Damage Treatment 1 Active Not Recruiting NCT04522817 2020-09-01 CSL324 A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19) Treatment 2 Active Not Recruiting NCT04519424 2020-09-01 Cholecalciferol PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams (PROTECT) Prevention 3 Active Not Recruiting NCT04483635 2020-09-01 Ivermectin A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04482686 2020-09-01 Doxycycline A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04482686 2020-09-01 Apixaban FREEDOM COVID Anticoagulation Strategy Randomized Trial Treatment 4 Active Not Recruiting NCT04512079 2020-09-01 Enoxaparin FREEDOM COVID Anticoagulation Strategy Randomized Trial Treatment 4 Active Not Recruiting NCT04512079 2020-09-01 Heparin Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Mechanical Ventilation in Ireland Treatment 1, 2 Active Not Recruiting NCT04511923 2020-09-01 Genistein A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients Treatment 2 Active Not Recruiting NCT04482595 2020-09-01 Razuprotafib A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study) Treatment 2 Active Not Recruiting NCT04511650 2020-09-01 Ivermectin Ivermectin Inhalation Forms in the Management of COVID-19 Egyptian Patients Treatment 2 Active Not Recruiting NCT04510233 2020-09-01 Colchicine Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19) Treatment 2, 3 Active Not Recruiting NCT04510038 2020-09-01 Hydroxychloroquine Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and / or Gougerot's Disease Treatment Not Available Active Not Recruiting NCT04481633 2020-09-01 Ramelteon Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19 Treatment 2 Active Not Recruiting NCT04470297 2020-09-01 Peginterferon beta-1a A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19) Treatment 3 Active Not Recruiting NCT04552379 2020-09-01 Calcifediol A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue) Treatment 2 Active Not Recruiting NCT04551911 2020-09-01 Ribavirin An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 Treatment 1 Active Not Recruiting NCT04551768 2020-09-01 Doxycycline The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases : a Randomized Double Blind Placebo Controlled Trial Treatment 2 Active Not Recruiting NCT04551755 2020-09-01 Ivermectin The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases : a Randomized Double Blind Placebo Controlled Trial Treatment 2 Active Not Recruiting NCT04551755 2020-09-01 BCG vaccine Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial Prevention 3 Active Not Recruiting NCT04534803 2020-09-01 AK119 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects Treatment 1 Active Not Recruiting NCT04516564 2020-09-01 Alpha-1-proteinase inhibitor A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19 Treatment 2 Active Not Recruiting NCT04547140 2020-09-01 Anti-SARS-CoV-2 immunoglobulin An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19 Treatment 3 Active Not Recruiting NCT04546581 2020-09-01 Famotidine A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection Treatment 1 Active Not Recruiting NCT04545008 2020-09-01 Cysteine A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection Treatment 1 Active Not Recruiting NCT04545008 2020-09-01 Poractant alfa Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS) Treatment 2 Active Not Recruiting NCT04502433 2020-09-01 Aminolevulinic acid An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19) Treatment Not Available Active Not Recruiting NCT04542850 2020-09-01 Ferric sodium citrate An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19) Treatment Not Available Active Not Recruiting NCT04542850 2020-09-01 Edoxaban Hamburg Edoxaban for Anticoagulation in COVID-19 Study Treatment 3 Active Not Recruiting NCT04542408 2020-09-01 Cyclosporine Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic Treatment 1, 2 Active Not Recruiting NCT04540926 2020-09-01 Colchicine Impact of Colchicine in Hospitalized Colombian Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04539873 2020-09-01 Aviptadil Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS : a Randomized, Placebo Controlled, Multicenter Trial Treatment 1 Active Not Recruiting NCT04536350 2020-09-01 Asunercept A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease Treatment 2 Active Not Recruiting NCT04535674 2020-09-01 Selinexor COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study. Treatment 3 Active Not Recruiting NCT04534725 2020-09-01 Lenzilumab COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study. Treatment 3 Active Not Recruiting NCT04534725 2020-09-01 Interferon alfa COVID-19 Prevention and Treatment in Cancer ; a Sequential Multiple Assignment Randomised Trial ; C-SMART Study. Treatment 3 Active Not Recruiting NCT04534725 2020-09-01 Artemisia annua leaf Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients Treatment 2 Active Not Recruiting NCT04530617 2020-09-01 Camostat Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients Treatment 2 Active Not Recruiting NCT04530617 2020-09-01 Mycobacterium w. Vaccine "Randomized Controlled Trial Of Immunomodulator Mycobacterium w In Mild And Moderate Cases of Covid-19 Pneumonia" Treatment 3 Active Not Recruiting CTRI/2020/08/027475 2020-09-01 Interferon beta-1b Randomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-ß-1a (IFNß-1a) in COVID-19 Patients Treatment 2 Active Not Recruiting NCT04449380 2020-09-01 Tocilizumab Role of Tocilizumab in Patients with Moderate to Severe COVID-19 Pneumonia Basic Science Not Available Active Not Recruiting CTRI/2020/08/027246 2020-09-01 Vitamin D Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease Prevention Not Available Active Not Recruiting NCT04476680 2020-08-31 Hydroxychloroquine Post Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients : A Double-blind Randomized Clinical Trial Prevention 2, 3 Active Not Recruiting NCT04437693 2020-08-31 Fish oil Randomized, Open-label, Parallel Study to Investigate Safety and Efficacy of CARDIO Softgels Plus Best Standard-of-care vs. Best Standard-of-care Alone on a Former Smoker and / or Steroid-resistant Asthma Population With COVID-19 Infection Treatment Not Available Active Not Recruiting NCT04465513 2020-08-31 Curcumin Evaluation the effectiveness of curcumin in the treatment of patients with covid-19 sever acute respiratory syndrome Treatment 2, 3 Recruiting IRCT20200418047119N1 2020-08-31 AG0302-COVID19 A Randomized, Open-label, Non-controlled Phase I / II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults Prevention 1, 2 Active Not Recruiting NCT04527081 2020-08-31 Recombinant Human Thrombopoietin The Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 Pandemic Treatment 2 Active Not Recruiting NCT04516837 2020-08-31 Eltrombopag The Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 Pandemic Treatment 2 Active Not Recruiting NCT04516837 2020-08-31 Ledipasvir Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial Treatment 3 Active Not Recruiting CTRI/2020/08/027345 2020-08-31 Sofosbuvir Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial Treatment 3 Active Not Recruiting CTRI/2020/08/027345 2020-08-31 Daclatasvir Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients : A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial Treatment 3 Active Not Recruiting CTRI/2020/08/027345 2020-08-31 Ivermectin Effectiveness of Ivermectin in preventing development of symptomatic Covid-19 among primary contacts of newly diagnosed Covid-19 positive patients at a tertiary care hospital in North India - an interventional study Treatment 3 Active Not Recruiting CTRI/2020/08/027282 2020-08-30 Tenofovir Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir / Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial Prevention 2, 3 Active Not Recruiting NCT04519125 2020-08-30 Emtricitabine Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir / Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial Prevention 2, 3 Active Not Recruiting NCT04519125 2020-08-30 Dexamethasone Time to Recover of Anosmia and / or Ageusia and Early Corticosteroid Use Treatment 4 Active Not Recruiting NCT04528329 2020-08-28 Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older : A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study Prevention 1 Active Not Recruiting NCT04530656 2020-08-28 Secukinumab Use of Anti-IL-17 in patients with the severe acute respiratory syndrome (SARS) associated with Covid-19 Treatment 2 Active Not Recruiting RBR-5vpyh4 2020-08-28 Losmapimod A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY) Treatment 3 Active Not Recruiting NCT04511819 2020-08-28 Janssen COVID-19 Vaccine A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older Prevention 2 Active Not Recruiting NCT04535453 2020-08-28 Ivermectin Ivermectin as a potential treatment for COVID 19 : A double blind randomized placebo-controlled trial Treatment Not Available Active Not Recruiting CTRI/2020/08/027225 2020-08-27 Nitazoxanide The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk : a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting Treatment 2, 3 Active Not Recruiting NCT04523090 2020-08-27 Dexamethasone Higher vs. Lower Doses of Dexamethasone in Patients With COVID-19 and Severe Hypoxia Treatment 3 Active Not Recruiting NCT04509973 2020-08-27 COVID-19 convalescent plasma IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-SARS-CoV2 Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04524507 2020-08-27 V591 A Phase 1 / Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants Prevention 1, 2 Active Not Recruiting NCT04498247 2020-08-27 Bacillus calmette-guerin substrain danish 1331 live antigen BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT SERIOUS RESPIRATORY TRACT INFECTION AND COVID-19 IN VULNERABLE ELDERLY – AN ADAPTIVE RANDOMIZED CONTROLLED TRIAL - BCG-PRIME Treatment 4 Unknown Status EUCTR2020-003470-47-NL 2020-08-27 Sotrovimab A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients Treatment 2, 3 Active Not Recruiting NCT04545060 2020-08-26 Dexamethasone Timing of Corticosteroids in COVID-19 Treatment 4 Active Not Recruiting NCT04530409 2020-08-26 AstraZeneca COVID-19 Vaccine A Phase III Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 Prevention 3 Active Not Recruiting NCT04540393 2020-08-25 Opaganib Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2 / 3 Study, in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia - - Treatment 2 Active Not Recruiting EUCTR2020-002677-95-IT 2020-08-25 Cenicriviroc Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Treatment 2 Active Not Recruiting NCT04500418 2020-08-25 COVID-19 convalescent plasma Phase 2b / 3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients. Treatment 2, 3 Active Not Recruiting NCT04388410 2020-08-25 BCG vaccine Bacillus Calmette-Guérin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial Prevention 4 Active Not Recruiting NCT04537663 2020-08-24 Placental Mesenchymal Stem Cells DSC-COVID-19 : An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19 Treatment Not Available Active Not Recruiting NCT04451291 2020-08-24 CYP-001 A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04537351 2020-08-24 AdimrSC-2f A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers Prevention 1 Active Not Recruiting NCT04522089 2020-08-24 FINLAY-FR-1 Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01 Treatment 1, 2 Active Not Recruiting RPCEC00000332 2020-08-24 OM85 Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85 Prevention 3 Active Not Recruiting NCT04496245 2020-08-24 AstraZeneca COVID-19 Vaccine A Phase 2 / 3, Observer-Blind, Randomized, Controlled Study to Determine the Safety and Immunogenicity of Covishield (COVID-19 Vaccine) in Healthy Indian Adults - ICMR / SII-COVISHIELD Treatment 2, 3 Active Not Recruiting CTRI/2020/08/027170 2020-08-23 AstraZeneca COVID-19 Vaccine A Phase I / II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 Prevention 1, 2 Active Not Recruiting NCT04568031 2020-08-22 Melatonin Evaluation of the efficacy and safety of Melatonin in patients with COVID-19 : a randomized clinical trial Treatment 3 Active Not Recruiting IRCT20200506047323N5 2020-08-22 Sodium chloride Evaluating the effectiveness of intravenous ozonized saline in treatment of severe COVID-19 disease : A randomized Control trial Treatment 3 Active Not Recruiting IRCT20200730048253N1 2020-08-22 Ozone Evaluating the effectiveness of intravenous ozonized saline in treatment of severe COVID-19 disease : A randomized Control trial Treatment 3 Active Not Recruiting IRCT20200730048253N1 2020-08-22 Hydroxychloroquine Evaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatment Treatment 3 Active Not Recruiting IRCT20200718048129N1 2020-08-22 Clarithromycin Evaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatment Treatment 3 Active Not Recruiting IRCT20200718048129N1 2020-08-22 Garlic The effect of garlic and cinnamon essential oil on the treatment of patients with corona (COVID-19) Treatment Not Available Active Not Recruiting IRCT20200705048011N1 2020-08-22 Cinnamon The effect of garlic and cinnamon essential oil on the treatment of patients with corona (COVID-19) Treatment Not Available Active Not Recruiting IRCT20200705048011N1 2020-08-22 Ivermectin Evaluation effects of the standard regimen along with ivermectin on treatment of corona virus type 2 pneumonia Treatment 3 Active Not Recruiting IRCT20190624043993N2 2020-08-22 Isotretinoin The evaluation of isotretinoin effects on treatment of COVID-19 infections Treatment 3 Active Not Recruiting IRCT20190624043993N3 2020-08-22 Ethanol Prophylaxis and treatment of COVID-19 using a nasal spray containing 3% dimethyl sulfoxide (DMSO) and 20% ethanol solution Treatment 3 Recruiting IRCT20200727048217N1 2020-08-22 Dimethyl sulfoxide Prophylaxis and treatment of COVID-19 using a nasal spray containing 3% dimethyl sulfoxide (DMSO) and 20% ethanol solution Treatment 3 Recruiting IRCT20200727048217N1 2020-08-22 Diphenhydramine Clinical Trial on Diphenhydramine Compound in Covid-19 Treatment Treatment 3 Recruiting IRCT20200504047298N3 2020-08-22 Water Evaluation of the effect of inhaled solution based on silver colloid with the brand name colloide silver nasal spray 10ppm to control COVID-19-induced lung infection and increase patients' respiratory volume Treatment 3 Active Not Recruiting IRCT20190226042851N1 2020-08-22 Silver Evaluation of the effect of inhaled solution based on silver colloid with the brand name colloide silver nasal spray 10ppm to control COVID-19-induced lung infection and increase patients' respiratory volume Treatment 3 Active Not Recruiting IRCT20190226042851N1 2020-08-22 Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine A randomized, observer-blind, placebo-controlled, Phase I / II study to evaluate the safety, reactogenicity and immunogenicity of Receptor Binding Domain (RBD) SARS-CoV-2 (COVID-19) Hepatitis B surface antigen (HBsAg) virus like particle (VLP) Vaccine in Healthy Adults Treatment 1, 2 Active Not Recruiting ACTRN12620000817943 2020-08-22 Vadadustat Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treatment 2 Active Not Recruiting NCT04478071 2020-08-21 Opaganib Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2 / 3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia Treatment 2, 3 Active Not Recruiting NCT04467840 2020-08-21 COVID-19 convalescent plasma Study to assess and establish safety of convalescent plasma (CVP) drawn from mild symptomatic COVID-19 patients. - mCCP Basic Science Not Available Active Not Recruiting CTRI/2020/08/027285 2020-08-20 Glycine Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation Treatment Not Available Active Not Recruiting NCT04443673 2020-08-20 Atorvastatin Effect of atorvastatin on mortality rate and symptom improvement in hospitalized patients with COVID-19 Treatment 2 Recruiting IRCT20190831044653N5 2020-08-20 Interferon beta-1a the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 Treatment 2 Active Not Recruiting NCT04521400 2020-08-20 Cyclosporine Randomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of Covid-19(+) Non-ICU Hospital Inpatients Treatment 2 Active Not Recruiting NCT04492891 2020-08-20 COVID-19 convalescent plasma PERUCONPLASMA : Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04497324 2020-08-20 Favipiravir A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients Treatment 3 Active Not Recruiting NCT04529499 2020-08-20 CHO Cells Recombinant Vaccine A randomized, double-blind, placebo-controlled phase I clinical trial for evaluation of the safety and tolerability of recombinant novel coronavirus vaccines (CHO cells) in healthy people aged 60 years and above Prevention 1 Active Not Recruiting ChiCTR2000035691 2020-08-20 Inosine pranobex An Open-Label, Prospective, Randomized, Comparative, Parallel Group, Multi-Center, Proof of Concept Study to Assess the Efficacy and Safety of Inosine Pranobex Added to Current Standard of Care (CSC) in COVID-19 Patients. Treatment 2 Active Not Recruiting CTRI/2020/08/027162 2020-08-19 Cysteine Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia Treatment Not Available Active Not Recruiting NCT04570254 2020-08-19 Pentoxifylline Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia Treatment Not Available Active Not Recruiting NCT04570254 2020-08-19 Ascorbic acid Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia Treatment Not Available Active Not Recruiting NCT04570254 2020-08-19 Melatonin Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia Treatment Not Available Active Not Recruiting NCT04570254 2020-08-19 Vitamin E Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia Treatment Not Available Active Not Recruiting NCT04570254 2020-08-19 Chloroquine A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 Treatment 3 Active Not Recruiting NCT04303299 2020-08-19 Lopinavir A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 Treatment 3 Active Not Recruiting NCT04303299 2020-08-19 Oseltamivir A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 Treatment 3 Active Not Recruiting NCT04303299 2020-08-19 Darunavir A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 Treatment 3 Active Not Recruiting NCT04303299 2020-08-19 Ritonavir A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 Treatment 3 Active Not Recruiting NCT04303299 2020-08-19 Favipiravir A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19 Treatment 3 Active Not Recruiting NCT04303299 2020-08-19 Bamlanivimab Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID) Treatment 2, 3 Active Not Recruiting NCT04518410 2020-08-19 Ivermectin Ivermectin to Prevent Hospitalizations in COVID-19 : Randomized, Double-blind, Placebo-controlled Treatment 2, 3 Active Not Recruiting NCT04529525 2020-08-19 Pediococcus acidilactici Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota : A Randomized Clinical Trial Treatment Not Available Active Not Recruiting NCT04517422 2020-08-19 Lactobacillus plantarum Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota : A Randomized Clinical Trial Treatment Not Available Active Not Recruiting NCT04517422 2020-08-19 Collagen-polyvinylpyrrolidone Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial Treatment 1 Active Not Recruiting NCT04517162 2020-08-18 Ozone Study of intra-venous ozonated auto-hemotherapy on severe cases of COVID-19 : A randomized clinical trial Treatment Not Available Active Not Recruiting IRCT20200616047792N1 2020-08-18 COVID-19 convalescent plasma Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support Treatment 2 Active Not Recruiting NCT04528368 2020-08-18 Fenofibrate FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 Treatment Not Available Active Not Recruiting NCT04517396 2020-08-18 AZD7442 A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults Treatment 1 Active Not Recruiting NCT04507256 2020-08-18 Dexamethasone Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia : the COVID STEROID 2 trial - COVID STEROID 2 Treatment 3 Active Not Recruiting EUCTR2020-003363-25-DK 2020-08-18 Sargramostim A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia Treatment 2 Active Not Recruiting NCT04411680 2020-08-18 Rosuvastatin Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial Treatment 2, 3 Active Not Recruiting NCT04359095 2020-08-18 Tenofovir Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial Treatment 2, 3 Active Not Recruiting NCT04359095 2020-08-18 Colchicine Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial Treatment 2, 3 Active Not Recruiting NCT04359095 2020-08-18 Emtricitabine Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled Trial Treatment 2, 3 Active Not Recruiting NCT04359095 2020-08-18 OM85 Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85 Treatment 3 Active Not Recruiting ACTRN12620000473965 2020-08-18 Oxygen Multicenter, prospective, randomized, double-blind clinical trial for the use of Hyperbaric Oxygen Therapy in patients hospitalized with Covid-19 Treatment Not Available Active Not Recruiting RBR-2fvjjm 2020-08-17 Matrix-M A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV Prevention 2 Active Not Recruiting NCT04533399 2020-08-17 Nuvaxovid A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV Prevention 2 Active Not Recruiting NCT04533399 2020-08-17 Zinc citrate Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study Treatment Not Available Active Not Recruiting ACTRN12620000557932 2020-08-17 Cholecalciferol Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study Treatment Not Available Active Not Recruiting ACTRN12620000557932 2020-08-17 Hydroxychloroquine Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study Treatment Not Available Active Not Recruiting ACTRN12620000557932 2020-08-17 Ascorbic acid Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study Treatment Not Available Active Not Recruiting ACTRN12620000557932 2020-08-17 Mecobalamin Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE Study Treatment Not Available Active Not Recruiting ACTRN12620000557932 2020-08-17 AstraZeneca COVID-19 Vaccine A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 Treatment 3 Active Not Recruiting NCT04516746 2020-08-17 Acetylcysteine Safety and efficacy of intranasal delivery of BromAc® (Bromelain & Acetylcysteine) in swab positive SARS-CoV-2 patients – inactivating the COVID-19 virus by cleavage of the spike and other glycoproteins Treatment 1 Active Not Recruiting ACTRN12620000788976 2020-08-17 Bromelains Safety and efficacy of intranasal delivery of BromAc® (Bromelain & Acetylcysteine) in swab positive SARS-CoV-2 patients – inactivating the COVID-19 virus by cleavage of the spike and other glycoproteins Treatment 1 Active Not Recruiting ACTRN12620000788976 2020-08-17 Citrus bioflavonoids A single centric, prospective, open label, interventional study to evaluate the efficacy and safety of CitriobioShield as an adjunct with standard of care therapy in improving immunity in mild to moderate COVID 19 patients through inhalation of fog. Treatment Not Available Active Not Recruiting CTRI/2020/08/027085 2020-08-17 Mumps virus strain B level jeryl lynn live antigen Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / Inflammation Prevention 3 Active Not Recruiting NCT04475081 2020-08-17 Rubella virus vaccine Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / Inflammation Prevention 3 Active Not Recruiting NCT04475081 2020-08-17 Measles virus vaccine live attenuated Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / Inflammation Prevention 3 Active Not Recruiting NCT04475081 2020-08-16 Silibinin Trial of Silymarin in Adults With COVID-19 Pneumonia Treatment 3 Active Not Recruiting NCT04394208 2020-08-15 Sirolimus Efficacy and Safety of Sirolimus for Treating COVID-19 Infection Treatment 2 Active Not Recruiting NCT04461340 2020-08-15 Methylene blue Methylene Blue for the Treatment of COVID-19 : A Randomized Clinical Trial Treatment 3 Recruiting IRCT20090701002113N2 2020-08-15 Lopinavir Preventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-Surg Treatment 3, 4 Active Not Recruiting CTRI/2020/06/026196 2020-08-15 Ritonavir Preventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-Surg Treatment 3, 4 Active Not Recruiting CTRI/2020/06/026196 2020-08-15 Oxygen High Flow Nasal Oxygen Versus Continuous Positive Airway Pressure Helmet Evaluation : A Randomized Crossover Trial in COVID-19 Pneumonia Supportive Care Not Available Active Not Recruiting NCT04381923 2020-08-15 Povidone-iodine Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers Treatment 1, 2 Active Not Recruiting NCT04347954 2020-08-15 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins COVID-19 Stem Cell Therapy : A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells Treatment 1 Active Not Recruiting NCT04486001 2020-08-15 Epoprostenol Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation Treatment 2 Active Not Recruiting NCT04452669 2020-08-14 Ascorbic acid Lessening Organ Dysfunction With VITamin C - COVID Treatment 3 Active Not Recruiting NCT04401150 2020-08-14 COVID-19 convalescent plasma Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection Treatment 2 Active Not Recruiting NCT04513158 2020-08-13 Pentoxifylline Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients Treatment 1, 2 Active Not Recruiting NCT04433988 2020-08-13 Nafamostat Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal Treatment 3 Active Not Recruiting NCT04390594 2020-08-13 Nitazoxanide Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19 Treatment 3 Active Not Recruiting NCT04486313 2020-08-13 Rivaroxaban A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection Treatment 3 Active Not Recruiting NCT04508023 2020-08-13 Thymalfasin A Prospective, Single-Center, Investigator Initiated Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α-1 (Tα1) in severe COVID-19 patients Treatment Not Available Active Not Recruiting CTRI/2020/08/027061 2020-08-12 Zinc chloride A Phase 2 evaluation of the efficacy of homoeopathic remedy Zincum Muriaticum as an adjuvant therapy to standard of care in adult patients with moderate to severe COVID-19 : Randomized, double-blind, parallel group, placebo controlled, multicenter trial (ZIMCOV) Treatment 2 Active Not Recruiting CTRI/2020/08/027005 2020-08-12 COVID-19 convalescent plasma Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19 Treatment 2 Active Not Recruiting NCT04438057 2020-08-12 Cholecalciferol Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients Treatment 4 Active Not Recruiting NCT04411446 2020-08-12 Vitamin D Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients Treatment 4 Active Not Recruiting NCT04411446 2020-08-12 AZD-1656 A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 Treatment 2 Active Not Recruiting NCT04516759 2020-08-11 Hydroxychloroquine Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator Trial Treatment 2 Active Not Recruiting NCT04387760 2020-08-11 Favipiravir Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator Trial Treatment 2 Active Not Recruiting NCT04387760 2020-08-11 COVID-19 convalescent plasma Clinical-trial of COVID-19 Convalescent Plasma in Outpatients Treatment 3 Active Not Recruiting NCT04355767 2020-08-11 Janssen COVID-19 Vaccine A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults Prevention 1 Active Not Recruiting NCT04509947 2020-08-11 Cepeginterferon alfa-2B A Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - a2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19) Treatment 2 Active Not Recruiting NCT04480138 2020-08-11 Remdesivir Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - Discovery Treatment 3 Active Not Recruiting EUCTR2020-000936-23-PT 2020-08-11 CIGB-258 peptide Evaluation of the effect and safety of the CIGB-258 peptide in the treatment of seriously or critically ill patients due to COVID-19. (COVID-19) Treatment 2 Completed RPCEC00000330 2020-08-11 Melatonin A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection Treatment 2 Active Not Recruiting NCT04474483 2020-08-10 GRAd-COV2 A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects Prevention 1 Active Not Recruiting NCT04528641 2020-08-10 BCG vaccine COVID-19 : BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Treatment 4 Active Not Recruiting NCT04369794 2020-08-10 Inactivated SARS-Cov-2 Vaccine A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia Prevention 3 Active Not Recruiting NCT04508075 2020-08-10 TMV-083 A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase Prevention 1 Active Not Recruiting NCT04497298 2020-08-10 Deferoxamine Evaluation of the effects of Desferal on clinical symptoms in patients with COVID-19 Treatment 2, 3 Active Not Recruiting IRCT20200506047323N4 2020-08-10 Placental Mesenchymal Stem Cells A Phase 1 clinical trial of intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with novel COVID-19 virus pneumonia. Treatment 1 Active Not Recruiting CTRI/2020/08/027043 2020-08-10 Human Umbilical Cord Mesenchymal Stem Cells A Phase 1 clinical trial of intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with novel COVID-19 virus pneumonia. Treatment 1 Active Not Recruiting CTRI/2020/08/027043 2020-08-09 Curcumin Curcumin for COVID-19 Pre Exposure Prophylaxis : A Randomised Controlled Trail Treatment 4 Active Not Recruiting CTRI/2020/07/026820 2020-08-08 COVID-19 convalescent plasma Convalescent Plasma for Patients With COVID-19 : A Randomized, Single Blinded, Parallel, Controlled Clinical Study Treatment 2, 3 Active Not Recruiting NCT04332835 2020-08-08 Mometasone furoate Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients Treatment 3 Active Not Recruiting NCT04484493 2020-08-07 Icosapent ethyl A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE) Prevention 4 Active Not Recruiting NCT04505098 2020-08-07 COVID-19 convalescent plasma CSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19 Basic Science Not Available Active Not Recruiting NCT04545047 2020-08-07 XAV-19 A randomized, double-blind, placebo-controlled phase 2a and 2b study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia - POLYCOR Treatment 1 Active Not Recruiting EUCTR2020-002574-27-FR 2020-08-07 MW33 A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW33 Injection in Healthy Subjects Treatment 1 Active Not Recruiting NCT04533048 2020-08-06 Conestat alfa Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 : a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19). Treatment 2 Active Not Recruiting NCT04414631 2020-08-05 BCG vaccine To evaluate efficacy of Bacillus Calmette-Guerin (BCG) in Reducing the Incidence and severity of COVID-19 in the high-risk population (BRIC) : a phase III, Multicentric, Quadruple blind Randomized controlled trial Treatment Not Available Active Not Recruiting CTRI/2020/07/026668 2020-08-05 Curcumin Investigating the effect of curcumin-piperine supplementation in accelerating the recovery period of patients with covid-19 Treatment 3 Active Not Recruiting IRCT20200514047445N1 2020-08-05 Peginterferon lambda-1a Pegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot Trial Treatment 2 Active Not Recruiting NCT04534673 2020-08-05 Clopidogrel A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients Prevention 4 Active Not Recruiting NCT04409834 2020-08-05 Enoxaparin A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients Prevention 4 Active Not Recruiting NCT04409834 2020-08-05 Heparin A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients Prevention 4 Active Not Recruiting NCT04409834 2020-08-05 Ifenprodil A Randomized Open Label Phase 2b / 3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease Treatment 2, 3 Active Not Recruiting NCT04382924 2020-08-05 Omega-3 fatty acids The Effect of Omega-3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People Prevention Not Available Active Not Recruiting NCT04483271 2020-08-05 Anti-SARS-CoV-2 immunoglobulin A Phase 1 / 2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia Treatment 1, 2 Active Not Recruiting NCT04550325 2020-08-05 BCG vaccine BCG revaccination of health care professionals working in the COVID-19 pandemic, a preventive strategy to improve innate immune response Treatment Not Available Active Not Recruiting RBR-4kjqtg 2020-08-05 Angiotensin 1-7 Randomized clinical trial phase I / II for the use of angiotensin-(1-7) in the treatment of severe infection by Sara-CoV-2 Treatment 1, 2 Active Not Recruiting RBR-35734p 2020-08-05 Cholecalciferol The Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D Deficiency Prevention Not Available Active Not Recruiting NCT04476745 2020-08-04 Remdesivir A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3) Treatment 3 Active Not Recruiting NCT04492475 2020-08-04 Interferon beta-1a A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3) Treatment 3 Active Not Recruiting NCT04492475 2020-08-04 Bamlanivimab A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04501978 2020-08-04 Remdesivir A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04501978 2020-08-03 Turmeric Efficacy of Ayurvedic Medicine Haldi 30 drops as an Add on medication to standard of care in adult patients of mild to moderate COVID 19. A Phase II randomized, single - blind, parallel group, placebo - controlled trial. Treatment 2 Active Not Recruiting CTRI/2020/07/026841 2020-08-03 Aloe vera leaf A clinical study to evaluate the efficacy of tablet of Aloe Vera gel (Aloe barbadenesis),Mur Makki (Commiphora myrrha) and Sanna-e-Makki (Senna Alexandrina) in the management of mild cases of confirmed Covid -19 Treatment Not Available Active Not Recruiting CTRI/2020/07/026669 2020-08-03 Losartan RAAS blockagE in SARS COV-2 Critically ill patiEnts– a Randomized controlled trial Treatment 4 Active Not Recruiting ISRCTN48734830 2020-08-03 Remestemcel-L Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation Treatment 1 Active Not Recruiting NCT04397796 2020-08-03 Platelet Lysate Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome Treatment Not Available Active Not Recruiting NCT04487691 2020-08-03 Ruxolitinib PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM (RUXCOVID) Treatment 3 Active Not Recruiting PER-030-20 2020-08-03 Fisetin COVID-FISETIN : A Phase 2 Placebo-Controlled Pilot Study in Covid-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults Treatment 2 Active Not Recruiting NCT04476953 2020-08-02 Methylprednisolone The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19 Treatment 3 Active Not Recruiting NCT04499313 2020-08-02 Dexamethasone The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19 Treatment 3 Active Not Recruiting NCT04499313 2020-08-02 Bamlanivimab A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff ; a NIAID and Lilly Collaborative Study Prevention 3 Active Not Recruiting NCT04497987 2020-08-01 COVID-19 convalescent plasma A randomized control trial comparing convalescent plasma therapy plus standard treatment versus standard treatment alone in patients with severe COVID-19 pneumonia at a tertiary hospital Treatment 3 Active Not Recruiting PACTR202007653923168 2020-08-01 Centella asiatica Survey on depression, anxiety and stress during Covid-19 in general population of Hassan district and its management with Brahmi (Bacopa monnieri (L.) Pennell) - DAS-COVID-19-AYU Treatment 2, 3 Active Not Recruiting CTRI/2020/07/026952 2020-08-01 Favipiravir An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection Treatment 2 Active Not Recruiting NCT04445467 2020-08-01 Acetylcysteine Pilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19 Treatment 3 Active Not Recruiting NCT04455243 2020-08-01 Acetylsalicylic acid A Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial) - RESIST Trial Treatment 2, 3 Active Not Recruiting CTRI/2020/07/026791 2020-08-01 Atorvastatin A Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial) - RESIST Trial Treatment 2, 3 Active Not Recruiting CTRI/2020/07/026791 2020-08-01 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins Clinical Study for the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus 2019 (COVID-19) Treatment 2 Active Not Recruiting NCT04428801 2020-08-01 Abivertinib A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19 Treatment 2 Active Not Recruiting NCT04440007 2020-08-01 Betamethasone Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease Treatment 1 Active Not Recruiting NCT04569825 2020-08-01 Camostat The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Treatment 1, 2 Active Not Recruiting NCT04435015 2020-08-01 COVID-19 convalescent plasma Phase I Study of the Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2 Treatment 1 Active Not Recruiting NCT04462848 2020-08-01 Nelfinavir Clinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian Patients Treatment 2 Active Not Recruiting NCT04471662 2020-08-01 Favipiravir Clinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian Patients Treatment 2 Active Not Recruiting NCT04471662 2020-08-01 Daclatasvir Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients Treatment 2, 3 Active Not Recruiting NCT04460443 2020-08-01 Sofosbuvir Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients Treatment 2, 3 Active Not Recruiting NCT04460443 2020-08-01 Ledipasvir Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients Treatment 2, 3 Active Not Recruiting NCT04460443 2020-08-01 Cholecalciferol Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19 Treatment 2 Active Not Recruiting CTRI/2020/06/026191 2020-08-01 Vitamin K7 Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19 Treatment 2 Active Not Recruiting CTRI/2020/06/026191 2020-08-01 Menadione Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19 Treatment 2 Active Not Recruiting CTRI/2020/06/026191 2020-08-01 Magnesium Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19 Treatment 2 Active Not Recruiting CTRI/2020/06/026191 2020-08-01 Menaquinone 6 Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19 Treatment 2 Active Not Recruiting CTRI/2020/06/026191 2020-08-01 Magnesium glycinate Randomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - Covid Treatment 2 Active Not Recruiting CTRI/2020/06/026189 2020-08-01 Vitamin D Randomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - Covid Treatment 2 Active Not Recruiting CTRI/2020/06/026189 2020-08-01 Rivaroxaban Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19) Prevention 3 Active Not Recruiting NCT04416048 2020-08-01 Placental Mesenchymal Stem Cells A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19 Treatment 2 Active Not Recruiting NCT04389450 2020-08-01 Protoporphyrin Efficacy of Based MRI Contrast Media Against Covid-19 Treatment 1 Active Not Recruiting NCT04371822 2020-08-01 Angiotensin 1-7 Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19 Treatment 2 Active Not Recruiting NCT04401423 2020-08-01 Ad5-nCoV A Randomized, Observer-Blind, Dose-escalation Phase I / II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada Prevention 1, 2 Active Not Recruiting NCT04398147 2020-08-01 Remestemcel-L Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID19-Induced ARDS : A Randomized, Controlled Study Treatment 1 Active Not Recruiting NCT04345601 2020-08-01 Chlorpromazine Administration of Chlorpromazine as a Treatment for COVID-19 Treatment 2, 3 Active Not Recruiting NCT04354805 2020-08-01 Niclosamide Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy Volunteers Treatment 1 Active Not Recruiting NCT04524052 2020-08-01 Heparin Intranasal Heparin Tolerability Study Prevention 1 Active Not Recruiting NCT04490239 2020-08-01 Sildenafil Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch : A Pilot Randomised Trial Treatment 1, 2 Active Not Recruiting NCT04489446 2020-08-01 Duvelisib Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection Treatment 2 Active Not Recruiting NCT04487886 2020-08-01 COVID-19 convalescent plasma Assessment of the Safety of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness Treatment 1 Active Not Recruiting NCT04516954 2020-08-01 Dexamethasone Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04513184 2020-08-01 Ebselen A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients Treatment 2 Active Not Recruiting NCT04484025 2020-08-01 Ebselen A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients Treatment 2 Active Not Recruiting NCT04483973 2020-08-01 Rivaroxaban A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19 Treatment 2 Active Not Recruiting NCT04504032 2020-08-01 COVID-19 convalescent plasma A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos State Treatment 2 Active Not Recruiting PACTR202006760881890 2020-08-01 Allocetra A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction Prevention 1 Active Not Recruiting NCT04513470 2020-08-01 Telmisartan Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19 Treatment 2 Active Not Recruiting NCT04510662 2020-08-01 Povidone-iodine Phase I / II Trial (Safety and Dosing) of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects Prevention 1, 2 Active Not Recruiting NCT04510402 2020-08-01 COVID-19 convalescent plasma Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis / Plasmaféresis terapéutica en Pacientes Adultos críticamente Enfermos Con diagnóstico Confirmado de COVID-19 Treatment 2 Active Not Recruiting NCT04480632 2020-08-01 Favipiravir A Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Currently Used Therapy in Severe Adults With COVID-19 Treatment 2 Active Not Recruiting NCT04475991 2020-08-01 Maraviroc A Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Currently Used Therapy in Severe Adults With COVID-19 Treatment 2 Active Not Recruiting NCT04475991 2020-08-01 Rosuvastatin Colchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial Treatment 3 Active Not Recruiting NCT04472611 2020-08-01 Colchicine Colchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial Treatment 3 Active Not Recruiting NCT04472611 2020-08-01 Famotidine Role of Famotidine in the Symptomatic Improvement of Moderate to Severe COVID-19 Patients Treatment 3 Active Not Recruiting NCT04504240 2020-08-01 Opaganib Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen But Not Mechanical Ventilation Treatment 1, 2 Active Not Recruiting NCT04502069 2020-08-01 Efineptakin alfa A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19 Treatment 1 Active Not Recruiting NCT04501796 2020-08-01 Apixaban COVID-19 Outpatient Thrombosis Prevention Trial : A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis Prevention 3 Active Not Recruiting NCT04498273 2020-08-01 Acetylsalicylic acid COVID-19 Outpatient Thrombosis Prevention Trial : A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis Prevention 3 Active Not Recruiting NCT04498273 2020-08-01 Otilimab A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease Treatment 2 Active Not Recruiting PER-042-20 2020-08-01 Linagliptin Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04542213 2020-08-01 COVID-19 convalescent plasma A Randomized, Double-blind, Placebo-controlled Trial of Anti-SARS-CoV-2 Plasma in Hospitalized Non-ICU Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04467151 2020-08-01 Abatacept Abatacept for Patients With COVID-19 and Respiratory Distress Treatment 1, 2 Active Not Recruiting NCT04477642 2020-07-31 Clove Clinical trials to evaluate prophylactic action of Twakadi herbal tea in police professionals working in COVID19 pandemic Treatment 3, 4 Active Not Recruiting CTRI/2020/07/026925 2020-07-31 Indian frankincense A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC Treatment 2 Active Not Recruiting CTRI/2020/07/026789 2020-07-31 Artemisinin A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC Treatment 2 Active Not Recruiting CTRI/2020/07/026789 2020-07-31 Curcumin A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC Treatment 2 Active Not Recruiting CTRI/2020/07/026789 2020-07-31 Ascorbic acid A Phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 - ArtemiC Treatment 2 Active Not Recruiting CTRI/2020/07/026789 2020-07-31 Ivermectin Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19 Treatment 2 Active Not Recruiting NCT04438850 2020-07-31 Tenofovir alafenamide Randomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) Prevention 3 Active Not Recruiting NCT04405271 2020-07-31 Emtricitabine Randomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) Prevention 3 Active Not Recruiting NCT04405271 2020-07-31 Ivermectin Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission Treatment 2 Active Not Recruiting NCT04390022 2020-07-31 AZD-1656 A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCADIA Trial - ARCADIA Treatment 2 Active Not Recruiting EUCTR2020-002211-21-GB 2020-07-31 Icatibant I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients Treatment 2 Active Not Recruiting NCT04488081 2020-07-31 Remdesivir I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients Treatment 2 Active Not Recruiting NCT04488081 2020-07-31 Apremilast I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients Treatment 2 Active Not Recruiting NCT04488081 2020-07-31 Cenicriviroc I-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients Treatment 2 Active Not Recruiting NCT04488081 2020-07-31 Cholecalciferol The Role of Vitamin D in Mitigating COVID-19 Infection Severity : Focusing on Reducing Health Disparities in South Carolina Prevention 4 Active Not Recruiting NCT04482673 2020-07-31 Ascorbic acid A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm Treatment 2 Active Not Recruiting IRCT20200525047570N1 2020-07-31 Tocilizumab A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm Treatment 2 Active Not Recruiting IRCT20200525047570N1 2020-07-31 Interferon Gamma A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm Treatment 2 Active Not Recruiting IRCT20200525047570N1 2020-07-31 Acalabrutinib An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19 Treatment 1 Active Not Recruiting NCT04497948 2020-07-30 Nuvaxovid A Phase 2A / B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV. COVID-19 Treatment 2 Recruiting PACTR202009726132275 2020-07-30 COVID-19 convalescent plasma Compassionate Use of Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Prospective Observational Study (Amended Protocol) Basic Science Not Available Active Not Recruiting NCT04570982 2020-07-30 Human Umbilical Cord Mesenchymal Stem Cells Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) Treatment 2 Active Not Recruiting NCT04466098 2020-07-30 Lithium carbonate A randomized control study to evaluate the therapeutic effects of Lithium in Covid-19 patients Treatment Not Available Active Not Recruiting CTRI/2020/06/026193 2020-07-30 Thimerosal A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection Treatment 2 Active Not Recruiting NCT04522830 2020-07-30 Tocilizumab A Nested Interventional Cohort Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin-6 Receptor Blocker Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation Related Mortality in SARS-Cov2 Positive Patients Treatment 3 Active Not Recruiting NCT04423042 2020-07-30 Recombinant human plasma gelsolin A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia Treatment 2 Active Not Recruiting NCT04358406 2020-07-30 Enoxaparin Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04486508 2020-07-30 Atorvastatin Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04486508 2020-07-30 Heparin Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04486508 2020-07-30 Ivermectin Evaluating the efficacy and safety of Ivermectin in the treatment of COVID-19 patients : A double-blind randomized controlled trial, phase II Treatment 2 Recruiting IRCT20200404046937N4 2020-07-30 Aviptadil RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol Treatment Not Available Active Not Recruiting NCT04453839 2020-07-30 RUTI® Vaccine Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI® Vaccine to Prevent SARS-CoV-2 Infection Prevention 3 Active Not Recruiting NCT04453488 2020-07-29 Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media Emergency Use Pilot Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of COVID-19 Related Acute Respiratory Distress Syndrome Treatment 1 Active Not Recruiting NCT04565665 2020-07-29 Tofacitinib Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC) Treatment 2 Active Not Recruiting NCT04415151 2020-07-29 Sitagliptin The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Treatment 3 Active Not Recruiting NCT04365517 2020-07-29 Anakinra Early Treatment of Cytokine Storm Syndrome in Covid-19 Treatment 3 Active Not Recruiting NCT04362111 2020-07-29 Ribavirin An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection Treatment 2 Active Not Recruiting NCT04494399 2020-07-29 Interferon beta-1b An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection Treatment 2 Active Not Recruiting NCT04494399 2020-07-28 Camostat RECOVER : Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor Treatment 2 Active Not Recruiting NCT04470544 2020-07-28 Nimesulide The role of Nimesulide in the treatment of COVID-19 infection Treatment Not Available Active Not Recruiting IRCT20200723048178N1 2020-07-27 Oxygen Comparison of High Flow Nasal Oxygen and Non Invasive Ventilation in Acute Hypoxemic Respiratory Failure due to Severe COVID-19 pneumonia : A Randomized Controlled Trial Treatment 3, 4 Active Not Recruiting CTRI/2020/07/026835 2020-07-27 Chloroquine Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients Prevention 1 Active Not Recruiting NCT04443270 2020-07-27 Turmeric "Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ?? Treatment 1 Active Not Recruiting CTRI/2020/07/026674 2020-07-27 Ginger "Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ?? Treatment 1 Active Not Recruiting CTRI/2020/07/026674 2020-07-27 Glycyrrhiza glabra "Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ?? Treatment 1 Active Not Recruiting CTRI/2020/07/026674 2020-07-27 Licorice "Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ?? Treatment 1 Active Not Recruiting CTRI/2020/07/026674 2020-07-27 Black pepper "Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ?? Treatment 1 Active Not Recruiting CTRI/2020/07/026674 2020-07-27 Cinnamon "Randomized Clinical Trial of Ayurveda Spice Mix Tablet for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel / High-Risk patientsâ?? Treatment 1 Active Not Recruiting CTRI/2020/07/026674 2020-07-27 Ozone A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment Treatment Not Available Active Not Recruiting CTRI/2020/07/026671 2020-07-27 Dexamethasone Randomized Study Of the Effect of Dexamethasone and Methylprednisolone on levels of IL-6 and clinical outcome in severe COVID-19 - REDMIC Treatment Not Available Active Not Recruiting CTRI/2020/07/026608 2020-07-27 Methylprednisolone Randomized Study Of the Effect of Dexamethasone and Methylprednisolone on levels of IL-6 and clinical outcome in severe COVID-19 - REDMIC Treatment Not Available Active Not Recruiting CTRI/2020/07/026608 2020-07-27 Camostat A Randomised Phase II / III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion Treatment 2, 3 Active Not Recruiting NCT04455815 2020-07-27 EpiVacCorona Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase) Prevention 1, 2 Active Not Recruiting NCT04527575 2020-07-27 Moderna COVID-19 Vaccine A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older Prevention 3 Active Not Recruiting NCT04470427 2020-07-27 Magnesium sulfate Evaluation of the efficacy and safety of inhaled magnesium sulfate in combination with standard treatment in Covid-19 patients : a clinical trial Treatment 3 Recruiting IRCT20191211045691N1 2020-07-27 Nintedanib Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019 : Historical control study. Treatment 2 Active Not Recruiting JPRN-jRCTs051200036 2020-07-27 PlasmaCord Clinical study to evaluate the safety and tolerability of intravenous infusion of plasma from human umbilical cord and placental blood (Plasmacord®) in patients with Severe Acute Respiratory Syndrome resulting from Sars-Cov-2 infection Treatment 1, 2 Active Not Recruiting RBR-4pfygr 2020-07-27 Aspartyl-alanyl-diketopiperazine A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampion™ in Adult COVID-19 Patients Requiring Oxygen Supplementation Treatment 1 Active Not Recruiting NCT04456452 2020-07-27 Mavrilimumab A Phase 2 / 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation Treatment 2, 3 Active Not Recruiting NCT04447469 2020-07-26 Anti-SARS-CoV-2 REGN-COV2 A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers Treatment 1 Active Not Recruiting NCT04519437 2020-07-26 Taraxacum officinale leaf Determination of dandelion herbal capsule (Dandelherb) efficacy on symptom of patient with Covid-19 virus : a clinical trial study Treatment 3 Recruiting IRCT20180513039641N2 2020-07-26 Taraxacum officinale pollen Determination of dandelion herbal capsule (Dandelherb) efficacy on symptom of patient with Covid-19 virus : a clinical trial study Treatment 3 Recruiting IRCT20180513039641N2 2020-07-25 Human Umbilical Cord Mesenchymal Stem Cells Safety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19 Treatment 1 Active Not Recruiting NCT04467047 2020-07-25 DAS-181 DAS181 for COVID-19 : A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Treatment 2, 3 Active Not Recruiting NCT04354389 2020-07-25 Interferon beta-1a Evaluation of the efficacy and safety of Favipiravir and Interferon beta compared to Lopinavir / Ritonavir and Interferon beta in patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200506047323N3 2020-07-25 Favipiravir Evaluation of the efficacy and safety of Favipiravir and Interferon beta compared to Lopinavir / Ritonavir and Interferon beta in patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200506047323N3 2020-07-24 Clazakizumab A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. - CLiCK Study Treatment 2 Active Not Recruiting EUCTR2020-002476-13-GB 2020-07-24 iota-Carrageenan Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02) Prevention 4 Active Not Recruiting NCT04521322 2020-07-24 Nitric Oxide A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients Treatment 1, 2 Active Not Recruiting NCT04476992 2020-07-23 Favipiravir A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19 Treatment 2, 3 Active Not Recruiting NCT04464408 2020-07-23 Human Umbilical Cord Mesenchymal Stem Cells Phase 1 / 2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19 Treatment 1, 2 Active Not Recruiting NCT04494386 2020-07-23 Losartan Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19 Treatment 2 Active Not Recruiting NCT04447235 2020-07-23 Ivermectin Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19 Treatment 2 Active Not Recruiting NCT04447235 2020-07-22 Ibrutinib Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In Treatment 2 Active Not Recruiting NCT04439006 2020-07-22 Copper A Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19. Treatment 3 Active Not Recruiting CTRI/2020/07/026515 2020-07-22 Sodium copper chlorophyllin A Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19. Treatment 3 Active Not Recruiting CTRI/2020/07/026515 2020-07-22 Resveratrol A Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19. Treatment 3 Active Not Recruiting CTRI/2020/07/026515 2020-07-22 Resveratrol A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19. Treatment 2 Active Not Recruiting CTRI/2020/07/026514 2020-07-22 Sodium copper chlorophyllin A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19. Treatment 2 Active Not Recruiting CTRI/2020/07/026514 2020-07-22 Copper A Phase-II, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Symptomatic Or have Pneumonia for Covid 19. Treatment 2 Active Not Recruiting CTRI/2020/07/026514 2020-07-22 Nelfinavir Evaluation of Nelfinavir for asymptomatic and mild COVID-19 : A multicenter open-label, blinded outcome, randomized controlled trial - NFV trial for asymptomatic and mild COVID-19 Treatment 1, 2 Active Not Recruiting JPRN-jRCT2071200023 2020-07-22 Nitrous acid Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite : A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study Treatment 2 Active Not Recruiting NCT04401527 2020-07-22 Human Umbilical Cord Mesenchymal Stem Cells Clinical trial of efficacy and safety of mesenchymal stem cell transplantation in patients with COVID-19 pneumonia Treatment 3 Active Not Recruiting IRCT20200426047206N2 2020-07-22 Cyclosporine Evaluating the effect of Cyclosporine in prognosis and clinical improvement in patients with COVID-19 : A Randomized Clinical Trial Study Treatment 3 Active Not Recruiting IRCT20200426047206N3 2020-07-22 Ivermectin Evaluation of the effect of Ivermectin in hospitalized patients with COVID-19 in Imam Reza Hospital in Mashhad Treatment 3 Active Not Recruiting IRCT20190602043787N3 2020-07-22 Fluvoxamine Effect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU ward Treatment 2, 3 Active Not Recruiting IRCT20131115015405N4 2020-07-22 Mavrilimumab A PHASE 2 / 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAVRILIMUMAB (KPL-301) TREATMENT IN ADULT SUBJECTS HOSPITALIZED WITH SEVERE COVID-19 PNEUMONIA AND HYPER-INFLAMMATION Treatment 2 Recruiting PER-032-20 2020-07-22 Atovaquone Atovaquone for Treatment of COVID-19 Treatment 2 Active Not Recruiting NCT04456153 2020-07-21 BCG vaccine Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial Prevention 3 Active Not Recruiting NCT04461379 2020-07-21 Azadirachta indica leaf Prophylaxis with Neem Capsules (Azadirachta indica) in Healthcare personnel and relatives in Contact with COVID-19 Patients Treatment 3 Active Not Recruiting CTRI/2020/07/026560 2020-07-21 Allogeneic Cardiosphere-Derived Cells A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients With Severe COVID-19 Treatment Not Available Active Not Recruiting NCT04338347 2020-07-21 Leflunomide Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19) - DEFEAT- Covid Study Treatment 2 Active Not Recruiting EUCTR2020-002952-18-GB 2020-07-21 Lopinavir An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19) Treatment 3 Active Not Recruiting NCT04483960 2020-07-21 COVID-19 convalescent plasma An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19) Treatment 3 Active Not Recruiting NCT04483960 2020-07-21 Hydroxychloroquine An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19) Treatment 3 Active Not Recruiting NCT04483960 2020-07-21 Ritonavir An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19) Treatment 3 Active Not Recruiting NCT04483960 2020-07-21 Atorvastatin Evaluation of atorvastatin tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad : A double-blind randomized placebo controlled clinical trial Treatment 2 Active Not Recruiting IRCT20200408046990N3 2020-07-21 Montelukast Effect of Montelukast on inflammatory factors in patients with COVID-19 Treatment 3 Recruiting IRCT20180624040213N2 2020-07-21 Remdesivir A Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19 Treatment 2, 3 Active Not Recruiting NCT04431453 2020-07-21 CoronaVac Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac Prevention 3 Active Not Recruiting NCT04456595 2020-07-20 Aprepitant A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04470622 2020-07-20 Sodium bicarbonate A randomized open label parallel group trial to study the safety and efficacy of steam impregnated with 8.4 % Sodium Bicarbonate in patients with Covid-19 infection Treatment Not Available Active Not Recruiting CTRI/2020/07/026535 2020-07-20 Eflornithine An open label, randomized, three treatment, three arm, parallel group, investigator initiated, comparative clinical trial to evaluate the safety and efficacy of Eflornithine against the standard of care in human adult hospitalized COVID-19 patients Treatment 2, 3 Active Not Recruiting CTRI/2020/07/026529 2020-07-20 Ivermectin Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis Prevention Not Available Active Not Recruiting NCT04384458 2020-07-20 Hydroxychloroquine Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis Prevention Not Available Active Not Recruiting NCT04384458 2020-07-20 Heparin Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial Study Treatment 3 Active Not Recruiting NCT04485429 2020-07-20 Methylprednisolone Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial Study Treatment 3 Active Not Recruiting NCT04485429 2020-07-20 Ritonavir Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial Treatment 2 Active Not Recruiting PACTR202007720062393 2020-07-20 Lopinavir Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical Trial Treatment 2 Active Not Recruiting PACTR202007720062393 2020-07-20 Lopinavir An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19 Treatment 3 Active Not Recruiting PACTR202006537901307 2020-07-20 Ritonavir An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19 Treatment 3 Active Not Recruiting PACTR202006537901307 2020-07-20 Hydroxychloroquine An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19 Treatment 3 Active Not Recruiting PACTR202006537901307 2020-07-20 Abatacept Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise Treatment 2 Active Not Recruiting NCT04472494 2020-07-20 COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection Conducting an Initial Small, Controlled Clinical Trial to Assess for COVID-19 Therapeutic Biologics Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients. Treatment 1 Active Not Recruiting NCT03348670 2020-07-20 BNT162b1 SARS-CoV-2 Vaccine Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects : A Phase I, Randomized, Placebo-controlled, Observer-blind Study Treatment 1 Active Not Recruiting ChiCTR2000034825 2020-07-18 Mometasone Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19 Treatment 1 Recruiting IRCT20200522047542N1 2020-07-17 Ruxolitinib Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection Treatment 2, 3 Active Not Recruiting NCT04477993 2020-07-16 Favipiravir Favipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARE Treatment 2 Active Not Recruiting EUCTR2020-002106-68-GB 2020-07-16 Lopinavir Favipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARE Treatment 2 Active Not Recruiting EUCTR2020-002106-68-GB 2020-07-16 Ritonavir Favipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARE Treatment 2 Active Not Recruiting EUCTR2020-002106-68-GB 2020-07-16 Inactivated SARS-Cov-2 Vaccine Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and above Treatment 3 Recruiting ChiCTR2000034780 2020-07-16 COVID-19 convalescent plasma ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS) Treatment 2 Active Not Recruiting NCT04432272 2020-07-16 Probiorinse Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection Treatment Not Available Active Not Recruiting NCT04458519 2020-07-16 Budesonide Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation Treatment 2 Active Not Recruiting NCT04416399 2020-07-16 Hydroxychloroquine Controlled clinical trial of hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting Treatment 2 Active Not Recruiting EUCTR2020-002038-33-FI 2020-07-16 COVID-19 convalescent plasma Convalescent Plasma for Severe COVID-19 Patients : a Randomized, Open-label, Phase 3 Trial Treatment 3 Active Not Recruiting NCT04547660 2020-07-16 Inactivated SARS-Cov-2 Vaccine Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above Prevention 3 Active Not Recruiting NCT04510207 2020-07-16 Tocilizumab Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 Treatment 2 Active Not Recruiting NCT04476979 2020-07-16 Dexamethasone Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 Treatment 2 Active Not Recruiting NCT04476979 2020-07-15 INO-4800 A Phase I / IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers Prevention 1, 2 Active Not Recruiting NCT04447781 2020-07-15 Omega-3 fatty acids COVID-19 Anosmia Study Treatment 2 Active Not Recruiting NCT04495816 2020-07-15 Apilimod A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19 Treatment 2 Active Not Recruiting NCT04446377 2020-07-15 Oral Polio Vaccine Oral Polio Vaccine as Potential Protection Against COVID-19 : A Cluster-randomised Trial in Guinea-Bissau Prevention 4 Active Not Recruiting NCT04445428 2020-07-15 Janssen COVID-19 Vaccine A Randomized, Double-blind, Placebo-controlled Phase 1 / 2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older Treatment 1, 2 Active Not Recruiting NCT04436276 2020-07-15 Cinnamon â??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â?? Treatment Not Available Active Not Recruiting CTRI/2020/06/026231 2020-07-15 Cow milk â??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â?? Treatment Not Available Active Not Recruiting CTRI/2020/06/026231 2020-07-15 Ginger â??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â?? Treatment Not Available Active Not Recruiting CTRI/2020/06/026231 2020-07-15 Turmeric â??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â?? Treatment Not Available Active Not Recruiting CTRI/2020/06/026231 2020-07-15 Vitamin D Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19 : Open Controlled Clinical Trial Treatment 3 Active Not Recruiting NCT04502667 2020-07-15 Sofosbuvir Efficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled Trial Treatment 4 Active Not Recruiting NCT04498936 2020-07-15 Nitazoxanide Efficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled Trial Treatment 4 Active Not Recruiting NCT04498936 2020-07-15 Ledipasvir Efficacy of Adding Sofosbuvir / Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19 : A Randomized Controlled Trial Treatment 4 Active Not Recruiting NCT04498936 2020-07-15 BCG vaccine BCG vaccine as preventive measure against COVID-19 in health care workers Treatment 2, 3 Active Not Recruiting RBR-5ysj54 2020-07-15 Favipiravir A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Type Treatment 3 Active Not Recruiting EUCTR2020-001608-40-DE 2020-07-15 Vitamin D Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial Treatment 3 Active Not Recruiting NCT04535791 2020-07-15 Cholecalciferol Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial Treatment 3 Active Not Recruiting NCT04535791 2020-07-15 Nitric Oxide Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 Treatment 2 Active Not Recruiting NCT04456088 2020-07-15 Hydroxychloroquine Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19 Treatment Not Available Active Not Recruiting NCT04477083 2020-07-15 Enzalutamide A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19) Treatment 2 Active Not Recruiting NCT04475601 2020-07-14 Iodine Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients Treatment 1, 2 Active Not Recruiting NCT04473261 2020-07-14 Ivermectin Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients Treatment 1, 2 Active Not Recruiting NCT04472585 2020-07-14 Zinc Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients Treatment 1, 2 Active Not Recruiting NCT04472585 2020-07-14 Clofazimine An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection Treatment 2 Active Not Recruiting NCT04465695 2020-07-14 Interferon beta-1b An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection Treatment 2 Active Not Recruiting NCT04465695 2020-07-14 Remdesivir A Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 Treatment 2 Active Not Recruiting EUCTR2020-001803-17-GB 2020-07-14 Colchicine Colchicine in Moderate Symptomatic COVID-19 Patients : Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy Treatment Not Available Active Not Recruiting NCT04527562 2020-07-14 COVID-19 convalescent plasma Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak Treatment 2 Active Not Recruiting NCT04408040 2020-07-14 Ivermectin Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19 Treatment 2, 3 Active Not Recruiting NCT04405843 2020-07-13 Ritonavir TOGETHER 3 Trial : An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults. COVID-19 Treatment 2 Active Not Recruiting PACTR202007700757139 2020-07-13 Lopinavir TOGETHER 3 Trial : An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults. COVID-19 Treatment 2 Active Not Recruiting PACTR202007700757139 2020-07-13 BBV152 An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers Prevention 1, 2 Active Not Recruiting NCT04471519 2020-07-13 Enzalutamide A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) - COVIDENZA Treatment 2 Active Not Recruiting EUCTR2020-002027-10-SE 2020-07-13 Turmeric A clinical study to evaluate the effect of AYUSH medicines in the management of COVID-19 Treatment 3, 4 Active Not Recruiting CTRI/2020/07/026371 2020-07-13 ZYCOV-D A prospective, randomized, adaptive, phase I / II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M / s Cadila Healthcare Limited by intradermal route in healthy subjects Treatment 1, 2 Active Not Recruiting CTRI/2020/07/026352 2020-07-13 Ozone Phase I / II randomized controlled clinical trial to assess safety and efficacy of ozone therapy via rectal insufflation and minor auto haemotherapy as an adjuvant in mild to moderate Covid-19 subjects. - Nil Treatment 1, 2 Active Not Recruiting CTRI/2020/07/026354 2020-07-13 Alkaline Phosphatase Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19) Treatment Not Available Active Not Recruiting NL8578 2020-07-13 Rubella virus vaccine Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial) Prevention 3 Active Not Recruiting NCT04357028 2020-07-13 Measles virus vaccine live attenuated Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial) Prevention 3 Active Not Recruiting NCT04357028 2020-07-13 Mumps virus strain B level jeryl lynn live antigen Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial) Prevention 3 Active Not Recruiting NCT04357028 2020-07-13 SARS-CoV-2 Sclamp A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study To Evaluate The Safety And Immunogenicity Of An Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine (COVID-19 vaccine) In Healthy Adults Aged 18 To 55 Years Old Treatment 1 Active Not Recruiting ACTRN12620000674932 2020-07-13 Clazakizumab A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection Treatment 2 Active Not Recruiting NCT04494724 2020-07-13 Sofosbuvir Evaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : a double-blind randomized clinical trial Treatment 3 Active Not Recruiting IRCT20200624047908N1 2020-07-13 Daclatasvir Evaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : a double-blind randomized clinical trial Treatment 3 Active Not Recruiting IRCT20200624047908N1 2020-07-13 SARS-CoV-2 Sclamp A Phase 1 randomised, double-blind, placebo-controlled, dosage-escalation, single centre study to evaluate the safety and immunogenicity of an adjuvanted SARS-CoV-2 Sclamp protein subunit vaccine (COVID-19 vaccine) In healthy adults aged 18 to 55 years and healthy older adults, aged 56 years and over Treatment 1 Recruiting ISRCTN51232965 2020-07-13 SARS-CoV-2 Sclamp A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over Prevention 1 Active Not Recruiting NCT04495933 2020-07-13 Astegolimab A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA - COVASTIL Treatment 2 Unknown Status EUCTR2020-002713-17-ES 2020-07-13 Efmarodocokin alfa A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA - COVASTIL Treatment 2 Unknown Status EUCTR2020-002713-17-ES 2020-07-12 Nitric Oxide A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19) Treatment 3 Active Not Recruiting NCT04421508 2020-07-12 Favipiravir A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19 Treatment 2 Active Not Recruiting NCT04346628 2020-07-12 CHO Cells Recombinant Vaccine A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years Prevention 2 Active Not Recruiting NCT04466085 2020-07-11 Zinc Prospective study to assess therapeutic role of Zinc in COVID-19 patients Treatment Not Available Active Not Recruiting CTRI/2020/07/026340 2020-07-11 Nafamostat An Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 Disease Treatment 2 Active Not Recruiting CTRI/2020/06/026220 2020-07-11 Dactolisib Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults =65 Years in a Nursing Home in Which =1 Person(s) Have Lab Confirmed COVID19 Prevention 3 Active Not Recruiting NCT04409327 2020-07-11 Povidone-iodine Evaluation of the Effectiveness of Mouthwashes in Early Reducing the mouth Viral Load Among COVID-19 Patients : A double-blind randomized clinical trial Treatment 3 Recruiting IRCT20170117032025N7 2020-07-10 Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) A Randomized, Double-blind, Placebo-controlled, Phase Ib / IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ?60 Years Prevention 1, 2 Active Not Recruiting NCT04470609 2020-07-10 Coronavirus-Like Particle COVID-19 Vaccine A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age Prevention 1 Active Not Recruiting NCT04450004 2020-07-10 Methylprednisolone The efficacy of methylprednisolone mini pulse on the treatment of COVID-19 patients admitted to intensive care unit Treatment 3 Active Not Recruiting IRCT20170716035126N4 2020-07-10 Resveratrol Routine use of over-the-counter Nutraceuticals, Resveretrol-Copper with standard treatment in Hospitalized Patients With Pneumonia / Acute Respiratory Distress Syndrome Due To SARS-CoV-2 (Covid-19)- Retrospective Analysis Basic Science Not Available Active Not Recruiting CTRI/2020/06/026256 2020-07-10 Copper Routine use of over-the-counter Nutraceuticals, Resveretrol-Copper with standard treatment in Hospitalized Patients With Pneumonia / Acute Respiratory Distress Syndrome Due To SARS-CoV-2 (Covid-19)- Retrospective Analysis Basic Science Not Available Active Not Recruiting CTRI/2020/06/026256 2020-07-10 Ivermectin A Clinical Trial to Study the Efficacy of â??Ivermectinâ?? in the prevention of Covid-19. .A Single Arm Study. â?? Treatment 3 Active Not Recruiting CTRI/2020/06/026232 2020-07-10 Cepeginterferon alfa-2B A phase II, randomized, controlled, open-label study to evaluate the efficacy and safety of Pegylated IFN alfa-2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19). Treatment 2 Active Not Recruiting CTRI/2020/06/026087 2020-07-10 ABX-464 A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study). Treatment 2 Active Not Recruiting EUCTR2020-001673-75-DE 2020-07-10 Wormwood Evaluation of the effect of Afsantin in the treatment of COVID 19 patients Treatment 3 Recruiting IRCT20190415043279N6 2020-07-09 Crizanlizumab Crizanlizumab for Treating COVID-19 Vasculopathy Treatment 2 Active Not Recruiting NCT04435184 2020-07-09 Heparin A randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on the duration of mechanical ventilation. Treatment 3 Active Not Recruiting ACTRN12620000517976 2020-07-09 Ruxolitinib MATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) Treatment 2 Active Not Recruiting EUCTR2020-001750-22-GB 2020-07-09 Fostamatinib MATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) Treatment 2 Active Not Recruiting EUCTR2020-001750-22-GB 2020-07-09 Cysteine Effective of Elman tablet on illness severity and length of hospital stay in the patients with COVID-19 infection Treatment 3 Active Not Recruiting IRCT20200609047707N1 2020-07-09 Human immunoglobulin G Evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) in COVID-19 patients Treatment 2, 3 Active Not Recruiting IRCT20151227025726N20 2020-07-09 Ivermectin RANDOMIZED PHASE IIA CLINICAL TRIAL TO COMPARE THE EFFICACY OF IVERMECTIN VERSUS PLACEBO TO OBTAIN NEGATIVE PCR RESULTS IN PATIENTS WITH EARLY PHASE COVID-19 Treatment 2 Recruiting PER-034-20 2020-07-09 PTC299 Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19) Treatment 2, 3 Active Not Recruiting NCT04439071 2020-07-09 Icatibant Randomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilation compared with standard care - HUB-MdI-ICAT-COVID-201 Treatment 2 Unknown Status EUCTR2020-002166-13-ES 2020-07-08 Acetylsalicylic acid Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial Treatment 3 Active Not Recruiting NCT04466670 2020-07-08 Heparin Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial Treatment 3 Active Not Recruiting NCT04466670 2020-07-08 Enoxaparin Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial Treatment 3 Active Not Recruiting NCT04466670 2020-07-08 BCG vaccine BCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial - BRACE Treatment 3 Active Not Recruiting EUCTR2020-002503-19-NL 2020-07-07 Povidone-iodine Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission : SHIELD Study Prevention 1 Active Not Recruiting NCT04478019 2020-07-06 Montelukast Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19) : an investigator-initiated open labelled randomized controlled pragmatic trial Treatment 4 Active Not Recruiting EUCTR2020-001747-21-PT 2020-07-06 Cannabidiol Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019 : A Randomized, Double-blind, Placebo-controlled Clinical Trial Treatment 2, 3 Active Not Recruiting NCT04467918 2020-07-06 COVID-19 convalescent plasma Covid-19 Convalescent Plasma Used for Treatment of Patients in Norway - a Monitoring Study Basic Science Not Available Active Not Recruiting NCT04463823 2020-07-06 COVID-19 convalescent plasma Pilot Clinical, Statistical and Epidemiological Study on Efficacy and Safety of Convalescent Plasma for the Management of Patients With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04452812 2020-07-06 Tofacitinib A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE SAFETY AND EFFICACY OF TOFACITINIB IN HOSPITALIZED PARTICIPANTS WITH COVID-19 PNEUMONIA WHO ARE RECEIVING STANDARD OF CARE THERAPY Treatment 2 Active Not Recruiting NCT04412252 2020-07-06 Degarelix Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) : A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix Treatment 2 Active Not Recruiting NCT04397718 2020-07-06 Zanubrutinib A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress Treatment 2 Active Not Recruiting NCT04382586 2020-07-06 COVID-19 convalescent plasma PHASE 2 STUDY OF EFFICACY AND SAFETY OF PLASMA FROM CONVALESCENT PATIENTS WITH COVID-19 IN PATIENTS WITH MODERATE DISEASE (AUNA 20-01) Treatment 2 Active Not Recruiting PER-031-20 2020-07-06 Oxygen Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia Treatment 2 Active Not Recruiting NCT04477954 2020-07-05 Acalabrutinib A PHASE 2, OPEN LABEL, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ACALABRUTINIB WITH BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE IN SUBJECTS HOSPITALIZED WITH COVID-19 Treatment 2 Active Not Recruiting PER-018-20 2020-07-05 Curcumin Evaluation of the effect of nano micelles containing curcumin (Sina Ccurcumin) as a therapeutic supplement in patients with COVID-19 and investigating of immune responses balance changes following treatment : A randomized double blind clinical trial. Treatment Not Available Active Not Recruiting IRCT20200611047735N1 2020-07-05 Ozone Clinical, Open label, Phase III, Multicenter, Prospective, Comparative, Controlled, Randomized Study to Assess the Effectiveness of Systemic Oxygen Therapy with Medicinal Ozone in Early Control of Disease Progression in Patients with COVID-19 who have Acute Infectious Respiratory Symptoms Treatment 3 Recruiting RBR-5v3k5d 2020-07-04 Enoxaparin Utilização da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com síndrome respiratória Aguda Grave Por COVID-19 Treatment 3 Active Not Recruiting NCT04444700 2020-07-03 Olitigaltin Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19 Treatment 2, 3 Active Not Recruiting NCT04473053 2020-07-03 Nafamostat Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19 Treatment 2, 3 Active Not Recruiting NCT04473053 2020-07-03 Beractant Open-label Trial to Assess the Efficacy and Safety of Inhalation Use of the Approved Drug Surfactant-BL (Biosurf LLC, Russia) as a Part of Complex Therapy of Acute Respiratory Distress Syndrome (ARDS) in Patients With SARS-CoV-2 Coronavirus Infection (COVID-19) Basic Science Not Available Active Not Recruiting NCT04568018 2020-07-03 Dapagliflozin mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E) Treatment 2, 3 Active Not Recruiting NCT04393246 2020-07-03 Ambrisentan mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E) Treatment 2, 3 Active Not Recruiting NCT04393246 2020-07-03 Biomodulin T Evaluation of the effect and safety of BIOMODULIN T(R) for the stimulation of the immune response in patients with Stage 5 Chronic Kidney Disease under an iterated hemodialysis regimen. Exploratory study. (COVID-19) Treatment Not Available Completed RPCEC00000316 2020-07-02 ABX-464 A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study). Treatment 2 Active Not Recruiting EUCTR2020-001673-75-GB 2020-07-02 Opaganib Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia Treatment 2 Active Not Recruiting NCT04414618 2020-07-02 KB109 A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19 Treatment Not Available Active Not Recruiting NCT04414124 2020-07-02 Zinc chloride High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients : A pilot randomized controlled trial Treatment 1, 2 Active Not Recruiting ACTRN12620000454976 2020-07-02 Dutasteride Anti-Androgen Treatment for COVID-19 Treatment Not Available Active Not Recruiting NCT04446429 2020-07-01 Diosmin Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt Treatment 1 Active Not Recruiting NCT04452799 2020-07-01 Hesperidin Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt Treatment 1 Active Not Recruiting NCT04452799 2020-07-01 BACTEK-R Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare Personnel Prevention 3 Active Not Recruiting NCT04452643 2020-07-01 Povidone-iodine The Efficacy of Topical Povidone-Iodine Rinses in the Management of the Coronavirus Disease 2019 (COVID-19) Treatment 1 Active Not Recruiting NCT04449965 2020-07-01 Human interferon beta Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study Treatment 2 Active Not Recruiting NCT04469491 2020-07-01 Prasugrel Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients Treatment 3 Active Not Recruiting NCT04445623 2020-07-01 Measles virus vaccine live attenuated Measles Vaccine : Is There a Protective Role in COVID 19 Pandemic? Basic Science Not Available Active Not Recruiting NCT04445610 2020-07-01 Sofosbuvir Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19 Treatment 2, 3 Active Not Recruiting NCT04443725 2020-07-01 Hydroxychloroquine Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19 Treatment 2, 3 Active Not Recruiting NCT04443725 2020-07-01 Daclatasvir Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19 Treatment 2, 3 Active Not Recruiting NCT04443725 2020-07-01 Nitazoxanide Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita -RJ Treatment 2, 3 Active Not Recruiting NCT04441398 2020-07-01 Ivermectin Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir / Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection Treatment 4 Active Not Recruiting NCT04435587 2020-07-01 Ozone Randomized Clinical Trial to Evaluate Efficacy and Safety of Systemic Indirect Endovenous Ozone Therapy (SIEVOT) as Adjuvant Treatment in COVID19 Non-intubated Patients Treatment 3 Active Not Recruiting NCT04359303 2020-07-01 Ivermectin Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2) Treatment 2 Active Not Recruiting NCT04431466 2020-07-01 Icosapent ethyl PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial Treatment 3 Active Not Recruiting NCT04460651 2020-07-01 Human Umbilical Cord Mesenchymal Stem Cells Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Treatment 2 Active Not Recruiting NCT04429763 2020-07-01 Covax-19™ A Phase I Trial of a Therapeutic Vaccine (Covax-19™) in SARS-CoV-2 Infected Patients Treatment 1 Active Not Recruiting NCT04428073 2020-07-01 COVID-19 convalescent plasma Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 : A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma) Treatment 2, 3 Active Not Recruiting NCT04425837 2020-07-01 Lopinavir A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04459702 2020-07-01 Azithromycin A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04459702 2020-07-01 Hydroxychloroquine A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04459702 2020-07-01 Ritonavir A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04459702 2020-07-01 COVID-19 convalescent plasma Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients : A Feasibility Study Treatment 1 Active Not Recruiting NCT04458363 2020-07-01 Virus Specific T-Cell Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19 Treatment 1, 2 Active Not Recruiting NCT04457726 2020-07-01 Oseltamivir Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients Treatment 1 Active Not Recruiting NCT04457609 2020-07-01 Human Umbilical Cord Mesenchymal Stem Cells Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients Treatment 1 Active Not Recruiting NCT04457609 2020-07-01 Azithromycin Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients Treatment 1 Active Not Recruiting NCT04457609 2020-07-01 Ulinastatin A Phase 3, Prospective, Randomized, Open Label, Comparative, Clinical Study To Evaluate Efficacy And Safety Of Ulinastatin Plus Standard-Of-Care Compared To Standard-Of-Care In Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Hospitalized COVID-19 Infection Patient Treatment 3 Active Not Recruiting CTRI/2020/06/025704 2020-07-01 Human Umbilical Cord Mesenchymal Stem Cells Mesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome : a Pilot Clinical Study Treatment 1 Active Not Recruiting NCT04525378 2020-07-01 Nitazoxanide Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day, Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical Condition Treatment 2 Active Not Recruiting NCT04423861 2020-07-01 Garadacimab A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) Treatment 2 Active Not Recruiting NCT04409509 2020-07-01 Azithromycin Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical Trial Treatment 3 Active Not Recruiting NCT04405921 2020-07-01 Hydroxychloroquine Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical Trial Treatment 3 Active Not Recruiting NCT04405921 2020-07-01 Atibuclimab Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) Treatment 2 Active Not Recruiting NCT04391309 2020-07-01 Recombinant Bacterial ACE2 Receptors-like Enzyme Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2 Treatment 1 Active Not Recruiting NCT04382950 2020-07-01 Isotretinoin Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2 Treatment 1 Active Not Recruiting NCT04382950 2020-07-01 Tocilizumab A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia Treatment 2 Active Not Recruiting NCT04335305 2020-07-01 Pembrolizumab A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia Treatment 2 Active Not Recruiting NCT04335305 2020-07-01 Sodium bicarbonate Sodium Bicarbonate for Treatment of COVID-19 Pneumonia : A Preliminary Prospective Controlled Crossover Study Treatment Not Available Active Not Recruiting NCT04374591 2020-07-01 AMY-101 A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE) Treatment 2 Active Not Recruiting NCT04395456 2020-07-01 AV-COVID-19 Adaptive Phase IB-II Randomized Clinical Trial Of Preventive Vaccine Consisting Of Autologous Dendritic Cells Loaded With Antigens From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), With Or Without GM-CSF, In Subjects Negative For COVID-19 Infection And Anti-SARS-CoV-2 Antibodies Prevention 1, 2 Active Not Recruiting NCT04386252 2020-07-01 Beractant Phase I / II Trial : Exogenous Surfactant Administration for Patients With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04375735 2020-07-01 Telmisartan Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients Treatment 2 Active Not Recruiting NCT04360551 2020-07-01 Aviptadil Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19 Treatment 2, 3 Active Not Recruiting NCT04360096 2020-07-01 Ruxolitinib Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study Treatment 2 Active Not Recruiting NCT04359290 2020-07-01 DAS-181 A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection Treatment 2 Active Not Recruiting NCT04298060 2020-07-01 Alpha-1-proteinase inhibitor A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (Prolastin®) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19 Treatment 2 Active Not Recruiting NCT04495101 2020-07-01 Enoxaparin Early Thromboprophylaxis in COVID-19 (ETHIC Trial) : an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care in COVID-19 Positive Patients Treatment 3 Active Not Recruiting NCT04492254 2020-07-01 KB109 An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting Treatment Not Available Active Not Recruiting NCT04486482 2020-07-01 COVID-19 convalescent plasma Therapeutic effectiveness of COVID-19 convalescent plasma produced by HEMOPE : a multicenter, randomized and controlled clinical trial - PLAVID-TRIAL : Covid convalescent plasma - Clinical Trial Treatment 3 Active Not Recruiting RBR-7jqpnw 2020-07-01 Rubella virus vaccine Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19 Treatment 3 Active Not Recruiting PACTR202006883882711 2020-07-01 Mumps virus strain B level jeryl lynn live antigen Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19 Treatment 3 Active Not Recruiting PACTR202006883882711 2020-07-01 Measles virus vaccine live attenuated Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19 Treatment 3 Active Not Recruiting PACTR202006883882711 2020-07-01 Favipiravir Japanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trial Treatment 2 Active Not Recruiting JPRN-jRCTs041200025 2020-07-01 Methylprednisolone Japanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trial Treatment 2 Active Not Recruiting JPRN-jRCTs041200025 2020-07-01 Camostat Multiple-dose study of FOY-305 in Japanese healthy adult male subject(FOY-305-02)(COVID-19) Treatment 1 Active Not Recruiting JPRN-JapicCTI-205326 2020-07-01 Bacillus calmette-guerin substrain connaught live antigen Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India Prevention 3 Active Not Recruiting NCT04475302 2020-07-01 Pyronaridine A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients Treatment 2 Active Not Recruiting NCT04475107 2020-07-01 Artesunate A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients Treatment 2 Active Not Recruiting NCT04475107 2020-07-01 Povidone-iodine Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo : an Open Label Randomized Clinical Trial Prevention 2 Active Not Recruiting NCT04549376 2020-07-01 Daclatasvir Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients : A Randomized Controlled Trial. Treatment 2, 3 Active Not Recruiting NCT04497649 2020-07-01 Sofosbuvir Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients : A Randomized Controlled Trial. Treatment 2, 3 Active Not Recruiting NCT04497649 2020-07-01 Hydroxychloroquine Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers : A Randomized-Controlled Trial Prevention Not Available Active Not Recruiting NCT04438837 2020-07-01 Diphenhydramine Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) Treatment Not Available Active Not Recruiting NCT04456439 2020-07-01 Remestemcel-L Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) Treatment Not Available Active Not Recruiting NCT04456439 2020-07-01 Hydrocortisone Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) Treatment Not Available Active Not Recruiting NCT04456439 2020-07-01 Enzalutamide COVID_ENZA Trial : Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1 Treatment 2 Active Not Recruiting NCT04456049 2020-07-01 Tramadol Safety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients : A Randomized Double Blind Controlled Clinical Trial Treatment 1, 2 Active Not Recruiting NCT04454307 2020-06-30 Olokizumab A Multicenter, Randomized, Double-blind, Adaptive, Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe SARS-CoV-2 Infection (COVID-19) Treatment 2, 3 Active Not Recruiting NCT04452474 2020-06-30 Prednisolone acetate Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot Study Treatment Not Available Active Not Recruiting NCT04451239 2020-06-30 Cyclosporine Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot Study Treatment Not Available Active Not Recruiting NCT04451239 2020-06-30 VPM1002 A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of the recombinant BCG VPM1002 on the Incidence or Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk Participants in Australia Treatment 3 Active Not Recruiting ACTRN12620000707965 2020-06-30 Interleukin-7 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort Treatment 2 Active Not Recruiting NCT04442178 2020-06-30 Acetylcysteine A randomized, double blind, placebo controlled, comparative study to investigate the efficacy of N-acetylcysteine in COVID-19 patients with standard therapy. Treatment Not Available Active Not Recruiting CTRI/2020/06/026194 2020-06-30 Gold To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB Treatment 3 Active Not Recruiting CTRI/2020/06/025998 2020-06-30 Arsenic trioxide To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB Treatment 3 Active Not Recruiting CTRI/2020/06/025998 2020-06-30 Silver To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB Treatment 3 Active Not Recruiting CTRI/2020/06/025998 2020-06-30 Celery To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB Treatment 3 Active Not Recruiting CTRI/2020/06/025998 2020-06-30 Zinc To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNB Treatment 3 Active Not Recruiting CTRI/2020/06/025998 2020-06-30 Povidone-iodine Povidone Iodine Gargle and Intranasal application : A Quasi-Experimental study to reduce the spread of coronavirus infection in community with Covid-19 positive clusters. Treatment Not Available Active Not Recruiting CTRI/2020/06/025928 2020-06-30 COVID-19 convalescent plasma Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients Treatment Not Available Active Not Recruiting NCT04420988 2020-06-30 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 Treatment 2 Active Not Recruiting NCT04362189 2020-06-30 Ruxolitinib A Pilot Study of Ruxolitinib to Combat COVID-19 Treatment 2 Active Not Recruiting NCT04354714 2020-06-30 Stem-cell derived exosome vesicle products Effect of stromal vascular fraction (SVF), blood and condition medium derived exosomes on treatment of covid-19 patients with Acute Respiratory Distress Syndrome(ARDS) / clinical Trial Treatment 2, 3 Recruiting IRCT20200510047385N1 2020-06-30 Interferon beta-1a Efficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patients Treatment 3 Active Not Recruiting IRCT20200511047396N1 2020-06-30 Cetylpyridinium Evaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settings Treatment Not Available Recruiting ISRCTN95933274 2020-06-30 Povidone-iodine Evaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settings Treatment Not Available Recruiting ISRCTN95933274 2020-06-30 Chlorhexidine Evaluating the comparative efficacy of virucidal mouth-rinses in reducing SARS-CoV-2 viral load in saliva as a pre-procedural prophylactic strategy in healthcare settings Treatment Not Available Recruiting ISRCTN95933274 2020-06-30 Pomegranate Evaluation of the effectiveness of dietary plan for pulmonary diseases based on Persian medicine in patients infected with COVID-19 Treatment 3 Recruiting IRCT20200105046009N4 2020-06-30 Covax-19™ A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects Prevention 1 Active Not Recruiting NCT04453852 2020-06-29 Interferon beta-1a An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY Treatment 3 Active Not Recruiting EUCTR2020-001549-38-DE 2020-06-29 Remdesivir An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY Treatment 3 Active Not Recruiting EUCTR2020-001549-38-DE 2020-06-29 Lopinavir An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY Treatment 3 Active Not Recruiting EUCTR2020-001549-38-DE 2020-06-29 Ritonavir An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANY Treatment 3 Active Not Recruiting EUCTR2020-001549-38-DE 2020-06-29 AG0301-COVID19 A Non-randomized, Open-label, Non-controlled Phase I / II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg / 2mg) in Healthy Adults Prevention 1, 2 Active Not Recruiting NCT04463472 2020-06-29 Amniotic Epithelial Cells Allogeneic Amniotic Epithelial Cells for the Treatment of COVID-19 related respiratory failure, a pilot feasibility randomised controlled trial Treatment 1, 2 Active Not Recruiting ACTRN12620000676910 2020-06-29 Selenium The effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19 Treatment 3 Recruiting IRCT20190312043030N2 2020-06-29 Methylprednisolone The effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19 Treatment 3 Recruiting IRCT20190312043030N2 2020-06-29 Ascorbic acid The effect of combination of selenium, vitamin C and methylprednisolone in acute respiratory distress syndrome mortality and morbidity from COVID-19 Treatment 3 Recruiting IRCT20190312043030N2 2020-06-29 Peppermint The effect of nebulizing Peppermint extract and Rose extract on percentage of blood oxygen saturation in patients with COVID-19 Treatment 3 Recruiting IRCT20190131042569N5 2020-06-29 Human immunoglobulin G A Phase II Safety and Efficacy Study on prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin Therapy Treatment 2 Active Not Recruiting CTRI/2020/06/026222 2020-06-29 Acalabrutinib A Phase II, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 Treatment 2 Active Not Recruiting CTRI/2020/06/026228 2020-06-29 Umifenovir A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients. Treatment 3 Active Not Recruiting CTRI/2020/06/025957 2020-06-29 Favipiravir A Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients. Treatment 3 Active Not Recruiting CTRI/2020/06/025957 2020-06-29 Fenretinide RESOLUTION : A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease Treatment 2 Active Not Recruiting NCT04417257 2020-06-29 Heparin CoV-Hep Study : Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19 Treatment Not Available Active Not Recruiting NCT04487990 2020-06-29 Sodium citrate CoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19 Treatment Not Available Recruiting RBR-45kf9p 2020-06-29 Heparin CoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19 Treatment Not Available Recruiting RBR-45kf9p 2020-06-28 Bivalirudin Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial Supportive Care 4 Active Not Recruiting NCT04445935 2020-06-27 Indian frankincense Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients Treatment 2 Active Not Recruiting CTRI/2020/06/025999 2020-06-27 Clove Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients Treatment 2 Active Not Recruiting CTRI/2020/06/025999 2020-06-27 Azadirachta indica leaf Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients Treatment 2 Active Not Recruiting CTRI/2020/06/025999 2020-06-27 Spearmint Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients Treatment 2 Active Not Recruiting CTRI/2020/06/025999 2020-06-27 Orange Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients Treatment 2 Active Not Recruiting CTRI/2020/06/025999 2020-06-27 Cinnamon Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patients Treatment 2 Active Not Recruiting CTRI/2020/06/025999 2020-06-27 COVID-19 convalescent plasma A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19 Treatment 1 Active Not Recruiting NCT04353206 2020-06-26 Maraviroc Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19). Treatment 2 Active Not Recruiting NCT04441385 2020-06-26 BCG vaccine A multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in Poland during the COVID-19 pandemic. Treatment 3 Active Not Recruiting EUCTR2020-002111-22-PL 2020-06-26 Nitazoxanide Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study Treatment 2, 3 Active Not Recruiting NCT04463264 2020-06-25 Tocilizumab An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive decline in respiratory function and evolving systemic inflammation on time to intubation, non-invasive ventilation and / or all-cause mortality Treatment 2 Active Not Recruiting EUCTR2020-001767-86-IE 2020-06-25 SARS-CoV-2 mRNA vaccine A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above Prevention 1 Active Not Recruiting ChiCTR2000034112 2020-06-25 Ciclesonide Ciclesonide Clinical Trial for COVID-19 Treatment Treatment 2, 3 Active Not Recruiting NCT04435795 2020-06-25 COVID-19 convalescent plasma A phase II, Open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID-19. - PLATINA TRIAL. Treatment 2 Active Not Recruiting CTRI/2020/06/026123 2020-06-25 Ivermectin Randomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 - RIVET-COV Treatment 2, 3 Active Not Recruiting CTRI/2020/06/026001 2020-06-25 BCG vaccine Study to Evaluate the Effectiveness of BCG vaccine in Reducing Morbidity and Mortality in Elderly individuals in COVID-19 Hotspots in India - BCG for COVID-19 Treatment Not Available Active Not Recruiting CTRI/2020/06/025854 2020-06-25 COVID-19 convalescent plasma Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma Treatment 2 Active Not Recruiting NCT04468009 2020-06-25 IMM-101 COV-IMMUNO : A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure Treatment 3 Active Not Recruiting NCT04442048 2020-06-25 Brequinar The CRISIS Study : A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19) Treatment 1, 2 Active Not Recruiting NCT04425252 2020-06-25 Plasma protein fraction (human) A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX) - PEX in severe COVID-19 Treatment 2 Active Not Recruiting EUCTR2020-002668-29-GB 2020-06-25 Tocilizumab PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVID Treatment 3 Unknown Status EUCTR2020-001707-16-ES 2020-06-25 Methylprednisolone PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVID Treatment 3 Unknown Status EUCTR2020-001707-16-ES 2020-06-24 VPM1002 A Randomized, Double-blind, Placebo-controlled Phase 3 Study : Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity Prevention 3 Active Not Recruiting NCT04439045 2020-06-24 AstraZeneca COVID-19 Vaccine An Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV Prevention 1, 2 Active Not Recruiting NCT04444674 2020-06-24 COVID-19 convalescent plasma CONCOR-1 : A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness Treatment 3 Active Not Recruiting NCT04418518 2020-06-24 AstraZeneca COVID-19 Vaccine COVID-19 : An Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARSCoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV. Treatment 1 Active Not Recruiting PACTR202006922165132 2020-06-23 Nafamostat Rapid Experimental Medicine for COVID-19 - DEFINE Treatment 2 Active Not Recruiting EUCTR2020-002230-32-GB 2020-06-23 Olitigaltin Rapid Experimental Medicine for COVID-19 - DEFINE Treatment 2 Active Not Recruiting EUCTR2020-002230-32-GB 2020-06-23 Chloroquine Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19? Treatment 3 Active Not Recruiting NCT04447534 2020-06-23 Zinc Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19? Treatment 3 Active Not Recruiting NCT04447534 2020-06-23 Prednisone Early Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia (PREDCOVID) Treatment 3 Active Not Recruiting NCT04451174 2020-06-23 Sodium chloride Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19 : Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19) Treatment Not Available Active Not Recruiting NCT04382131 2020-06-23 Interferon beta-1a Randomized, controlled, open label, phase 2 clinical trial of Interferon-ß-1a (IFNß-1a) in COVID-19 patients. - Clinical study for the treatment with Interferon-ß-1a (IFNß-1a) of COVID-19 patients Treatment 2 Unknown Status EUCTR2020-002458-25-IT 2020-06-23 COVID-19 convalescent plasma Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease Treatment 2 Active Not Recruiting NCT04542967 2020-06-22 Oseltamivir Prospective, randomized, parallel-group, open-label study to evaluate the efficacy and safety of IMU-838, in combination with oseltamivir, in adults with coronavirus disease COVID-19 Treatment 2 Recruiting ISRCTN53038326 2020-06-22 Vidofludimus Prospective, randomized, parallel-group, open-label study to evaluate the efficacy and safety of IMU-838, in combination with oseltamivir, in adults with coronavirus disease COVID-19 Treatment 2 Recruiting ISRCTN53038326 2020-06-22 CHO Cells Recombinant Vaccine A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age Prevention 1 Active Not Recruiting NCT04445194 2020-06-22 Doxycycline RepurpoSing Old Drugs TO SuppRess a Modern Threat : The STORM Trial Treatment 2 Active Not Recruiting NCT04433078 2020-06-22 COVID-19 convalescent plasma Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19 Treatment Not Available Active Not Recruiting NCT04445207 2020-06-22 Ritonavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting EUCTR2020-002060-31-CZ 2020-06-22 Remdesivir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting EUCTR2020-002060-31-CZ 2020-06-22 Hydroxychloroquine An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting EUCTR2020-002060-31-CZ 2020-06-22 Interferon beta-1a An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting EUCTR2020-002060-31-CZ 2020-06-22 Lopinavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting EUCTR2020-002060-31-CZ 2020-06-22 Interleukin-7 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort Treatment 2 Active Not Recruiting NCT04426201 2020-06-22 Pentaglobin The effect of pentaglobin in the treatment of critically ill patients with COVID-19 Treatment 2, 3 Active Not Recruiting IRCT20151227025726N18 2020-06-22 Nitric Oxide Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or moderate corona virus disease (COVID-19) Treatment 2 Active Not Recruiting EUCTR2020-002394-94-BE 2020-06-22 Cyclosporine Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19 Treatment 1 Active Not Recruiting NCT04412785 2020-06-22 Povidone-iodine A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients Treatment 2 Active Not Recruiting NCT04410159 2020-06-22 Water A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients Treatment 2 Active Not Recruiting NCT04410159 2020-06-22 Ivermectin A double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19 Treatment 3 Completed ISRCTN40302986 2020-06-22 Zinc A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Prevention 2 Active Not Recruiting NCT04335084 2020-06-22 Hydroxychloroquine A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Prevention 2 Active Not Recruiting NCT04335084 2020-06-22 Vitamin D A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Prevention 2 Active Not Recruiting NCT04335084 2020-06-22 Ascorbic acid A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Prevention 2 Active Not Recruiting NCT04335084 2020-06-22 Azithromycin A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04334512 2020-06-22 Ascorbic acid A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04334512 2020-06-22 Zinc A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04334512 2020-06-22 Vitamin D A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04334512 2020-06-22 Hydroxychloroquine A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection Treatment 2 Active Not Recruiting NCT04334512 2020-06-22 Peginterferon lambda-1a A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19 Treatment 2 Active Not Recruiting NCT04343976 2020-06-22 Baricitinib A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2) Treatment 3 Active Not Recruiting JPRN-jRCT2031200035 2020-06-22 Remdesivir A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2) Treatment 3 Active Not Recruiting JPRN-jRCT2031200035 2020-06-21 Anakinra ?Evaluation of Safety and efficacy of anakinra utilization in COVID-19, a randomized controlled clinical trial Treatment 3 Active Not Recruiting IRCT20120703010178N20 2020-06-21 Famotidine The effect of Famotidine on the improvement of patients with COVID-19 Treatment 3 Recruiting IRCT20200509047364N2 2020-06-21 Erythropoietin Evaluation of the effect of recombinant erythropoietin on the improvement of COVID-19 patients Treatment 2 Recruiting IRCT20200509047364N1 2020-06-21 Transcrocetinate Evaluation of the effect of trans sodium crocetinate in respiratory distress caused by COVID-19 Treatment 2 Active Not Recruiting IRCT20081019001369N6 2020-06-21 Rivaroxaban Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial Treatment 4 Active Not Recruiting NCT04394377 2020-06-21 Tocilizumab A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIA Treatment 3 Recruiting PER-027-20 2020-06-21 Edaravone Effect of edaravone on clinical improvement and outcome of patients with respiratory distress syndrome caused by COVID-19 Treatment 3 Active Not Recruiting IRCT20200317046797N6 2020-06-21 Vitamin D Effect of vitamin D supplementation in diagnosed cases of 2019 Novel Coronavirus ; a randomized clinical trial Treatment 3 Recruiting IRCT20110726007117N11 2020-06-21 Hydroxychloroquine The prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patients Treatment 3 Recruiting IRCT20200513047426N1 2020-06-21 COVID-19 convalescent plasma Plasma exchange in patients with COVID-19 to reduce viral load and inflammatory molecules Treatment 2 Recruiting IRCT20200416047099N2 2020-06-21 Albumin human Plasma exchange in patients with COVID-19 to reduce viral load and inflammatory molecules Treatment 2 Recruiting IRCT20200416047099N2 2020-06-20 Pamrevlumab Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 Disease Treatment 2 Active Not Recruiting NCT04432298 2020-06-20 Melatonin A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study) Treatment 2 Active Not Recruiting NCT04568863 2020-06-20 Quercetin The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Treatment 4 Active Not Recruiting NCT04468139 2020-06-20 Zinc The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Treatment 4 Active Not Recruiting NCT04468139 2020-06-20 Bromelains The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Treatment 4 Active Not Recruiting NCT04468139 2020-06-20 Ascorbic acid The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Treatment 4 Active Not Recruiting NCT04468139 2020-06-20 Ritonavir Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200517047485N1 2020-06-20 Lopinavir Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200517047485N1 2020-06-20 Hydroxychloroquine Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200517047485N1 2020-06-20 Atazanavir Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200517047485N1 2020-06-20 COVID-19 convalescent plasma Inactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19 Treatment 2 Active Not Recruiting NCT04385186 2020-06-20 Enoxaparin Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection Treatment Not Available Active Not Recruiting NCT04508439 2020-06-20 Sofosbuvir Efficacy & Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled study Treatment 2, 3 Active Not Recruiting DRKS00022203 2020-06-20 Daclatasvir Efficacy & Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled study Treatment 2, 3 Active Not Recruiting DRKS00022203 2020-06-19 COVID-19 convalescent plasma Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma Treatment 3 Active Not Recruiting NCT04432103 2020-06-19 Interferon beta-1b Evaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020 Treatment 3 Active Not Recruiting IRCT20200412047042N1 2020-06-19 Raltegravir Evaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020 Treatment 3 Active Not Recruiting IRCT20200412047042N1 2020-06-19 SCB-2019 A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers. Prevention 1 Active Not Recruiting NCT04405908 2020-06-19 ISS-1018 A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers. Prevention 1 Active Not Recruiting NCT04405908 2020-06-19 Losartan Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Valsartan Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Angiotensin II Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Candesartan Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Eprosartan Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Telmisartan Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Olmesartan Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Irbesartan Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Treatment 4 Active Not Recruiting NCT04394117 2020-06-19 Camostat The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients : An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial Treatment 2 Active Not Recruiting NCT04353284 2020-06-19 Anti-SARS-CoV-2 immunoglobulin Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients Treatment 1, 2 Active Not Recruiting NCT04521309 2020-06-18 CVnCoV A Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults Prevention 1 Active Not Recruiting NCT04449276 2020-06-18 Camostat SPIKE-1 TRIAL : A Randomised Phase II / III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. - SPIKE-1 Treatment 2 Active Not Recruiting EUCTR2020-002110-41-GB 2020-06-18 Chlorhexidine Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado médico en Casa en Cali - 2020. Treatment Not Available Active Not Recruiting NCT04563689 2020-06-18 Cetylpyridinium Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado médico en Casa en Cali - 2020. Treatment Not Available Active Not Recruiting NCT04563689 2020-06-18 COVID-19 convalescent plasma Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control Trial Treatment 3 Active Not Recruiting CTRI/2020/06/025803 2020-06-18 Dornase alfa Pulmozyme to Improve COVID-19 ARDS Outcomes Treatment 2 Active Not Recruiting NCT04402944 2020-06-18 Human Umbilical Cord Mesenchymal Stem Cells Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) Treatment 1, 2 Active Not Recruiting NCT04399889 2020-06-18 VPM1002 A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and / or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System Prevention 3 Active Not Recruiting NCT04435379 2020-06-17 Melatonin PHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) - MELCOVID Treatment 2 Unknown Status EUCTR2020-001808-42-ES 2020-06-17 Camostat A randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (“NICCAM”) Treatment 2 Active Not Recruiting EUCTR2020-002233-15-DE 2020-06-17 Niclosamide A randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (“NICCAM”) Treatment 2 Active Not Recruiting EUCTR2020-002233-15-DE 2020-06-17 Gam-COVID-Vac An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac Lyo" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers Prevention 1, 2 Active Not Recruiting NCT04437875 2020-06-17 Gam-COVID-Vac An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers Prevention 1, 2 Active Not Recruiting NCT04436471 2020-06-17 Favipiravir A Randomized, Open Label, Prospective, Comparative, Parallel Group, Multicentre Study To Evaluate Efficacy And Safety Of Favipiravir With Supportive Care Versus Supportive Care Alone In Subjects With Mild To Moderate Coronavirus Disease (COVID-19). - NA Treatment 3 Active Not Recruiting CTRI/2020/06/025799 2020-06-17 Sofosbuvir Efficacy of Sofosbuvir in the management of hospitalized COVID 19 patients. Treatment 3 Active Not Recruiting CTRI/2020/06/025760 2020-06-17 Eculizumab SOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency Treatment Treatment Not Available Active Not Recruiting NCT04355494 2020-06-17 Heparin Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient Treatment 3 Recruiting IRCT20200515047456N1 2020-06-17 Alteplase Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient Treatment 3 Recruiting IRCT20200515047456N1 2020-06-17 Tocilizumab COVIDSTORM - study protocol COVID-19 : Slavage TOcilizumab as a Rescue Measure - COVIDSTORM Treatment 3 Active Not Recruiting EUCTR2020-002039-31-FI 2020-06-17 GX-19 Vaccine A Phase 1 / 2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects Prevention 1, 2 Active Not Recruiting NCT04445389 2020-06-17 Etesevimab A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness Treatment 2 Active Not Recruiting NCT04427501 2020-06-17 Bamlanivimab A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness Treatment 2 Active Not Recruiting NCT04427501 2020-06-16 Nitrous acid An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 requiring supplemental oxygen (NOCoV2) Treatment 2 Active Not Recruiting EUCTR2020-002120-37-GB 2020-06-16 Merimepodib A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19) Treatment 2 Active Not Recruiting NCT04410354 2020-06-16 Remdesivir A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19) Treatment 2 Active Not Recruiting NCT04410354 2020-06-16 Tocilizumab A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia Treatment 3 Active Not Recruiting NCT04409262 2020-06-16 Remdesivir A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia Treatment 3 Active Not Recruiting NCT04409262 2020-06-16 Ivermectin Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial. Treatment 2 Active Not Recruiting NCT04407130 2020-06-16 Doxycycline Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial. Treatment 2 Active Not Recruiting NCT04407130 2020-06-16 Molnupiravir A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19 Treatment 2 Active Not Recruiting NCT04405570 2020-06-16 Human interleukin-6 Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19) Basic Science Not Available Active Not Recruiting NCT04359667 2020-06-16 LNP-nCoVsaRNA Vaccine A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19 Treatment 1 Active Not Recruiting ISRCTN17072692 2020-06-16 Chloroquine Remdesivir in COVID 19 Treatment : A Randomised Trial Treatment 2, 3 Active Not Recruiting NCT04345419 2020-06-16 Remdesivir Remdesivir in COVID 19 Treatment : A Randomised Trial Treatment 2, 3 Active Not Recruiting NCT04345419 2020-06-16 Hydroxychloroquine Remdesivir in COVID 19 Treatment : A Randomised Trial Treatment 2, 3 Active Not Recruiting NCT04345419 2020-06-16 Nitazoxanide Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment Treatment 2, 3 Active Not Recruiting NCT04351347 2020-06-16 Ivermectin Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment Treatment 2, 3 Active Not Recruiting NCT04351347 2020-06-16 COVID-19 convalescent plasma Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda ; A Randomised Controlled Trial Treatment Not Available Active Not Recruiting NCT04542941 2020-06-16 Cannabidiol Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19 : a Randomised Controlled Trial Prevention 2, 3 Active Not Recruiting NCT04504877 2020-06-16 Anti-SARS-CoV-2 REGN-COV2 A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04425629 2020-06-16 Pioglitazone Controlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. - ESCORPIO Treatment 4 Unknown Status EUCTR2020-001929-31-ES 2020-06-15 Hydroxychloroquine Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine : a Case-control Study Basic Science Not Available Active Not Recruiting NCT04471649 2020-06-15 Remestemcel-L Double-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 Treatment 2 Unknown Status EUCTR2020-002193-27-ES 2020-06-15 Fosaprepitant To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients Treatment 3 Active Not Recruiting NCT04468646 2020-06-15 Aprepitant To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients Treatment 3 Active Not Recruiting NCT04468646 2020-06-15 COVID-19 convalescent plasma Effectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 Trial Treatment 2 Active Not Recruiting NCT04428021 2020-06-15 Vitamin D Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease : Double Blind, Controlled, Study Treatment Not Available Active Not Recruiting NCT04459247 2020-06-15 Sodium chloride Homeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial - Homeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial (Covid-Simile study) Treatment 2 Active Not Recruiting JPRN-UMIN000040602 2020-06-15 Nitazoxanide A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 Patients Treatment 2 Active Not Recruiting CTRI/2020/06/025849 2020-06-15 Hydroxychloroquine A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 Patients Treatment 2 Active Not Recruiting CTRI/2020/06/025849 2020-06-15 Melatonin Melatonin For COVID 19 pre exposure prophylaxis in High Risk population . (MELATONIN IMMUNE BOOST COVID 19 STUDY ) Treatment 4 Active Not Recruiting CTRI/2020/06/025613 2020-06-15 Iloprost Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng) / Kilo(kg) / Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy Treatment 2 Active Not Recruiting NCT04420741 2020-06-15 Sevoflurane SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study Treatment 3 Active Not Recruiting NCT04415060 2020-06-15 Isoflurane SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study Treatment 3 Active Not Recruiting NCT04415060 2020-06-15 Nivolumab Study of the Efficiency and Security of NIVOLUMAB Therapy, Used in Immuno-stimulation, in Hospitalized Obese Individuals at Risk to Evolve Towards Severe Forms of COVID-19 Infection. Multicentric, Paralleled, Randomized, Controlled Trial Treatment 2 Active Not Recruiting NCT04413838 2020-06-15 Sulodexide Sulodexide in the treatment of early stages of COVID-19 Treatment Not Available Active Not Recruiting ISRCTN59048638 2020-06-15 Angiotensin II Angiotensin II Infusion in COVID-19-Associated Vasodilatory Shock : A multinational, multicentre registry Basic Science Not Available Active Not Recruiting ACTRN12620000620921 2020-06-15 Enoxaparin Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus : The Multicenter Randomized Controlled Ovid Trial Treatment 3 Active Not Recruiting NCT04400799 2020-06-15 Hydroxychloroquine A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19 Treatment Not Available Active Not Recruiting CTRI/2020/05/025067 2020-06-15 AstraZeneca COVID-19 Vaccine A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating ChAdOx1 nCoV-19 vaccine Treatment 3 Active Not Recruiting ISRCTN89951424 2020-06-15 Oseltamivir Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19 Treatment 2 Active Not Recruiting NCT04516915 2020-06-15 Vidofludimus Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19 Treatment 2 Active Not Recruiting NCT04516915 2020-06-15 Heparin Nebulized heparin in patients with mainly moderate coronavirus disease 2019 : Randomized controlled trial. COVID-19 Treatment Not Available Recruiting PACTR202007606032743 2020-06-15 Anakinra Anti-interleukin IL-1 receptor antagonist (anakinra) for the treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome in patients admitted at Sultan Qaboos University Hospital Treatment Not Available Completed ISRCTN74727214 2020-06-15 Hydroxychloroquine Pilot trial on early treatment with hydroxychloroquine in patients with COVID-19 who do not have hospital admission at diagnosis. - PRE-COVID Treatment 3 Unknown Status EUCTR2020-002449-41-ES 2020-06-15 Metoprolol Intravenous Metoprolol in Respiratory Distress Due to COVID-19 : Pilot Study "MADRID-COVID" - “MADRID-COVID” Treatment 2 Unknown Status EUCTR2020-002310-41-ES 2020-06-14 COVID-19 convalescent plasma Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control Trial Treatment 3 Active Not Recruiting NCT04425915 2020-06-14 Human Umbilical Cord Mesenchymal Stem Cells Evolution of Allogenic Mesenchymal stem cell- derived Umbilical cord transplantation for ARDS patients infected with COVID19. Treatment 2, 3 Active Not Recruiting IRCT20160809029275N1 2020-06-14 Atazanavir Evaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir Treatment 3 Active Not Recruiting IRCT20200504047298N1 2020-06-14 Ritonavir Evaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir Treatment 3 Active Not Recruiting IRCT20200504047298N1 2020-06-14 Resveratrol Evaluation of the effect of Resveratrol on the effectiveness of antiviral drug regimen in patients with COVID-19 Treatment 3 Recruiting IRCT20200112046089N1 2020-06-14 Valsartan Treatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial - CovidVal01 Treatment Not Available Active Not Recruiting DRKS00021732 2020-06-13 Oral Polio Vaccine Short-term Protection for COVID-19 by Oral Polio Vaccine Treatment 3 Active Not Recruiting IRCT20140428017469N1 2020-06-13 Nitric Oxide Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial) Treatment Not Available Active Not Recruiting NCT04397692 2020-06-13 Acalabrutinib A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19 Treatment 2 Active Not Recruiting NCT04380688 2020-06-12 Remestemcel-L Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection Treatment 1, 2 Active Not Recruiting NCT04445454 2020-06-12 COVID-19 convalescent plasma The efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19) : A medical records based retrospective cohort study Basic Science Not Available Active Not Recruiting ChiCTR2000033798 2020-06-12 Hydroxychloroquine â??Relative efficacy of hydroxy-chloroquine prophylaxis to healthcare-professionals for Covid-19 mitigation : a pragmatic prospective observational study (RE-HCP2 COVID study)â?? - RE-HCP2 COVID study Basic Science Not Available Active Not Recruiting CTRI/2020/06/025593 2020-06-12 Baricitinib A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection Treatment 3 Active Not Recruiting NCT04421027 2020-06-12 Acalabrutinib A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19 Treatment 2 Active Not Recruiting NCT04346199 2020-06-12 Ivermectin Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19 - COVER Treatment 2 Unknown Status EUCTR2020-002283-32-IT 2020-06-12 Human Umbilical Cord Mesenchymal Stem Cells Mesenchymal stromal cell therapy for severe COVID-19 infection - MSC therapy for severe COVID-19 infection Treatment 2 Active Not Recruiting EUCTR2020-002102-58-BE 2020-06-11 Aprotinin An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19 Treatment Not Available Active Not Recruiting NCT04527133 2020-06-11 Anakinra A Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study Treatment 2 Active Not Recruiting NCT04412291 2020-06-11 Tocilizumab A Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study Treatment 2 Active Not Recruiting NCT04412291 2020-06-11 Vidofludimus A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 Treatment 2, 3 Active Not Recruiting NCT04379271 2020-06-11 Favipiravir Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia Treatment 3 Active Not Recruiting JPRN-jRCTs031200026 2020-06-11 Nafamostat Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia Treatment 3 Active Not Recruiting JPRN-jRCTs031200026 2020-06-11 Favipiravir An ObservationaI Study to Evaluate the Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age Who Are Receiving Favipiravir Basic Science Not Available Active Not Recruiting NCT04474457 2020-06-10 Tocilizumab A randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6 Treatment 3 Active Not Recruiting EUCTR2020-001903-17-ES 2020-06-10 Cholecalciferol A randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6 Treatment 3 Active Not Recruiting EUCTR2020-001903-17-ES 2020-06-10 Acalabrutinib A Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVI Treatment 2 Active Not Recruiting EUCTR2020-001644-25-DE 2020-06-10 Nafamostat Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia : Open Labelled Randomized Controlled Clinical Trial Treatment 2, 3 Active Not Recruiting NCT04418128 2020-06-10 COVID-19 convalescent plasma Convalescent Plasma to Stem Coronavirus : A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19 Treatment 2 Active Not Recruiting NCT04323800 2020-06-10 Ivermectin In vivo use of ivermectin (IVR) for treatment for corona virus infected patients : a randomized controlled trial Treatment 0 Active Not Recruiting ChiCTR2000033627 2020-06-10 BACTEK-R A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19 Treatment 3 Active Not Recruiting NCT04363814 2020-06-10 Human Umbilical Cord Mesenchymal Stem Cells Use of mesenchymal cells for the treatment of patients with severe acute respiratory syndrome caused by SARS-CoV-2 - : Coronavirus infections Treatment Not Available Active Not Recruiting RBR-3fz9yr 2020-06-10 Anti-SARS-CoV-2 REGN-COV2 A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04426695 2020-06-10 Silibinin Phase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infection by COVID-19 positive. - SilCOVID19 Treatment 2 Unknown Status EUCTR2020-001794-77-ES 2020-06-10 Human immunoglobulin G Double-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19 Treatment 4 Unknown Status EUCTR2020-001890-56-ES 2020-06-09 Ivermectin The Use of Ivermectin In the Treatment of COVID 19 Patients Treatment Not Available Active Not Recruiting NCT04425707 2020-06-09 COVID-19 convalescent plasma A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients Treatment 2 Active Not Recruiting NCT04421404 2020-06-08 Interleukin-7 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium Treatment 2 Active Not Recruiting NCT04407689 2020-06-08 Ciclesonide A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection Treatment 3 Active Not Recruiting NCT04377711 2020-06-08 Ozone EXPLORATORY STUDY OF THE THERAPEUTIC EFFECT AND SAFETY OF RECTAL OZONE THERAPY IN PATIENTS POSITIVE TO SARS-CoV 2 WITH MILD TO MODERATE SYMPTOMS (COVID-19) - ORC Treatment Not Available Completed RPCEC00000320 2020-06-08 Nitazoxanide Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19 Treatment 2 Active Not Recruiting NCT04552483 2020-06-08 Nitazoxanide Effects of Early Use of Nitazoxanide in Patients with COVID-19 Treatment 2 Recruiting RBR-4nr86m 2020-06-06 Pembrolizumab The evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19 Treatment 2 Active Not Recruiting IRCT20150303021315N19 2020-06-06 Ibrutinib IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE) Treatment 2 Active Not Recruiting NCT04375397 2020-06-06 Acetylcysteine Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery process Treatment 3 Active Not Recruiting IRCT20200324046850N1 2020-06-06 Cholecalciferol Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery process Treatment 3 Active Not Recruiting IRCT20200324046850N1 2020-06-06 COVID-19 convalescent plasma Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2) Treatment 2, 3 Active Not Recruiting NCT04502472 2020-06-05 Curcumin Evaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200519047510N1 2020-06-05 Hydroxychloroquine Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study Supportive Care Not Available Active Not Recruiting NCT04380818 2020-06-05 Lopinavir Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study Supportive Care Not Available Active Not Recruiting NCT04380818 2020-06-05 Heparin Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study Supportive Care Not Available Active Not Recruiting NCT04380818 2020-06-05 Azithromycin Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study Supportive Care Not Available Active Not Recruiting NCT04380818 2020-06-05 Ritonavir Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study Supportive Care Not Available Active Not Recruiting NCT04380818 2020-06-05 Tocilizumab Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective Study Supportive Care Not Available Active Not Recruiting NCT04380818 2020-06-05 Sulodexide Sulodexide in the Treatment of Early Stages of COVID-19 Treatment 2, 3 Active Not Recruiting NCT04483830 2020-06-05 Valsartan Treatment of Sars-CoV2 infections (Covid-19) in patients without or with chronic kidney disease (CKD) with valsartan vs placebo, a three-armed randomized, partly blinded trial Treatment 2 Active Not Recruiting EUCTR2020-001431-27-DE 2020-06-04 Omega-3 fatty acids The effect of omega-3 supplementation on inflammatory and biochemical markers in critical ill patients with COVID-19 a randomized clinical trial Treatment Not Available Active Not Recruiting IRCT20151226025699N3 2020-06-04 Acetylcysteine Evaluating the effect of intravenous N-acetyl cysteine versus placebo in the treatment of patients with mild and moderate acute respiratory distress syndrome caused by COVID-19 : A double-blind randomized clinical trial Treatment 2 Active Not Recruiting IRCT20120215009014N355 2020-06-04 BCG vaccine Investigating the Effect of BCG Vaccine on Preventing COVID-19 Infection in Healthcare Staff Exposed to SARS-CoV-2 Treatment 3 Active Not Recruiting IRCT20200411047019N1 2020-06-04 Bemiparin A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19 Treatment 2 Active Not Recruiting NCT04420299 2020-06-04 Icosapent ethyl An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19) Treatment 2 Active Not Recruiting NCT04412018 2020-06-04 Ethanol Evaluation of Shift, a smartphone application for New South Wales Junior Medical Officers, on depression and anxiety during the COVID-19 epidemic. Treatment 1 Active Not Recruiting ACTRN12620000571976 2020-06-04 Dexamethasone Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trial Treatment 2 Active Not Recruiting IRCT20120215009014N354 2020-06-04 Methylprednisolone Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trial Treatment 2 Active Not Recruiting IRCT20120215009014N354 2020-06-04 Hydrocortisone Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trial Treatment 2 Active Not Recruiting IRCT20120215009014N354 2020-06-04 Deoxyribonuclease I Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study Treatment 2 Active Not Recruiting NCT04541979 2020-06-04 COVID-19 convalescent plasma Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2. Prevention Not Available Active Not Recruiting NCT04479163 2020-06-03 Hydroxychloroquine The NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19 Treatment 3 Active Not Recruiting EUCTR2020-000982-18-SE 2020-06-03 Remdesivir The NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19 Treatment 3 Active Not Recruiting EUCTR2020-000982-18-SE 2020-06-03 Ritonavir Hydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition" Treatment 3 Active Not Recruiting NCT04403100 2020-06-03 Hydroxychloroquine Hydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition" Treatment 3 Active Not Recruiting NCT04403100 2020-06-03 Lopinavir Hydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition" Treatment 3 Active Not Recruiting NCT04403100 2020-06-03 COVID-19 convalescent plasma Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19 Treatment 2 Active Not Recruiting NCT04373460 2020-06-03 Methylprednisolone Efficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS) in COVID-19 Treatment 4 Unknown Status EUCTR2020-002186-34-ES 2020-06-02 Budesonide Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation - The STOIC Study (STerOids in COVID) Treatment 2 Active Not Recruiting EUCTR2020-001889-10-GB 2020-06-02 Imatinib Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19 Treatment 3 Active Not Recruiting NCT04394416 2020-06-02 Azithromycin EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA Treatment 3 Active Not Recruiting NCT04347512 2020-06-02 Hydroxychloroquine EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA Treatment 3 Active Not Recruiting NCT04347512 2020-06-02 Sargramostim Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial Treatment 2 Active Not Recruiting NCT04400929 2020-06-02 Enoxaparin COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial Prevention 2 Active Not Recruiting NCT04354155 2020-06-02 Meningococcal polysaccharide vaccine group Y A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine Prevention 3 Active Not Recruiting NCT04536051 2020-06-02 Meningococcal polysaccharide vaccine group W-135 A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine Prevention 3 Active Not Recruiting NCT04536051 2020-06-02 Meningococcal polysaccharide vaccine group C A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine Prevention 3 Active Not Recruiting NCT04536051 2020-06-02 AstraZeneca COVID-19 Vaccine A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine Prevention 3 Active Not Recruiting NCT04536051 2020-06-02 Meningococcal polysaccharide vaccine group A A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine Prevention 3 Active Not Recruiting NCT04536051 2020-06-02 Ivermectin Pragmatic study "CORIVER" : Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19) - CORIVER Treatment 3 Unknown Status EUCTR2020-001971-33-ES 2020-06-01 Vitamin D Vitamin D Supplementation in Patients With COVID-19 : A Randomized, Double-blind, Placebo-controlled Trial Treatment Not Available Active Not Recruiting NCT04449718 2020-06-01 COVID-19 convalescent plasma A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19 Treatment 2 Active Not Recruiting NCT04433910 2020-06-01 COVID-19 convalescent plasma Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection Treatment 1, 2 Active Not Recruiting NCT04438694 2020-06-01 Human Umbilical Cord Mesenchymal Stem Cells Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients Treatment 2 Active Not Recruiting NCT04437823 2020-06-01 Nitazoxanide Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable Communities Prevention 2 Active Not Recruiting NCT04435314 2020-06-01 Ivermectin USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel Basic Science Not Available Active Not Recruiting NCT04425850 2020-06-01 iota-Carrageenan USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel Basic Science Not Available Active Not Recruiting NCT04425850 2020-06-01 Human immunoglobulin G A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19 Treatment 2 Active Not Recruiting NCT04432324 2020-06-01 Infliximab A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). Treatment 2 Active Not Recruiting NCT04425538 2020-06-01 Favipiravir A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate Type Treatment 3 Active Not Recruiting NCT04425460 2020-06-01 Cisatracurium The Use of Neuromuscular Blockade Monitor as a Strategy for Neuromuscular Blockade Agents Saving in ICU COVID-19 Patients Basic Science Not Available Active Not Recruiting NCT04459533 2020-06-01 Atracurium The Use of Neuromuscular Blockade Monitor as a Strategy for Neuromuscular Blockade Agents Saving in ICU COVID-19 Patients Basic Science Not Available Active Not Recruiting NCT04459533 2020-06-01 Dornase alfa A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04459325 2020-06-01 COVID-19 convalescent plasma Randomized Prospective Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma in Prevention of Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients Treatment Not Available Active Not Recruiting NCT04383548 2020-06-01 Heparin Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2) Treatment 4 Active Not Recruiting NCT04530578 2020-06-01 Remdesivir Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study Treatment 1 Active Not Recruiting NCT04560231 2020-06-01 Hydroxychloroquine Randomized, placebo-controlled multiple dose study to evaluate the effect of hydroxychloroquine on the general immuno-competence in young and elderly healthy male volunteers Treatment Not Available Recruiting NL8726 2020-06-01 Imatinib Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia : A Pilot Study Treatment 3 Active Not Recruiting NCT04422678 2020-06-01 COVID-19 convalescent plasma A Pilot Study to Explore the Efficacy and Safety of Rescue Therapy With Antibodies From Convalescent Patients Obtained With Double-filtration Plasmapheresis (DFPP) and Infused in Patients With Coronavirus Disease 2019 (COVID-19) and Need of Oxygen Support Without Mechanical Ventilation Treatment Not Available Active Not Recruiting NCT04418531 2020-06-01 COVID-19 convalescent plasma Treatment of Patients With COVID-19 With Convalescent Plasma Transfusion : a Multicenter, Open-labeled, Randomized and Controlled Study Treatment 2 Active Not Recruiting NCT04415086 2020-06-01 Ruxolitinib Safety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2 Treatment 2 Active Not Recruiting NCT04414098 2020-06-01 Tocilizumab A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19 Treatment 3 Active Not Recruiting NCT04412772 2020-06-01 COVID-19 convalescent plasma An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19 Treatment 1 Active Not Recruiting NCT04412486 2020-06-01 Talactoferrin alfa Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory Therapy in Patients Diagnosed With COVID-19 Disease Treatment 2 Active Not Recruiting NCT04412395 2020-06-01 Prednisone Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up Treatment Not Available Active Not Recruiting NCT04410536 2020-06-01 Indomethacin Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up Treatment Not Available Active Not Recruiting NCT04410536 2020-06-01 Dornase alfa Phase I Pilot Study Investigating the Safety and Tolerability of Inhaled rhDNase1 and Its Impact on Neutrophil Extracellular Traps (NETs) in Non-Ventilated COVID-19 Infected Patients Treatment 1 Active Not Recruiting NCT04409925 2020-06-01 Lopinavir Evaluation of Additional Treatments for COVID-19 : a Randomized Trial in Niger Treatment 3 Active Not Recruiting NCT04409483 2020-06-01 Ritonavir Evaluation of Additional Treatments for COVID-19 : a Randomized Trial in Niger Treatment 3 Active Not Recruiting NCT04409483 2020-06-01 Angiotensin II Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome Basic Science Not Available Active Not Recruiting NCT04408326 2020-06-01 Anakinra Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome Basic Science Not Available Active Not Recruiting NCT04408326 2020-06-01 Nicotinamide riboside Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19 Treatment 2 Active Not Recruiting NCT04407390 2020-06-01 Molnupiravir A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults With PCR-Confirmed COVID-19 Treatment 2 Active Not Recruiting NCT04405739 2020-06-01 Heparin Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury Treatment 4 Active Not Recruiting NCT04397510 2020-06-01 Tamoxifen Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus Treatment 2 Active Not Recruiting NCT04389580 2020-06-01 Isotretinoin Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus Treatment 2 Active Not Recruiting NCT04389580 2020-06-01 Vitamin D Improving Vitamin D Status in the Management of COVID-19 Treatment 3 Active Not Recruiting NCT04385940 2020-06-01 Hydroxychloroquine Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT) Prevention Not Available Active Not Recruiting NCT04371926 2020-06-01 Ruxolitinib Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib Treatment 2 Active Not Recruiting NCT04366232 2020-06-01 Anakinra Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib Treatment 2 Active Not Recruiting NCT04366232 2020-06-01 Prednisone Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France Treatment 3 Active Not Recruiting NCT04359511 2020-06-01 Hydrocortisone Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France Treatment 3 Active Not Recruiting NCT04359511 2020-06-01 Aldesleukin Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 Treatment 2 Active Not Recruiting NCT04357444 2020-06-01 Remestemcel-L Exploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia Treatment 2 Active Not Recruiting NCT04315987 2020-06-01 Chloroquine An international, multi-site, Bayesian platform adaptive, randomised, placebo-controlled trial assessing the effectiveness of varied doses of oral Chloroquine in preventing or reducing the severity of COVID-19 disease in healthcare workers Treatment 3 Active Not Recruiting ISRCTN99916292 2020-06-01 Stem-cell derived exosome vesicle products Rationale and investigational study for the treatment of COVID-19 with severe viral pneumonia with isolated, placental, mesenchymal stem cell exosomes Treatment 2 Recruiting ISRCTN33578935 2020-06-01 Enoxaparin Randomised Controlled Trial Comparing High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Not Requiring Invasive Mechanical Ventilation Treatment 3 Active Not Recruiting NCT04408235 2020-06-01 Ivermectin Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms Treatment 2 Active Not Recruiting NCT04407507 2020-06-01 Lithium carbonate SARS-CoV-2 Specific Memory B and T- CD4+ Cells Basic Science Not Available Active Not Recruiting NCT04402892 2020-06-01 Budesonide ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA) Treatment 3 Active Not Recruiting NCT04193878 2020-06-01 Formoterol ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA) Treatment 3 Active Not Recruiting NCT04193878 2020-06-01 Ivermectin The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment Treatment 2, 3 Active Not Recruiting NCT04403555 2020-06-01 Doxycycline The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment Treatment 2, 3 Active Not Recruiting NCT04403555 2020-06-01 Human immunoglobulin G Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression Prevention 3 Active Not Recruiting NCT04400058 2020-06-01 Povidone-iodine A pilot study of virucidal activity of povidone-iodine (PVP-I) 0.5% aqueous solution oral / nasal spray and mouthwash in people with COVID-19 and confirmed oral / nasal shedding of SARS-CoV-2 Treatment Not Available Active Not Recruiting ISRCTN13447477 2020-06-01 CYP-001 A pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with COVID-19 Treatment 1, 2 Active Not Recruiting ACTRN12620000612910 2020-06-01 Heparin Heparins for Thromboprophylaxis in COVID-19 Patients : HETHICO Study in Veneto Basic Science Not Available Active Not Recruiting NCT04393805 2020-06-01 COVID-19 convalescent plasma Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection : A Randomized, Open Label Clinical Trial Treatment 3 Active Not Recruiting NCT04391101 2020-06-01 Ritonavir Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19 Treatment 2 Active Not Recruiting NCT04372628 2020-06-01 Lopinavir Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19 Treatment 2 Active Not Recruiting NCT04372628 2020-06-01 Tranexamic acid Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients Treatment 2 Active Not Recruiting NCT04338074 2020-06-01 Tofacitinib TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label Trial Treatment 2 Active Not Recruiting NCT04390061 2020-06-01 Hydroxychloroquine TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label Trial Treatment 2 Active Not Recruiting NCT04390061 2020-06-01 Deferoxamine The Use of Desferal and Adjuvants for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection : A Randomized Controlled Trial Treatment 4 Active Not Recruiting NCT04389801 2020-06-01 Doxycycline Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria : Prospective, Multicenter, Randomized, Double-blind Study Treatment 3 Active Not Recruiting NCT04371952 2020-06-01 Lucinactant A Multicenter, Single-Treatment Study to Assess the Safety and Preliminary Efficacy of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury Treatment 1, 2 Active Not Recruiting NCT04389671 2020-06-01 Resiniferatoxin A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin (RTX) Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed Due to the COVID-19-related Moratoria on Elective Procedures Treatment 3 Active Not Recruiting NCT04386980 2020-06-01 Favipiravir An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia â?? An open-label randomized controlled study â?? Treatment 2, 3 Active Not Recruiting TCTR20200514001 2020-06-01 COVID19 s-vax loaded autologous dendritic cell vaccine A safety and immune response study of novel coronavirus pneumonia (COVID-19) s-vax loaded autologous dendritic cells Prevention 0 Active Not Recruiting ChiCTR2000033003 2020-06-01 Tocilizumab Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab Treatment 2 Active Not Recruiting NCT04363853 2020-06-01 MRx-4DP0004 A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection) Treatment 2 Active Not Recruiting NCT04363372 2020-06-01 COVID-19 convalescent plasma Expanded Access Protocol For The Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) Treatment Not Available Active Not Recruiting NCT04360486 2020-06-01 Umbilical Cord Blood Hematopoietic Stem Cells Cord Blood Therapy to prevent progression of COVID-19 related pneumonia Treatment Not Available Active Not Recruiting ACTRN12620000478910 2020-06-01 Hydroxychloroquine Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection Treatment 4 Active Not Recruiting NCT04338906 2020-06-01 Camostat Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection Treatment 4 Active Not Recruiting NCT04338906 2020-06-01 Morphine Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon Basic Science Not Available Active Not Recruiting NCT04522037 2020-06-01 COVID-19 convalescent plasma A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients. Treatment Not Available Active Not Recruiting CTRI/2020/05/025346 2020-06-01 Resveratrol A Phase-III, Open Label, Randomized Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Asymptomatic Or Mildly Symptomatic Patients With SARS-CoV-2 Infection (Covid-19) Treatment 3 Active Not Recruiting CTRI/2020/05/025336 2020-06-01 COVID-19 convalescent plasma To Assess the Safety and Efficacy of Convalescent Plasma on outcome of COVID-19 Associated Complications - COVID PLASMA STUDY Treatment 2 Active Not Recruiting CTRI/2020/05/025328 2020-06-01 Losartan Angiotensin Receptor Blocker Losartan for prevention of COVID 19 complications : a randomized placebo controlled trial - LICCI Treatment 3 Active Not Recruiting CTRI/2020/05/025319 2020-06-01 COVID-19 convalescent plasma Convalescent Plasma to Limit Coronavirus Associated Complications : An Open label Clinical Study of Anti-SARS-CoV-2 Plasma in Hospitalized Patients with COVID-19 Treatment 2 Active Not Recruiting CTRI/2020/05/025299 2020-06-01 COVID-19 convalescent plasma PERUCONPLASMA : RANDOMIZED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF CONVALESCENT PLASMA IN HOSPITALIZED PATIENTS WITH COVID-19 Treatment 2 Recruiting PER-016-20 2020-06-01 COVID-19 convalescent plasma CONVALESCENT PLASMA USE AS TREATMENT FOR HOSPITALIZED PATIENTS WITH COVID-19 IN ESSALUD Treatment 2 Recruiting PER-013-20 2020-06-01 Azithromycin A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic Treatment 2 Recruiting RBR-3rywwg 2020-06-01 Naproxen A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic Treatment 2 Recruiting RBR-3rywwg 2020-06-01 Clavulanic acid A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic Treatment 2 Recruiting RBR-3rywwg 2020-06-01 Amoxicillin A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic Treatment 2 Recruiting RBR-3rywwg 2020-06-01 Levofloxacin A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic Treatment 2 Recruiting RBR-3rywwg 2020-06-01 Oseltamivir A phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic Treatment 2 Recruiting RBR-3rywwg 2020-06-01 Ivermectin A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care Treatment 3 Active Not Recruiting NCT04523831 2020-06-01 Doxycycline A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care Treatment 3 Active Not Recruiting NCT04523831 2020-06-01 Hydroxychloroquine Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19 Treatment 3 Active Not Recruiting PACTR202005622389003 2020-06-01 Azithromycin Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19 Treatment 3 Active Not Recruiting PACTR202005622389003 2020-06-01 Zinc Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19 Treatment 3 Active Not Recruiting PACTR202005622389003 2020-06-01 Inosine A low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM) Treatment Not Available Completed ISRCTN34160010 2020-06-01 Glutathione A low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM) Treatment Not Available Completed ISRCTN34160010 2020-06-01 Potassium chloride A low-intervention study to determine whether pre-exposure prophylaxis with low dose aerosol combination medication (ACM) can reduce SARS-CoV-2 incidence in healthcare workers exposed to routing COVID-19 positive contacts (LOWACM) Treatment Not Available Completed ISRCTN34160010 2020-06-01 Amodiaquine Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications Treatment 2 Active Not Recruiting NCT04502342 2020-06-01 Artesunate Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications Treatment 2 Active Not Recruiting NCT04502342 2020-06-01 Azithromycin Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament " ACAR " en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes Treatment 2 Active Not Recruiting NCT04501965 2020-06-01 Hydroxychloroquine Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament " ACAR " en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes Treatment 2 Active Not Recruiting NCT04501965 2020-05-31 Ivermectin Use of Ivermectin as a Therapeutic Option for Patients With COVID-19 Treatment 2, 3 Active Not Recruiting NCT04445311 2020-05-31 Ivermectin Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19 Prevention 2, 3 Active Not Recruiting NCT04422561 2020-05-31 Dipyridamole Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 Treatment 2 Active Not Recruiting NCT04391179 2020-05-31 COVID-19 convalescent plasma Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19) Treatment Not Available Active Not Recruiting ChiCTR2000030039 2020-05-31 Mycobacterium w. Vaccine Observational study to assess safety and efficacy of Inj Sepsivac in patients of Covid-19 at R D Gardi Medical College, Ujjain, India Treatment 2 Active Not Recruiting CTRI/2020/05/025350 2020-05-31 Mycobacterium w. Vaccine A Randomized, Double-blind, Two arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in preventing COVID-19 in subjects at risk of getting infected with COVID-19. Treatment 3 Active Not Recruiting CTRI/2020/05/025277 2020-05-31 Mycobacterium w. Vaccine A Randomized, Double-blind, Two arm, controlled clinical trial to compare the Efficacy and Safety of Mycobacterium w (Mw) administered along with Standard of care versus Placebo administered along with Standard of care, in adult, COVID 19 positive patients hospitalized but not critically ill. Treatment 3 Active Not Recruiting CTRI/2020/05/025271 2020-05-31 Metronidazole Evaluation of therapeutic effects of Metronidazole In Inpatients with Pneuomonia Due to COVID-19 Treatment 2 Active Not Recruiting IRCT20200608047686N1 2020-05-30 Ivermectin A randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19) Treatment 2, 3 Active Not Recruiting IRCT20200422047168N2 2020-05-30 Honey Comparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trial Treatment Not Available Recruiting IRCT20200209046427N1 2020-05-30 Propolis wax Comparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trial Treatment Not Available Recruiting IRCT20200209046427N1 2020-05-30 Enoxaparin Full versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19 : clinical, randomized, open and controlled study - HeSAcovid trial Treatment 2 Active Not Recruiting RBR-949z6v 2020-05-29 Omega-3 fatty acids Resolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility study Treatment 2 Active Not Recruiting EUCTR2020-002293-28-SE 2020-05-29 COVID-19 convalescent plasma Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients Treatment 1 Active Not Recruiting NCT04530370 2020-05-29 Azithromycin A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2) Treatment 3 Active Not Recruiting NCT04381962 2020-05-29 Liothyronine Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support) Treatment 2 Active Not Recruiting NCT04348513 2020-05-29 Peginterferon lambda-1a Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection Prevention 2 Active Not Recruiting NCT04344600 2020-05-29 VPM1002 A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and / or severe respiratory infectious diseases in elderly in the SARS-CoV-2 pandemic by modulating the immune system Treatment 3 Active Not Recruiting EUCTR2020-001675-33-DE 2020-05-29 MRx-4DP0004 A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection) Treatment 2 Active Not Recruiting EUCTR2020-001597-30-GB 2020-05-29 Moderna COVID-19 Vaccine A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older Prevention 2 Active Not Recruiting NCT04405076 2020-05-29 Ritonavir Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection Treatment 4 Unknown Status EUCTR2020-001605-23-ES 2020-05-29 Hydroxychloroquine Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection Treatment 4 Unknown Status EUCTR2020-001605-23-ES 2020-05-29 Azithromycin Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection Treatment 4 Unknown Status EUCTR2020-001605-23-ES 2020-05-29 Lopinavir Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection Treatment 4 Unknown Status EUCTR2020-001605-23-ES 2020-05-29 Poractant alfa Randomized Controlled Phase II Trial of Poractant Alfa (Curosurf®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia Treatment 2 Active Not Recruiting NCT04384731 2020-05-29 Ciclesonide Inhalation of Ciclesonide for Patients With COVID-19 : A Randomised Open Treatment Study (HALT COVID-19) Treatment 2 Active Not Recruiting NCT04381364 2020-05-28 Vidofludimus A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1 Treatment 2 Active Not Recruiting EUCTR2020-001264-28-DE 2020-05-28 Ciclesonide Inhalation of Ciclesonide for patients with Covid-19 : A randomised open treatment study (HALT Covid-19). Treatment 2 Active Not Recruiting EUCTR2020-001928-34-SE 2020-05-28 Anakinra Subcutaneous and Intravenous IL-1Ra (Anakinra) in COVID-19 Infection - Feasibility & Pharmacokinetics / Pharmacodynamics Study Health Services Research 2 Active Not Recruiting NCT04462757 2020-05-28 Vidofludimus A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1 Treatment 2 Active Not Recruiting EUCTR2020-001264-28-HU 2020-05-28 Bamlanivimab A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19 Basic Science 1 Active Not Recruiting NCT04411628 2020-05-28 COVID-19 convalescent plasma Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2 Treatment 1 Active Not Recruiting NCT04377672 2020-05-28 Otilimab A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease Treatment 2 Active Not Recruiting NCT04376684 2020-05-28 Tocilizumab Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19) Treatment 2 Active Not Recruiting NCT04370834 2020-05-28 AstraZeneca COVID-19 Vaccine A Phase 2 / 3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 Prevention 2, 3 Active Not Recruiting NCT04400838 2020-05-28 Cholecalciferol Clinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-19 HUSO). - Efficacy of high dose vitamin D in COVID-19 pneumonia Treatment 3 Unknown Status EUCTR2020-002312-43-ES 2020-05-28 Ruxolitinib Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept study Treatment 2 Active Not Recruiting EUCTR2020-001732-10-DE 2020-05-28 Bacillus calmette-guerin substrain danish 1331 live antigen Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUS Treatment 4 Active Not Recruiting EUCTR2020-002456-21-NL 2020-05-28 Alendronic acid Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUS Treatment 4 Active Not Recruiting EUCTR2020-002456-21-NL 2020-05-28 Mosedipimod Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia Treatment 2 Active Not Recruiting NCT04500132 2020-05-27 Vidofludimus A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1 Treatment 2 Active Not Recruiting EUCTR2020-001264-28-BG 2020-05-27 COVID-19 convalescent plasma Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression. Prevention 2, 3 Active Not Recruiting NCT04374526 2020-05-27 Ivermectin A Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicable Treatment 3 Active Not Recruiting CTRI/2020/05/025068 2020-05-27 Tocilizumab A Multi-center, Randomized Controlled, Phase III Study to evaluate the Clinical Outcomes and Safety of Tocilizumab along with Standard of Care in Patients with Cytokine Release Syndrome associated with COVID-19 infection - None Treatment 3 Active Not Recruiting CTRI/2020/05/025369 2020-05-27 Eculizumab Eculizumab for the treatment of Covid-19 severe cases - : Eculizumabe for COVID Treatment 1, 2 Recruiting RBR-876qb5 2020-05-26 BCG vaccine A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19 : The ACTIVATE II Trial Prevention 4 Active Not Recruiting NCT04414267 2020-05-26 Zilucoplan A prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - ZILU-COV Treatment 2 Active Not Recruiting EUCTR2020-002130-33-BE 2020-05-26 Ibuprofen Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19 : a Multicentre, Randomised, Controlled Trial Treatment 4 Active Not Recruiting NCT04334629 2020-05-26 BCG vaccine A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ?? COVID-19 : THE ACTIVATE II TRIAL Treatment 4 Active Not Recruiting EUCTR2020-002448-21-GR 2020-05-26 Turmeric ASSESSMENT OF CLINICAL ACCEPTABILITY OF MOUTH-DISSOLVING TURMERIC LOZENGES IN HEALTHCARE WORKERS INVOLVED IN COVID-19 Other 4 Completed CTRI/2020/05/025317 2020-05-25 Dornase alfa Determination of Dornase Alpha Effectiveness in COVID-19 Treatment Treatment 2 Active Not Recruiting NCT04432987 2020-05-25 VPM1002 A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System Prevention 3 Active Not Recruiting NCT04387409 2020-05-25 Colchicine PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19) Prevention 3 Active Not Recruiting NCT04416334 2020-05-25 Ozone A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia Treatment 3 Active Not Recruiting NCT04370223 2020-05-25 Nitazoxanide Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition. Treatment Not Available Active Not Recruiting NCT04348409 2020-05-25 Nuvaxovid A 2-Part, Phase 1 / 2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects Prevention 1, 2 Active Not Recruiting NCT04368988 2020-05-25 Matrix-M A 2-Part, Phase 1 / 2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects Prevention 1, 2 Active Not Recruiting NCT04368988 2020-05-25 Colchicine Colchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19 Treatment 3 Unknown Status EUCTR2020-001841-38-ES 2020-05-25 Vitamin D Efficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19) Treatment 4 Unknown Status EUCTR2020-001960-28-ES 2020-05-25 Sarilumab Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients Treatment 2 Unknown Status EUCTR2020-002037-15-ES 2020-05-25 Rubella virus vaccine Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) Treatment Not Available Active Not Recruiting NL8609 2020-05-25 BCG vaccine Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) Treatment Not Available Active Not Recruiting NL8609 2020-05-25 Alendronic acid Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) Treatment Not Available Active Not Recruiting NL8609 2020-05-25 Measles virus vaccine live attenuated Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) Treatment Not Available Active Not Recruiting NL8609 2020-05-25 Mumps virus strain B level jeryl lynn live antigen Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) Treatment Not Available Active Not Recruiting NL8609 2020-05-25 Tocilizumab A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in Japan Treatment 3 Active Not Recruiting JPRN-JapicCTI-205270 2020-05-25 Nafamostat Treatment effect of Nafamostat mesilate in patients with COVID-19 pneumonia : open labelled randomized controlled clinical trial Treatment 2 Active Not Recruiting KCT0005003 2020-05-25 Hydroxychloroquine Population pharmacokinetics of hydroxychloroquine sulphate in healthcare workers given for prophylaxis against Corona Virus Disease 2019 (COVID 19) pandemic in India Treatment Not Available Active Not Recruiting CTRI/2020/05/025242 2020-05-25 Ascorbic acid A prospective, single centre, randomized open labelled comparative clinical study to evaluate the effectiveness of Siddha medicine, Kabasura kudineer and vitamin c-zinc supplementation in the management of asymptomatic COVID 19 patients. Treatment 1, 2 Active Not Recruiting CTRI/2020/05/025215 2020-05-25 COVID-19 convalescent plasma Immediate uses of convalescent covid-19 plasma in the treatment of new infected patients at the first day of hospitalization in a clinical trail Treatment 3 Recruiting IRCT20200525047562N1 2020-05-25 Oxygen A Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing ICU admission, Morbidity and Mortality in Adult Patients With COVID-19 - COVID-19-HBO Treatment 2 Active Not Recruiting DRKS00021626 2020-05-24 Ruxolitinib A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) Treatment 3 Active Not Recruiting NCT04377620 2020-05-24 Ivermectin Interventional study to assess the efficacy of Ivermectin with standard of care treatment versus standard of care in patients of COVID-19 at R D Gardi Medical College, Ujjain, India Treatment 2 Active Not Recruiting CTRI/2020/05/025224 2020-05-23 Iloprost Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure Treatment 2 Active Not Recruiting NCT04445246 2020-05-23 COVID19 s-vax loaded autologous dendritic cell vaccine A safety and immune response trial of novel coronavirus pneumonia (COVID-19) S-Vax loaded autologous dendritic cells Treatment 0 Recruiting ChiCTR2000034076 2020-05-23 Interferon alfa Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19 Treatment 2, 3 Recruiting IRCT20161206031256N3 2020-05-23 Human interferon beta Evaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19 Treatment 2, 3 Recruiting IRCT20161206031256N3 2020-05-22 Tocilizumab A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia : the BREATH-19 Study Treatment 2 Active Not Recruiting NCT04445272 2020-05-22 Enoxaparin Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19 : A Pilot Phase II Single-arm Study, INHIXACOVID19 Treatment 2 Active Not Recruiting NCT04427098 2020-05-22 Pacritinib A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer Treatment 3 Active Not Recruiting NCT04404361 2020-05-22 Mavrilimumab A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial) Treatment 2 Active Not Recruiting NCT04397497 2020-05-22 Azithromycin Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19 Treatment 3 Active Not Recruiting NCT04332107 2020-05-22 Hydroxychloroquine Prevention of COVID19 infection with hydroxychloroquine in institutionalized older people and nursing home staff. An open, randomized controlled stepped-wedge clinical trial by clusters. PREVICHARM Study - PREVICHARM Treatment 3 Unknown Status EUCTR2020-002287-31-ES 2020-05-22 CoronaVac A Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged =60 Years Prevention 1, 2 Active Not Recruiting NCT04383574 2020-05-22 Zilucoplan A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure Treatment 2 Active Not Recruiting NCT04382755 2020-05-21 Ginger The effects of Ginger on clinical manifestations and paraclinical features of patients with COVID-19 : A randomized double-blind placebo-control clinical trial Treatment 3 Recruiting IRCT20200506047323N1 2020-05-21 Selenium Effect of the combination of BCc1 & Hep-S on the improvement of clinical & laboratory symptoms of hospitalized COVID-19 patients in a randomized, double-blind, clinical trial Treatment 3 Recruiting IRCT20170731035423N2 2020-05-21 Licorice Evaluation of the effects of Licorice on clinical symptoms and laboratory signs in patients with COVID-19 : An open-label randomized clinical trial Treatment 3 Recruiting IRCT20200506047323N2 2020-05-21 Acetylcysteine Evaluation of the efficacy and safety of oral N-acetylcysteine in treatment and recovery of patients with COVID-19 who are under treatment with routine protocols Treatment 3 Active Not Recruiting IRCT20200623047897N1 2020-05-21 Cinnamon Comparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19 Treatment 2, 3 Active Not Recruiting IRCT20081011001323N25 2020-05-21 Ginger oil Comparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19 Treatment 2, 3 Active Not Recruiting IRCT20081011001323N25 2020-05-21 Vitamin A The effect of supplementation with vitamin A on improvement of symptoms of acute respiratory syndrome in patients with COVID-19 : A randomized clinical trial Treatment 3 Recruiting IRCT20200405046951N1 2020-05-21 Filgrastim Evaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia (less than 1000) Treatment 1, 2 Active Not Recruiting IRCT20200502047268N1 2020-05-21 Nitazoxanide Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide Treatment 4 Active Not Recruiting NCT04406246 2020-05-21 Dexamethasone High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS : a Multicenter and Randomized Open-label Clinical Trial Treatment 3 Active Not Recruiting NCT04395105 2020-05-21 Hydroxychloroquine A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19 Treatment Not Available Active Not Recruiting NCT04392973 2020-05-21 Favipiravir A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19 Treatment Not Available Active Not Recruiting NCT04392973 2020-05-21 Tocilizumab Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapy Treatment 3 Active Not Recruiting IRCT20200510047383N1 2020-05-21 CoviGlobulin Evaluation of the efficacy and safety of Rabbit polyclonal antibody (CoviGlobulin) in patients with coronavirus COVID-19 virus moderate to severe Treatment 3 Active Not Recruiting IRCT20200508047346N1 2020-05-21 Propolis wax The effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200326046868N1 2020-05-21 Ivermectin Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020 Treatment 3 Recruiting IRCT20111224008507N3 2020-05-21 Favipiravir Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19 Treatment 3 Active Not Recruiting NCT04542694 2020-05-21 Curcumin Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19 Treatment Not Available Recruiting IRCT20131125015536N13 2020-05-21 COVID-19 convalescent plasma COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients : Multicenter Interventional Study Treatment 1 Active Not Recruiting NCT04474340 2020-05-20 Anakinra Subcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility & Pharmacokinetics / Pharmacodynamics study - SCIL-COV19 PK / PD trial Treatment 2 Active Not Recruiting EUCTR2020-001636-95-GB 2020-05-20 Heparin Antithrombotic Therapy to Ameliorate Complications of COVID-19 Treatment 2, 3 Active Not Recruiting NCT04372589 2020-05-20 COVID-19 convalescent plasma DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19 Treatment 1, 2 Active Not Recruiting NCT04356482 2020-05-20 Favipiravir Glasgow Early Treatment Arm FavIpiravir? : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients - GETAFIX Treatment 2 Active Not Recruiting EUCTR2020-001904-41-GB 2020-05-20 COVID-19 convalescent plasma Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial Treatment 2 Active Not Recruiting NCT04405310 2020-05-20 COVID-19 convalescent plasma Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT Treatment 2 Active Not Recruiting NCT04403477 2020-05-20 Mavrilimumab Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation Treatment 2 Active Not Recruiting NCT04399980 2020-05-20 Otilimab A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease. - OSCAR Treatment 2 Active Not Recruiting EUCTR2020-001759-42-GB 2020-05-20 Vidofludimus A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1 Treatment 2 Active Not Recruiting EUCTR2020-001264-28-GR 2020-05-20 Liothyronine Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study) - Thy-Support STUDY Treatment 2 Active Not Recruiting EUCTR2020-001623-13-GR 2020-05-20 Aprotinin A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo Treatment 2 Active Not Recruiting EUCTR2020-001739-28-BE 2020-05-20 Nadroparin A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo Treatment 2 Active Not Recruiting EUCTR2020-001739-28-BE 2020-05-20 Enoxaparin A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo Treatment 2 Active Not Recruiting EUCTR2020-001739-28-BE 2020-05-20 Anakinra A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCo Treatment 2 Active Not Recruiting EUCTR2020-001739-28-BE 2020-05-20 Acetaminophen Evaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19 Treatment 1, 2 Active Not Recruiting RPCEC00000309 2020-05-20 Sodium chloride Evaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19 Treatment 1, 2 Active Not Recruiting RPCEC00000309 2020-05-20 Brensocatib A randomised double-blind placebo-controlled trial of brensocatib (INS1007) in patients with severe COVID-19 Treatment 3 Active Not Recruiting ISRCTN30564012 2020-05-20 Baricitinib BARICIVID-19 STUDY : MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard Therapy Treatment 2 Active Not Recruiting NCT04393051 2020-05-20 Atorvastatin Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19 Treatment 2 Active Not Recruiting NCT04380402 2020-05-20 BCG vaccine Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers Prevention 3 Active Not Recruiting NCT04384549 2020-05-20 Favipiravir A Randomized, Open-label, multicenter study to evaluate the efficacy and safety of Favipiravir combined with STANDARD supportive care in adult Indian patients with mild to moderate COVID-19 Treatment 3 Completed CTRI/2020/05/025114 2020-05-20 Selenium The effect of addition of selenium to treatment regimen of hospitalized patients with COVID-19 on the outcome of disease compared with control group Treatment 2 Active Not Recruiting IRCT20160706028815N5 2020-05-20 COVID-19 convalescent plasma Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04376788 2020-05-20 Methylene blue Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04376788 2020-05-20 Levamisole Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 Prevention 3 Active Not Recruiting NCT04360122 2020-05-20 Inosine pranobex Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 Prevention 3 Active Not Recruiting NCT04360122 2020-05-20 Hydroxychloroquine Effectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers : The COVID-SHIELD Trial Treatment 2, 3 Active Not Recruiting ACTRN12620000501943 2020-05-20 Mavrilimumab Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Treatment 2 Active Not Recruiting NCT04492514 2020-05-20 COVID-19 convalescent plasma AN OPEN LABEL RANDOMISED CONTROL TRIAL ON PASSIVE IMMUNIZATION WITH CONVALESCENT PLASMA IN SEVERE COVID-19 DISEASE - PICP19 Treatment 2 Active Not Recruiting CTRI/2020/05/025209 2020-05-20 Dotatate gallium Ga-68 [68Ga]Ga-DOTA-(RGD)2 PET / CT imaging of activated endothelium in lung parenchyma of COVID-19 patients. - RDG-PET / CT imaging in COVID-19 patients. Treatment 2 Active Not Recruiting EUCTR2020-001325-31-NL 2020-05-20 Favipiravir Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2 / COVID-19) Treatment 3 Active Not Recruiting NCT04501783 2020-05-19 Azithromycin Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit Treatment 3 Recruiting IRCT20200428047228N2 2020-05-19 Hydroxychloroquine Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit Treatment 3 Recruiting IRCT20200428047228N2 2020-05-19 Telmisartan Telmisartan for Treatment of COVID-19 Patients : an Open Label Randomized Trial Treatment 4 Active Not Recruiting NCT04355936 2020-05-19 Cholecalciferol Vitamin D Testing and Treatment for Adults With COVID 19 Treatment 1 Active Not Recruiting NCT04407286 2020-05-19 Anakinra An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV Treatment 3 Active Not Recruiting EUCTR2020-001754-21-FR 2020-05-19 Ruxolitinib An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV Treatment 3 Active Not Recruiting EUCTR2020-001754-21-FR 2020-05-19 Tocilizumab An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV Treatment 3 Active Not Recruiting EUCTR2020-001754-21-FR 2020-05-19 Hydroxychloroquine Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care : A Double-blind Randomized Control Trial Prevention 3 Active Not Recruiting NCT04397328 2020-05-19 Cholecalciferol Usefulness of vitamin D on morbidity and mortality of SARS-COV-2 virus infection (Covid-19) at the Central University Hospital of Asturias - Vitamin D and COVID-19 Treatment 4 Unknown Status EUCTR2020-002274-28-ES 2020-05-19 Piperaquine A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients Treatment 4 Active Not Recruiting ChiCTR2000033049 2020-05-19 Artemisinin A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients Treatment 4 Active Not Recruiting ChiCTR2000033049 2020-05-19 Hydroxychloroquine Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19 Treatment 3 Active Not Recruiting IRCT20200428047228N1 2020-05-19 Favipiravir Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19 Treatment 3 Active Not Recruiting IRCT20200428047228N1 2020-05-19 Curcumin Evaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19 : An open label non-randomized clinical trial Treatment 3 Active Not Recruiting IRCT20200408046990N1 2020-05-18 Budesonide A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity Treatment 3 Active Not Recruiting NCT04361474 2020-05-18 Dornase alfa Aerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trial Treatment 2 Active Not Recruiting EUCTR2020-001849-39-SE 2020-05-18 Ivermectin A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19 Treatment 2 Active Not Recruiting NCT04381884 2020-05-18 COVID-19 convalescent plasma Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia Treatment 2, 3 Active Not Recruiting NCT04380935 2020-05-18 Glycyrrhiza glabra Observational Study of YASHTIMADHU TABLET intake as a preventive measure in pandemic of COVID-19 â?? An open label, Randomized, Controlled, Prospective, interventional, Community-based Cclinical study on healthy subjects Treatment 2, 3 Active Not Recruiting CTRI/2020/05/025093 2020-05-18 Hydroxychloroquine Effect of Hydroxychloroquine Prophylaxis on QTc Interval of Health Care Workers during COVID-19 Pandemic : An Observational Study Basic Science Not Available Active Not Recruiting CTRI/2020/05/025089 2020-05-18 Selinexor A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection Treatment 2 Active Not Recruiting EUCTR2020-001411-25-DE 2020-05-16 Curcumin Evaluation efficacy of "Curcumin and Resveratrol" capsule in controlling symptoms in patients with COVID-19 Treatment 3 Recruiting IRCT20080901001165N56 2020-05-16 Resveratrol Evaluation efficacy of "Curcumin and Resveratrol" capsule in controlling symptoms in patients with COVID-19 Treatment 3 Recruiting IRCT20080901001165N56 2020-05-16 Bromhexine Open Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalization Treatment 3 Active Not Recruiting NCT04424134 2020-05-16 Spironolactone Open Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalization Treatment 3 Active Not Recruiting NCT04424134 2020-05-16 Gemtuzumab ozogamicin A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. Treatment 2 Active Not Recruiting ISRCTN40580903 2020-05-16 Turmeric Evaluation of the Immuno-stimulatory(Shareera Bala) potential of Ayurveda management protocol in Cohort of Delhi Police - An Exploratory clinical Study - EBAMD Treatment 2 Active Not Recruiting CTRI/2020/05/025171 2020-05-16 Baricitinib Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19 : an Open-label, Pilot Study Treatment 2, 3 Active Not Recruiting NCT04320277 2020-05-16 Lavender oil Investigating the effect of Lavender (Lavandula angustifolia L.) syrup on improving the severity of cough in patients with definite or highly suspicious COVID-19 Treatment 3 Recruiting IRCT20110907007511N4 2020-05-15 COVID-19 convalescent plasma Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome Treatment Not Available Active Not Recruiting NCT04442958 2020-05-15 COVID-19 convalescent plasma Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04569188 2020-05-15 Methylprednisolone Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04438980 2020-05-15 Anakinra A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment. The Immunomodulation-CoV Assessment (ImmCoVA) study. - The Immunomodulation-CoV Assessment (ImmCoVA) study. Treatment 2 Active Not Recruiting EUCTR2020-001748-24-SE 2020-05-15 Tocilizumab A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment. The Immunomodulation-CoV Assessment (ImmCoVA) study. - The Immunomodulation-CoV Assessment (ImmCoVA) study. Treatment 2 Active Not Recruiting EUCTR2020-001748-24-SE 2020-05-15 Hydroxychloroquine Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study Treatment 3 Active Not Recruiting NCT04528927 2020-05-15 Doxycycline Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study Treatment 3 Active Not Recruiting NCT04528927 2020-05-15 Zinc Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study Treatment 3 Active Not Recruiting NCT04528927 2020-05-15 Azithromycin Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study Treatment 3 Active Not Recruiting NCT04528927 2020-05-15 Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) A Randomized, Double-blind, Placebo-controlled, Phase Ia / IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years Prevention 1, 2 Active Not Recruiting NCT04412538 2020-05-15 Aviptadil Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure Treatment 2 Active Not Recruiting NCT04311697 2020-05-15 Ivermectin Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and manifested clinical symptoms. Treatment 2 Active Not Recruiting EUCTR2020-002091-12-BG 2020-05-15 Baricitinib A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia Treatment 2 Active Not Recruiting NCT04399798 2020-05-15 V-SARS Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill Treatment 1, 2 Active Not Recruiting NCT04380532 2020-05-15 Chloride ion Hypernatremia in critically ill patients with Covid-19 Basic Science Not Available Active Not Recruiting DRKS00021611 2020-05-15 Urea Hypernatremia in critically ill patients with Covid-19 Basic Science Not Available Active Not Recruiting DRKS00021611 2020-05-15 Potassium Hypernatremia in critically ill patients with Covid-19 Basic Science Not Available Active Not Recruiting DRKS00021611 2020-05-15 Remestemcel-L Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) the Vanguard Study Treatment 1 Active Not Recruiting NCT04400032 2020-05-15 Lopinavir Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type) Basic Science Not Available Active Not Recruiting NCT04275388 2020-05-15 Ritonavir Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type) Basic Science Not Available Active Not Recruiting NCT04275388 2020-05-15 Hydroxychloroquine Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVID-19). - Sanitarios sin COVID -SANsinCOVID- Treatment 4 Unknown Status EUCTR2020-001704-42-ES 2020-05-15 Tocilizumab A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia : the BREATH-19 Study Treatment 2 Unknown Status EUCTR2020-001995-13-ES 2020-05-15 Ritonavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-IE 2020-05-15 Remdesivir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-IE 2020-05-15 Interferon beta-1a An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-IE 2020-05-15 Lopinavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-IE 2020-05-15 Calfactant A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults - COVID-19 Surfactant Clinical Trial Treatment 2 Active Not Recruiting EUCTR2020-001886-35-GB 2020-05-15 Vidofludimus Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel Coronavirus Treatment 2 Active Not Recruiting EUCTR2020-001805-21-GB 2020-05-15 Oseltamivir Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel Coronavirus Treatment 2 Active Not Recruiting EUCTR2020-001805-21-GB 2020-05-15 Brensocatib A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 - STOP-COVID19 : Superiority Trial Of Protease inhibition in COVID-19 Treatment 3 Active Not Recruiting EUCTR2020-001643-13-GB 2020-05-15 Hydroxychloroquine Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 Prevention 3 Active Not Recruiting NCT04386070 2020-05-15 Lopinavir Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 Prevention 3 Active Not Recruiting NCT04386070 2020-05-15 Ritonavir Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 Prevention 3 Active Not Recruiting NCT04386070 2020-05-15 COVID-19 convalescent plasma Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria Treatment Not Available Active Not Recruiting NCT04383535 2020-05-15 Niclosamide EFFICACY OF ORAL NICLOSAMIDE IN TREATMENT OF MILD AND VERY MILD COVID-19 CASES : AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - EONIC-COVID Treatment 2 Active Not Recruiting CTRI/2020/04/024949 2020-05-15 Ciclesonide EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID Treatment 2 Active Not Recruiting CTRI/2020/04/024948 2020-05-15 Hydroxychloroquine EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID Treatment 2 Active Not Recruiting CTRI/2020/04/024948 2020-05-15 Ivermectin EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID Treatment 2 Active Not Recruiting CTRI/2020/04/024948 2020-05-15 Heparin A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer Treatment 2 Active Not Recruiting NCT04377997 2020-05-15 Enoxaparin A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer Treatment 2 Active Not Recruiting NCT04377997 2020-05-15 Hydroxychloroquine Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure : Randomised Control Trial Prevention Not Available Active Not Recruiting NCT04370015 2020-05-14 Methylprednisolone Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectio Treatment 3 Unknown Status EUCTR2020-001921-30-IT 2020-05-14 Heparin Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectio Treatment 3 Unknown Status EUCTR2020-001921-30-IT 2020-05-14 Hydroxychloroquine Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - - Treatment 3 Unknown Status EUCTR2020-001528-32-IT 2020-05-14 Favipiravir Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - - Treatment 3 Unknown Status EUCTR2020-001528-32-IT 2020-05-14 Darunavir Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - - Treatment 3 Unknown Status EUCTR2020-001528-32-IT 2020-05-14 Ritonavir Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - - Treatment 3 Unknown Status EUCTR2020-001528-32-IT 2020-05-14 Lopinavir Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - - Treatment 3 Unknown Status EUCTR2020-001528-32-IT 2020-05-14 Hydroxychloroquine Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection Prevention 3 Active Not Recruiting NCT04372017 2020-05-14 Hydroxychloroquine PROTECT : A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19) Treatment 2 Active Not Recruiting NCT04363827 2020-05-14 Alteplase Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection : A Phase 2a Clinical Trial Treatment 2 Active Not Recruiting NCT04357730 2020-05-14 COVID-19 convalescent plasma A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1) Treatment 3 Active Not Recruiting NCT04348656 2020-05-14 Bromhexine Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease : a Randomised Controlled Trial Prevention 4 Active Not Recruiting NCT04405999 2020-05-14 Tocilizumab A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia Treatment 3 Active Not Recruiting NCT04372186 2020-05-14 Enoxaparin Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients : Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial Treatment 3 Active Not Recruiting NCT04366960 2020-05-14 FT516 Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia Treatment 1 Active Not Recruiting NCT04363346 2020-05-14 Interleukin-7 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK Treatment 2 Active Not Recruiting NCT04379076 2020-05-14 Interferon beta-1a Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20080901001165N53 2020-05-14 COVID-19 convalescent plasma Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19 : a randomized clinical trial Treatment 2 Active Not Recruiting IRCT20120215009014N353 2020-05-14 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19 Prevention 2 Active Not Recruiting NCT04348435 2020-05-14 MRx-4DP0004 Investigation of the effect of Lactocare® synbiotic on the prevention of COVID-19 infection in the staff of emergency department Treatment 3 Recruiting IRCT20101020004976N6 2020-05-14 Interleukin-7 InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK) Treatment 2 Recruiting ISRCTN15913068 2020-05-13 Hydroxychloroquine A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial) Prevention 3 Active Not Recruiting NCT04446104 2020-05-13 Zinc A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial) Prevention 3 Active Not Recruiting NCT04446104 2020-05-13 Ivermectin A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial) Prevention 3 Active Not Recruiting NCT04446104 2020-05-13 Povidone-iodine A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial) Prevention 3 Active Not Recruiting NCT04446104 2020-05-13 Acetylcysteine Investigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19 Treatment 3 Recruiting IRCT20080901001165N55 2020-05-13 Barley Investigating the effect of barely-based traditional remedy on controlling of clinical symptoms and paraclinical results in hospitalized patients with COVID-19 Treatment 3 Recruiting IRCT20180923041093N6 2020-05-13 Hydroxychloroquine Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy Treatment 3 Active Not Recruiting NCT04410562 2020-05-13 COVID-19 convalescent plasma An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2. Treatment 1 Active Not Recruiting NCT04397757 2020-05-13 Nitazoxanide A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection Prevention 3 Active Not Recruiting NCT04359680 2020-05-13 Hydroxychloroquine Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial Treatment 3 Active Not Recruiting NCT04339816 2020-05-13 Azithromycin Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial Treatment 3 Active Not Recruiting NCT04339816 2020-05-13 CYNK-001 A Phase I / II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 Treatment 1, 2 Active Not Recruiting NCT04365101 2020-05-13 VPM1002 A phase III, double-blind, randomized, placebo-controlled multicentre clinical trial to assess the efficacy and safety of VPM1002 in reducing healthcare professionals’ absenteeism in the SARS-CoV-2 pandemic by modulating the immune system Treatment 3 Active Not Recruiting EUCTR2020-001376-15-DE 2020-05-13 Human Umbilical Cord Mesenchymal Stem Cells A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19 Treatment 1, 2 Active Not Recruiting NCT04390139 2020-05-13 Enoxaparin Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Prevention 4 Active Not Recruiting NCT04373707 2020-05-13 Nadroparin Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Prevention 4 Active Not Recruiting NCT04373707 2020-05-13 Dalteparin Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Prevention 4 Active Not Recruiting NCT04373707 2020-05-13 Heparin Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Prevention 4 Active Not Recruiting NCT04373707 2020-05-13 Tinzaparin Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Prevention 4 Active Not Recruiting NCT04373707 2020-05-13 Prazosin Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome : A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection Treatment 2 Active Not Recruiting NCT04365257 2020-05-13 Peginterferon lambda-1a Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD) : A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19 Treatment 2 Active Not Recruiting NCT04354259 2020-05-13 Arsenic trioxide EFFECTIVENESS OF ARSENICUM ALBUM 30C IN PREVENTION OF COVID-19 IN INDIVIDUALS RESIDING IN HOSPOTS OF RED ZONES IN DELHIâ?? A PROSPECTIVE COHORT STUDY Treatment Not Available Active Not Recruiting CTRI/2020/05/024986 2020-05-13 COVID-19 convalescent plasma Convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infections Treatment Not Available Active Not Recruiting NL8633 2020-05-12 Hydroxychloroquine Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19 Treatment 4 Active Not Recruiting NCT04466540 2020-05-12 Ivermectin Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial Treatment Not Available Active Not Recruiting NCT04429711 2020-05-12 Melatonin Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients Treatment Not Available Active Not Recruiting NCT04409522 2020-05-12 Famotidine Famotidine Use in Non-hospitalized Patients With COVID-19 : A Case Series Basic Science Not Available Active Not Recruiting NCT04389567 2020-05-12 Plitidepsin Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization Treatment 1 Active Not Recruiting NCT04382066 2020-05-12 Nitazoxanide A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) Prevention 3 Active Not Recruiting NCT04343248 2020-05-12 Ravulizumab A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome Treatment 3 Active Not Recruiting EUCTR2020-001497-30-FR 2020-05-12 Anakinra Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOV Treatment 3 Active Not Recruiting EUCTR2020-001963-10-FR 2020-05-12 Ruxolitinib Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOV Treatment 3 Active Not Recruiting EUCTR2020-001963-10-FR 2020-05-12 Nitric Oxide Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide. Treatment 2 Active Not Recruiting NCT04388683 2020-05-12 Hydroxychloroquine #StayHome : Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland : A Double-blind, Randomised, Placebo-controlled Trial Treatment 2, 3 Active Not Recruiting NCT04385264 2020-05-12 Human Umbilical Cord Mesenchymal Stem Cells Assessment of safety, efficacy and effective dose determination of human umbilical cord Wharton’s jelly mesenchymal stem cell transplantation on treatment of COVID-19 (coronavirus) pneumonia and complications in humans Treatment 2, 3 Recruiting IRCT20200421047150N1 2020-05-12 COVID-19 convalescent plasma The Effect of Convalescent Plasma Therapy on the Outcomes of Patients with 19-COVID Treatment 1, 2 Active Not Recruiting IRCT20150808023559N21 2020-05-12 Molnupiravir AGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILE Treatment 1 Active Not Recruiting EUCTR2020-001860-27-GB 2020-05-12 Nomacopan AGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILE Treatment 1 Active Not Recruiting EUCTR2020-001860-27-GB 2020-05-11 AstraZeneca COVID-19 Vaccine A phase II / III study to determine the efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 Treatment 2, 3 Active Not Recruiting ISRCTN90906759 2020-05-11 Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Treatment 1, 2 Active Not Recruiting NCT04382547 2020-05-11 COVID-19 convalescent plasma Severe Reluctant COVID-19 Patients Responding to Convalescent Plasma ; A case series Treatment Not Available Active Not Recruiting ChiCTR2000033323 2020-05-11 Enoxaparin Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) Treatment 3 Active Not Recruiting NCT04362085 2020-05-11 Dalteparin Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) Treatment 3 Active Not Recruiting NCT04362085 2020-05-11 Heparin Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) Treatment 3 Active Not Recruiting NCT04362085 2020-05-11 Tinzaparin Coagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) Treatment 3 Active Not Recruiting NCT04362085 2020-05-11 COVID-19 convalescent plasma An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection Treatment 2 Active Not Recruiting NCT04354831 2020-05-11 Hydroxychloroquine ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial) Prevention 3 Active Not Recruiting NCT04352933 2020-05-11 Bromhexine Low-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial) Prevention 1 Active Not Recruiting NCT04340349 2020-05-11 Hydroxychloroquine Low-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial) Prevention 1 Active Not Recruiting NCT04340349 2020-05-11 Hydroxychloroquine Randomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZES Treatment 3 Active Not Recruiting CTRI/2020/04/024904 2020-05-11 Azithromycin Randomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZES Treatment 3 Active Not Recruiting CTRI/2020/04/024904 2020-05-11 COVID-19 convalescent plasma Open Label, parallel arm, phase I / II clinical trial to evaluate Safety and efficacy of Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease Treatment 1, 2 Active Not Recruiting CTRI/2020/04/024804 2020-05-11 Ravulizumab A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome Treatment 3 Active Not Recruiting NCT04369469 2020-05-11 Ramipril A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19 Treatment 2 Active Not Recruiting NCT04366050 2020-05-10 COVID-19 convalescent plasma Investigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration : IMPACT Treatment 2, 3 Recruiting ISRCTN85216856 2020-05-09 Human immunoglobulin G Intravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 disease Treatment 3 Active Not Recruiting IRCT20200501047259N1 2020-05-09 COVID-19 convalescent plasma A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Treatment 2 Active Not Recruiting CTRI/2020/04/024915 2020-05-09 Doxycycline Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200418047121N1 2020-05-09 Ascorbic acid Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200418047121N1 2020-05-09 Azithromycin Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200418047121N1 2020-05-09 Metformin Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200418047121N1 2020-05-09 Remestemcel-L Investigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19 : a pilot study Treatment 1, 2 Active Not Recruiting IRCT20200418047121N2 2020-05-09 COVID-19 convalescent plasma A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Treatment 2 Active Not Recruiting NCT04374487 2020-05-09 Thalidomide Effectiveness and safety of thalidomide in moderate COVID-19 pneumonia : A randomized clinical trial Treatment 3 Active Not Recruiting IRCT20200428047232N1 2020-05-08 Anakinra Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2 / 3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection Treatment 2, 3 Active Not Recruiting NCT04443881 2020-05-08 Chloroquine Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare setting Treatment 3 Unknown Status EUCTR2020-001441-39-IT 2020-05-08 Hydroxychloroquine Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare setting Treatment 3 Unknown Status EUCTR2020-001441-39-IT 2020-05-08 Hydroxychloroquine An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Treatment 3 Active Not Recruiting NCT04411433 2020-05-08 Azithromycin An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Treatment 3 Active Not Recruiting NCT04411433 2020-05-08 Favipiravir An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Treatment 3 Active Not Recruiting NCT04411433 2020-05-08 Baricitinib A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II) Treatment 3 Active Not Recruiting NCT04401579 2020-05-08 Remdesivir A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II) Treatment 3 Active Not Recruiting NCT04401579 2020-05-08 Artemisinin A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Treatment 2 Active Not Recruiting NCT04382040 2020-05-08 Curcumin A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Treatment 2 Active Not Recruiting NCT04382040 2020-05-08 Ascorbic acid A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Treatment 2 Active Not Recruiting NCT04382040 2020-05-08 Indian frankincense A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Treatment 2 Active Not Recruiting NCT04382040 2020-05-08 Verapamil Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIO Treatment 3 Active Not Recruiting EUCTR2020-001951-42-PL 2020-05-08 Amiodarone Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIO Treatment 3 Active Not Recruiting EUCTR2020-001951-42-PL 2020-05-08 Tocilizumab Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers : a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS) Treatment 3 Active Not Recruiting NCT04403685 2020-05-08 Colchicine COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial Treatment 2 Active Not Recruiting NCT04403243 2020-05-08 Secukinumab COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial Treatment 2 Active Not Recruiting NCT04403243 2020-05-08 Ruxolitinib COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial Treatment 2 Active Not Recruiting NCT04403243 2020-05-08 Baricitinib mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Treatment 4 Active Not Recruiting NCT04390464 2020-05-08 Ravulizumab mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Treatment 4 Active Not Recruiting NCT04390464 2020-05-08 Ivermectin Novel Treatment Regimens in Treatment of COVID-19 Treatment 3 Active Not Recruiting NCT04382846 2020-05-08 Nitazoxanide Novel Treatment Regimens in Treatment of COVID-19 Treatment 3 Active Not Recruiting NCT04382846 2020-05-08 Chloroquine Novel Treatment Regimens in Treatment of COVID-19 Treatment 3 Active Not Recruiting NCT04382846 2020-05-08 Azithromycin Novel Treatment Regimens in Treatment of COVID-19 Treatment 3 Active Not Recruiting NCT04382846 2020-05-08 Etoposide A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection Supportive Care 2 Active Not Recruiting NCT04356690 2020-05-08 Nitric Oxide Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection Prevention 2 Active Not Recruiting NCT04337918 2020-05-08 Indomethacin Efficacy and safety of oral indomethacin for treatment of covid 19 induced pneumonia Treatment 2, 3 Active Not Recruiting IRCT20200427047215N1 2020-05-08 COVID-19 convalescent plasma Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection Treatment 1 Active Not Recruiting NCT04333355 2020-05-08 Alpha-1-proteinase inhibitor A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19. Treatment 2 Active Not Recruiting EUCTR2020-001953-36-ES 2020-05-08 Human immunoglobulin G A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19 - Study to Evaluate the Safety and Efficacy of High Dose IVIG in Patients with Mild / Moderate COVID19 Treatment 2 Active Not Recruiting EUCTR2020-001696-32-ES 2020-05-08 Washed Microbiota Transplantation Clinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosis Treatment 0 Active Not Recruiting ChiCTR2000032737 2020-05-07 Mavrilimumab A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation : the COMBAT-19 trial - Mavrilimumab in COVID-19 pneumonia with hyperinflammation Treatment 2 Unknown Status EUCTR2020-001795-15-IT 2020-05-07 Hydroxychloroquine Hydroxychloroquine Use in Hospitalized Patients With COVID-19 : Impact on Progression to Severe or Critical Disease Treatment 4 Active Not Recruiting NCT04429867 2020-05-07 Ravulizumab COVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome Treatment 3 Active Not Recruiting EUCTR2020-001497-30-GB 2020-05-07 COVID-19 convalescent plasma Convalescent Plasma for Treatment of COVID-19 : An Exploratory Dose Identifying Study Treatment 1, 2 Active Not Recruiting NCT04384497 2020-05-07 Baricitinib mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R) Treatment 4 Recruiting ISRCTN11188345 2020-05-07 Ravulizumab mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R) Treatment 4 Recruiting ISRCTN11188345 2020-05-07 Clazakizumab A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection Treatment 2 Active Not Recruiting NCT04363502 2020-05-07 Hydroxychloroquine A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID) Prevention 2 Active Not Recruiting NCT04381988 2020-05-07 Remestemcel-L Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19 Treatment 2 Active Not Recruiting NCT04366271 2020-05-07 Piperaquine A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor Treatment 4 Recruiting ChiCTR2000032915 2020-05-07 Artemisinin A randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor Treatment 4 Recruiting ChiCTR2000032915 2020-05-07 Ivermectin Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission Treatment 2 Unknown Status EUCTR2020-001474-29-ES 2020-05-07 Hydroxychloroquine RANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDY Treatment 4 Unknown Status EUCTR2020-002123-11-ES 2020-05-07 Cyclosporine RANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDY Treatment 4 Unknown Status EUCTR2020-002123-11-ES 2020-05-07 Methylprednisolone USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 - USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION Treatment 4 Unknown Status EUCTR2020-001934-37-ES 2020-05-07 Clarithromycin ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY : THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL Treatment 2 Active Not Recruiting EUCTR2020-001882-36-GR 2020-05-07 Azithromycin A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization Treatment 3 Active Not Recruiting NCT04365582 2020-05-07 Lopinavir A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization Treatment 3 Active Not Recruiting NCT04365582 2020-05-07 Ritonavir A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization Treatment 3 Active Not Recruiting NCT04365582 2020-05-07 Hydroxychloroquine A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent Hospitalization Treatment 3 Active Not Recruiting NCT04365582 2020-05-07 Human immunoglobulin G An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2 Treatment 3 Active Not Recruiting NCT04500067 2020-05-06 Hydroxychloroquine PRECOV : a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk - PRECOV Treatment 3 Unknown Status EUCTR2020-001987-28-IT 2020-05-06 Defibrotide Use of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia - Defibrotide in COVID19 Treatment 2 Unknown Status EUCTR2020-001513-20-IT 2020-05-06 Clarithromycin Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early : The ACHIEVE Open-label Non-randomized Clinical Trial Prevention 2 Active Not Recruiting NCT04398004 2020-05-06 Iloprost Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng / kg / min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial Treatment 2 Active Not Recruiting EUCTR2020-001296-33-DK 2020-05-06 ABX-464 A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study). Treatment 2 Active Not Recruiting EUCTR2020-001673-75-FR 2020-05-06 Acalabrutinib A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVI Treatment 2 Active Not Recruiting EUCTR2020-001644-25-FR 2020-05-06 COVID-19 convalescent plasma Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04381858 2020-05-06 Human immunoglobulin G Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04381858 2020-05-06 Clevudine A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19 Treatment 2 Active Not Recruiting NCT04347915 2020-05-06 Hydroxychloroquine An open label randomised controlled trial to assess the efficacy of Hydroxychloroquine in patients with mild COVID -19 illness with risk factors for severe disease. Treatment 2 Active Not Recruiting CTRI/2020/05/025022 2020-05-06 BCG vaccine Phase 2 Clinical Trial for the Evaluation of BCG as potential therapy for CoVID-I9 - COVID-19 BCG Treatment 2 Active Not Recruiting CTRI/2020/05/025013 2020-05-06 Enoxaparin COVID-19-associated Coagulopathy : Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19 Treatment 4 Active Not Recruiting NCT04360824 2020-05-06 Ivermectin Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19 Treatment 3 Unknown Status EUCTR2020-001994-66-ES 2020-05-06 Colchicine A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING SEVERE PULMONARY COMPLICATIONS ASSOCIATED WITH CORONAVIRUS SARS-CoV2 PNEUMONIA (COVID-19) - COLCHI-COVID Treatment 3 Unknown Status EUCTR2020-001603-16-ES 2020-05-06 Ruxolitinib Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN - RAVEN Treatment 4 Active Not Recruiting EUCTR2020-001777-71-GB 2020-05-06 BCG vaccine REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION - BACH (BCG Against COVID-19 in Hunga Treatment 3 Active Not Recruiting EUCTR2020-001783-28-HU 2020-05-06 Interleukin-7 Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial” - ILIAD Treatment 2 Active Not Recruiting EUCTR2020-001786-36-GB 2020-05-06 Captopril Efficacy of captopril nebulization in Covid-19 patients suffering of SARS-CoV-2 pneumonia. A randomized phase II study - CAPTOCOVID Treatment 2 Active Not Recruiting EUCTR2020-001700-42-FR 2020-05-06 COVID-19 convalescent plasma Convalescent Plasma for the Treatment of Patients With COVID-19 Treatment Not Available Active Not Recruiting NCT04372368 2020-05-06 Reparixin Adaptive phase 2 / 3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia - REPAVID-19 Treatment 2 Unknown Status EUCTR2020-001645-40-IT 2020-05-05 COVID-19 convalescent plasma Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19) : A Double-blinded, Placebo-controlled, Proof-of-concept Study Treatment 2 Active Not Recruiting NCT04442191 2020-05-05 Inosine pranobex The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic Trial Treatment 3 Active Not Recruiting NCT04383717 2020-05-05 Levamisole The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic Trial Treatment 3 Active Not Recruiting NCT04383717 2020-05-05 Azithromycin Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia Treatment 4 Active Not Recruiting NCT04351919 2020-05-05 Hydroxychloroquine Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia Treatment 4 Active Not Recruiting NCT04351919 2020-05-05 COVID-19 convalescent plasma Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications : A Phase II Trial Treatment 2 Active Not Recruiting NCT04374565 2020-05-05 Tocilizumab A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg / kg or 4mg / kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia Treatment 2 Active Not Recruiting NCT04363736 2020-05-05 Ruxolitinib Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) - RUXCOVID Treatment 3 Active Not Recruiting EUCTR2020-001662-11-DE 2020-05-05 Human immunoglobulin G "STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19 Treatment 2 Active Not Recruiting NCT04403269 2020-05-05 Namilumab CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19 Treatment 2 Active Not Recruiting EUCTR2020-001684-89-GB 2020-05-05 Infliximab CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19 Treatment 2 Active Not Recruiting EUCTR2020-001684-89-GB 2020-05-05 Gemtuzumab ozogamicin CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19 Treatment 2 Active Not Recruiting EUCTR2020-001684-89-GB 2020-05-05 COVID-19 convalescent plasma A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection Treatment 2 Active Not Recruiting NCT04392232 2020-05-05 Leflunomide Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19 Treatment 1 Active Not Recruiting NCT04361214 2020-05-05 Remdesivir Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections. Basic Science Not Available Active Not Recruiting NCT04365725 2020-05-05 Hydroxychloroquine Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Treatment 2 Active Not Recruiting NCT04379492 2020-05-05 Lidocaine Usage of topical lignocaine to decrease the gag reflex while sampling for Covid-19 : Does it affect the yield of specimen? Treatment Not Available Active Not Recruiting CTRI/2020/05/024983 2020-05-05 Povidone-iodine Effectiveness of topical povidone iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic amongst COVID-19 positive patients in Andhra Pradesh, India Treatment Not Available Active Not Recruiting CTRI/2020/05/024962 2020-05-05 Hydroxychloroquine RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics Treatment 2 Active Not Recruiting NCT04374552 2020-05-05 Azithromycin RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics Treatment 2 Active Not Recruiting NCT04374552 2020-05-05 Azithromycin A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) - ATOMIC2, Version 1.0 Treatment 2 Active Not Recruiting EUCTR2020-001740-26-GB 2020-05-05 Captopril Efficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II Study Treatment 2 Active Not Recruiting NCT04355429 2020-05-05 Remestemcel-L Phase I trial on safety and tolerability of bone-marrow derived mesenchymal stromal cells (MSC) for deteriorating COVID-19 pneumonia Treatment 1 Recruiting ACTRN12620000840987 2020-05-05 COVID-19 convalescent plasma TRANSFUSION WITH CONVALING PLASMA IMMUNIZES THE ASYMPTOMATIC PATIENT WITH COVID INFECTION 19 THAT FOR MORE THAN 30 DAYS IS POSITIVE SARS CoV-2 PCR (COVID-19) Basic Science Not Available Completed RPCEC00000323 2020-05-05 Filgrastim Treatment of lung lesions with autologous stem cells in patients recovered from COVID-19 (COVID-19) Treatment Not Available Recruiting RPCEC00000322 2020-05-04 Tocilizumab Unicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04435717 2020-05-04 Vitamin A Assessment of vitamin A effectiveness on COVID-19 patients and treatment outcomes referred to health centers of Qom province Treatment 3 Active Not Recruiting IRCT20200314046774N1 2020-05-04 Tranilast Assessment of the effect of Tranilast on the efficacy of antiviral drug regimens in the treatment of patients with severe COVID19 Treatment 3 Active Not Recruiting IRCT20200419047128N1 2020-05-04 Hydroxychloroquine Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04391127 2020-05-04 Ivermectin Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04391127 2020-05-04 Interferon alfa-2b Pharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19). Treatment 1 Completed RPCEC00000308 2020-05-04 Ascorbic acid Effect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients : a medical records based retrospective study Basic Science Not Available Recruiting ChiCTR2000033050 2020-05-04 COVID-19 convalescent plasma The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease Treatment 2 Active Not Recruiting NCT04385199 2020-05-04 Hydroxychloroquine Generic Protocol on Hydroxychloroquine Prophylaxis for COVID-19 Infection Among Healthcare Workers : A Proof-of-Concept, Observational Study - HCQPRo Basic Science Not Available Active Not Recruiting CTRI/2020/05/025010 2020-05-04 Camphor Proving the efficacy of Homeopathic treatment in prevention and cure of COVID-19. Treatment 1, 2 Active Not Recruiting CTRI/2020/04/024857 2020-05-04 Hydroxychloroquine Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel : a placebo-controlled, randomized, clinical trial Treatment 4 Active Not Recruiting SLCTR/2020/011 2020-05-04 Colchicine Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19 Treatment 3 Recruiting IRCT20200418047126N1 2020-05-04 COVID-19 convalescent plasma Investigation of the effects of COVID-19 convalescent plasma in acute respiratory distress syndrome due to COVID-19 Treatment 2, 3 Active Not Recruiting IRCT20200501047258N1 2020-05-04 Curcumin Effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial study Treatment Not Available Active Not Recruiting IRCT20121216011763N46 2020-05-04 Piperine Effect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial study Treatment Not Available Active Not Recruiting IRCT20121216011763N46 2020-05-04 Deferiprone Investigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19) Treatment 3 Active Not Recruiting IRCT20180114038350N3 2020-05-04 Sitagliptin Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19 Treatment 2, 3 Active Not Recruiting IRCT20200420047147N1 2020-05-04 Trifluoperazine Evaluation of Trifluoperazine Effectiveness in Treatment Process, Survival rate and Cure rate of COVID-19 Patients Treatment 2, 3 Active Not Recruiting IRCT20200329046892N1 2020-05-04 Sugarcane Effect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of COVID-19 disease Treatment 2, 3 Active Not Recruiting IRCT20200415047082N1 2020-05-04 COVID-19 convalescent plasma Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients Treatment 2, 3 Active Not Recruiting IRCT20200406046968N2 2020-05-04 Ivermectin Dose-Finding study of Ivermectin treatment on patients infected with Covid-19 : A clinical trial Treatment 3 Active Not Recruiting IRCT20200408046987N1 2020-05-04 Levamisole Assessment of effect of levamisole on pneumonia caused by COVID-19 Treatment 4 Active Not Recruiting IRCT20131215015805N2 2020-05-04 BCG vaccine Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial Prevention 3 Active Not Recruiting NCT04379336 2020-05-04 Hydroxychloroquine A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit) Prevention 3 Active Not Recruiting NCT04377646 2020-05-04 Zinc A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit) Prevention 3 Active Not Recruiting NCT04377646 2020-05-04 COVID-19 convalescent plasma Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection : a Randomized Phase II Trial Treatment 2 Active Not Recruiting NCT04375098 2020-05-04 Tocilizumab Single-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19 Treatment 2 Unknown Status EUCTR2020-002032-69-ES 2020-05-04 Enoxaparin Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) - Heparin-SARS-CoV2 Treatment 2 Unknown Status EUCTR2020-001891-14-ES 2020-05-04 AstraZeneca COVID-19 Vaccine A phase 2 / 3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 - Investigating a Vaccine Against COVID-19 (COV002) Treatment 2 Active Not Recruiting EUCTR2020-001228-32-GB 2020-05-04 COVID-19 convalescent plasma A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVER Treatment 2 Active Not Recruiting EUCTR2020-001632-10-DE 2020-05-04 Poractant alfa Preliminary randomized controlled trial of poractant alfa (Curosurf®) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. - CAARDS-1 Treatment 2 Active Not Recruiting EUCTR2020-001598-66-FR 2020-05-04 Isoquercetin A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients. Treatment 2 Active Not Recruiting EUCTR2020-001635-27-FR 2020-05-04 Hydroxychloroquine A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients. Treatment 2 Active Not Recruiting EUCTR2020-001635-27-FR 2020-05-04 Masitinib A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients. Treatment 2 Active Not Recruiting EUCTR2020-001635-27-FR 2020-05-03 Dipyridamole A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients Treatment 2 Active Not Recruiting NCT04424901 2020-05-03 Basic Fibroblast Growth Factor Identification of predictive biomarkers for severe progression of COVID-19 Basic Science Not Available Active Not Recruiting DRKS00021591 2020-05-03 Interleukin-10 Identification of predictive biomarkers for severe progression of COVID-19 Basic Science Not Available Active Not Recruiting DRKS00021591 2020-05-03 Interleukin-1 alpha, human recombinant Identification of predictive biomarkers for severe progression of COVID-19 Basic Science Not Available Active Not Recruiting DRKS00021591 2020-05-03 Human interferon beta Identification of predictive biomarkers for severe progression of COVID-19 Basic Science Not Available Active Not Recruiting DRKS00021591 2020-05-03 Interferon Gamma Identification of predictive biomarkers for severe progression of COVID-19 Basic Science Not Available Active Not Recruiting DRKS00021591 2020-05-02 Hydroxychloroquine A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh Basic Science Not Available Active Not Recruiting NCT04434144 2020-05-02 Doxycycline A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh Basic Science Not Available Active Not Recruiting NCT04434144 2020-05-02 Azithromycin A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh Basic Science Not Available Active Not Recruiting NCT04434144 2020-05-02 Ivermectin A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh Basic Science Not Available Active Not Recruiting NCT04434144 2020-05-02 Placental Mesenchymal Stem Cells Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord Treatment 1, 2 Active Not Recruiting NCT04461925 2020-05-02 Human Umbilical Cord Mesenchymal Stem Cells Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord Treatment 1, 2 Active Not Recruiting NCT04461925 2020-05-02 COVID-19 convalescent plasma A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19 : DAWN-PLASMA Treatment 2 Active Not Recruiting NCT04429854 2020-05-02 Ruxolitinib Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) Treatment 3 Active Not Recruiting NCT04362137 2020-05-02 Heparin Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID) Treatment 4 Active Not Recruiting NCT04367831 2020-05-02 Enoxaparin Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID) Treatment 4 Active Not Recruiting NCT04367831 2020-05-02 Lithium carbonate Clinical trial of lithium in improving the clinical and laboratory symptoms of patients with COVID-19 Treatment 2 Active Not Recruiting IRCT20081019001369N5 2020-05-02 Azithromycin Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVID Treatment 3 Active Not Recruiting NCT04371406 2020-05-02 Hydroxychloroquine Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVID Treatment 3 Active Not Recruiting NCT04371406 2020-05-02 Enoxaparin Evaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients. Treatment 4 Active Not Recruiting NCT04520620 2020-05-01 Remestemcel-L Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19) Treatment 2 Active Not Recruiting NCT04444271 2020-05-01 Enoxaparin EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19 Basic Science Not Available Active Not Recruiting NCT04425863 2020-05-01 Dexamethasone EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19 Basic Science Not Available Active Not Recruiting NCT04425863 2020-05-01 Acetylsalicylic acid EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19 Basic Science Not Available Active Not Recruiting NCT04425863 2020-05-01 Ivermectin EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19 Basic Science Not Available Active Not Recruiting NCT04425863 2020-05-01 COVID-19 convalescent plasma Convalescent Plasma for Passive Immunization in COVID-19 ICU Patients : An Interventional Study Treatment 1 Active Not Recruiting NCT04565197 2020-05-01 Tocilizumab Tocilizumab : A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19 Treatment 1 Active Not Recruiting NCT04560205 2020-05-01 Methylprednisolone Perks of Methylprednisolone for Hospitalized COVID-19 Patients : A Clinical Trial Treatment Not Available Active Not Recruiting NCT04559113 2020-05-01 Remestemcel-L Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study Treatment 2 Active Not Recruiting NCT04416139 2020-05-01 COVID-19 convalescent plasma Convalescent Plasma Therapy in Patients With COVID-19 Health Services Research 1 Active Not Recruiting NCT04407208 2020-05-01 COVID-19 convalescent plasma Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease Treatment 2 Active Not Recruiting NCT04392414 2020-05-01 Ibuprofen Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19. Treatment Not Available Active Not Recruiting NCT04382768 2020-05-01 Calcium Evaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia : A Single Center Experience in Turkey Basic Science Not Available Active Not Recruiting NCT04379310 2020-05-01 Acetylcysteine Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection Treatment 2 Active Not Recruiting NCT04374461 2020-05-01 Hydroxychloroquine A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19 Treatment 2 Active Not Recruiting NCT04373044 2020-05-01 Baricitinib A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19 Treatment 2 Active Not Recruiting NCT04373044 2020-05-01 Azithromycin A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 Treatment 2 Active Not Recruiting NCT04358068 2020-05-01 Hydroxychloroquine A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 Treatment 2 Active Not Recruiting NCT04358068 2020-05-01 Tocilizumab A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection Treatment 2 Active Not Recruiting NCT04377659 2020-05-01 COVID-19 convalescent plasma Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial Treatment 3 Active Not Recruiting NCT04345289 2020-05-01 Favipiravir Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh Treatment 2, 3 Active Not Recruiting NCT04402203 2020-05-01 COVID-19 convalescent plasma A pilot randomized clinical trial of therapeutic plasma exchange (TPE) in serious SARS CoV-2 disease (COVID-19) Treatment Not Available Recruiting ISRCTN21363594 2020-05-01 COVID-19 convalescent plasma Convalescent Plasma To Limit COVID-19 Associated Complications : A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma To Placebo in COVID-19 Hospitalized Patients Treatment 2 Active Not Recruiting NCT04404634 2020-05-01 Human Umbilical Cord Mesenchymal Stem Cells A Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia Treatment 1, 2 Active Not Recruiting NCT04398303 2020-05-01 Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media A Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia Treatment 1, 2 Active Not Recruiting NCT04398303 2020-05-01 Povidone-iodine Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents? Treatment 1 Active Not Recruiting NCT04393792 2020-05-01 COVID-19 convalescent plasma Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2 : a Multicenter Open Label Randomized Control Trial Treatment 2 Active Not Recruiting NCT04393727 2020-05-01 ABX-464 A Phase 2 / 3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged = 65 and Patients Aged =18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2. Treatment 2, 3 Active Not Recruiting NCT04393038 2020-05-01 Hydroxychloroquine A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease Treatment 3 Active Not Recruiting NCT04358081 2020-05-01 Azithromycin A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease Treatment 3 Active Not Recruiting NCT04358081 2020-05-01 Colchicine Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19) Treatment 2 Active Not Recruiting NCT04355143 2020-05-01 COVID-19 convalescent plasma A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases Treatment 2 Active Not Recruiting NCT04390503 2020-05-01 COVID-19 convalescent plasma Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units. Treatment 3 Active Not Recruiting NCT04372979 2020-05-01 Hydroxychloroquine Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel Prevention 2 Active Not Recruiting NCT04359537 2020-05-01 Sarilumab Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection Treatment 1 Active Not Recruiting NCT04386239 2020-05-01 COVID-19 convalescent plasma Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection Treatment 2, 3 Active Not Recruiting NCT04385043 2020-05-01 COVID-19 convalescent plasma Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 Treatment Not Available Active Not Recruiting NCT04352751 2020-05-01 Clazakizumab A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection Treatment 2 Active Not Recruiting NCT04381052 2020-05-01 Itolizumab A Multi-Centre, Open label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications Treatment 2 Completed CTRI/2020/05/024959 2020-05-01 BCG vaccine Effect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers â?? a double blind randomized controlled trial Treatment Not Available Active Not Recruiting CTRI/2020/04/024833 2020-05-01 Lopinavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL Treatment 3 Active Not Recruiting CTRI/2020/04/024773 2020-05-01 Chloroquine An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL Treatment 3 Active Not Recruiting CTRI/2020/04/024773 2020-05-01 Remdesivir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL Treatment 3 Active Not Recruiting CTRI/2020/04/024773 2020-05-01 Ritonavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL Treatment 3 Active Not Recruiting CTRI/2020/04/024773 2020-05-01 Hydroxychloroquine An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIAL Treatment 3 Active Not Recruiting CTRI/2020/04/024773 2020-05-01 Azithromycin Evaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trial Treatment 2 Active Not Recruiting RBR-3k4wxb 2020-05-01 Hydroxychloroquine Evaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trial Treatment 2 Active Not Recruiting RBR-3k4wxb 2020-05-01 Hydroxychloroquine Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20080901001165N51 2020-05-01 Azithromycin Investigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20080901001165N50 2020-05-01 Dialyzable leukocyte extract Assessment of the Clinical Effect of Dialyzable Leukocyte Extracts in Individuals With Acute Respiratory Infection (Suspected or Confirmed Cases of COVID-19) (FUTURE-T) Treatment 2 Active Not Recruiting NCT04379479 2020-05-01 Methylprednisolone hemisuccinate Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial Treatment 2 Active Not Recruiting NCT04377503 2020-05-01 Tocilizumab Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial Treatment 2 Active Not Recruiting NCT04377503 2020-05-01 Fluoxetine Fluoxetine to Reduce Intubation and Death After COVID19 Infection Treatment 4 Active Not Recruiting NCT04377308 2020-05-01 Tridecactide An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection Treatment 2, 3 Active Not Recruiting NCT04374032 2020-05-01 Metenkefalin An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection Treatment 2, 3 Active Not Recruiting NCT04374032 2020-05-01 Ivermectin Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients Treatment 2 Active Not Recruiting NCT04374019 2020-05-01 Azithromycin Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients Treatment 2 Active Not Recruiting NCT04374019 2020-05-01 Wormwood Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients Treatment 2 Active Not Recruiting NCT04374019 2020-05-01 Camostat Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients Treatment 2 Active Not Recruiting NCT04374019 2020-05-01 Hydroxychloroquine Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients Treatment 2 Active Not Recruiting NCT04374019 2020-05-01 Sirolimus A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19) Treatment 1 Active Not Recruiting NCT04371640 2020-05-01 Ascorbic acid Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment Treatment 2 Active Not Recruiting NCT04363216 2020-05-01 Hydroxychloroquine Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label Trial Treatment Not Available Active Not Recruiting NCT04374903 2020-05-01 Azithromycin Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label Trial Treatment Not Available Active Not Recruiting NCT04374903 2020-05-01 Sirolimus Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label Trial Treatment Not Available Active Not Recruiting NCT04374903 2020-05-01 Favipiravir A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19 : Favipiravir and StaNdard Care vErsEs Standard CaRe Treatment 3 Active Not Recruiting NCT04373733 2020-05-01 BCG vaccine Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial Prevention 3 Active Not Recruiting NCT04373291 2020-05-01 Niclosamide Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled Trial Treatment 3 Active Not Recruiting NCT04372082 2020-05-01 Hydroxychloroquine Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled Trial Treatment 3 Active Not Recruiting NCT04372082 2020-05-01 Diltiazem Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled Trial Treatment 3 Active Not Recruiting NCT04372082 2020-05-01 Hydroxychloroquine Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health : A Randomized, Double-blind, Placebo-controlled Trial Prevention 3 Active Not Recruiting NCT04364815 2020-05-01 Fondaparinux Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19) Basic Science Not Available Active Not Recruiting NCT04359212 2020-05-01 Heparin Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19) Basic Science Not Available Active Not Recruiting NCT04359212 2020-05-01 Hydroxychloroquine A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients Prevention Not Available Active Not Recruiting NCT04354597 2020-05-01 Azithromycin A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients Prevention Not Available Active Not Recruiting NCT04354597 2020-05-01 Povidone-iodine Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? - SINUS WASH pilot study Treatment 2 Active Not Recruiting EUCTR2020-001721-31-GB 2020-05-01 Hydroxychloroquine Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE) : A Parallel Randomized Controlled Trial Prevention 3 Active Not Recruiting NCT04371523 2020-05-01 Dornase alfa A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19 Treatment 2 Active Not Recruiting NCT04359654 2020-05-01 Methotrexate Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles : A Phase I / II Study Treatment 1, 2 Active Not Recruiting NCT04352465 2020-05-01 Hydroxychloroquine A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19) Treatment 4 Active Not Recruiting NCT04363866 2020-05-01 Acetylsalicylic acid The LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Treatment 2 Active Not Recruiting NCT04363840 2020-05-01 Vitamin D The LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Treatment 2 Active Not Recruiting NCT04363840 2020-05-01 Nitazoxanide Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope Treatment 2, 3 Active Not Recruiting NCT04361318 2020-05-01 Hydroxychloroquine Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope Treatment 2, 3 Active Not Recruiting NCT04361318 2020-05-01 Chloroquine Multi-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa Treatment 3 Active Not Recruiting NCT04360759 2020-05-01 Hydroxychloroquine Multi-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa Treatment 3 Active Not Recruiting NCT04360759 2020-05-01 Ivermectin Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope Treatment 2, 3 Active Not Recruiting NCT04360356 2020-05-01 Nitazoxanide Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University Hope Treatment 2, 3 Active Not Recruiting NCT04360356 2020-05-01 COVID-19 convalescent plasma Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 Treatment Not Available Active Not Recruiting NCT04358211 2020-05-01 COVID-19 convalescent plasma Convalescent Plasma for Patients With COVID-19 : A Pilot Study Treatment 2 Active Not Recruiting NCT04332380 2020-05-01 Hydroxychloroquine Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection : HyPreC Trial Treatment 2 Active Not Recruiting NCT04354441 2020-05-01 Mavrilimumab Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation Treatment 2 Active Not Recruiting NCT04337216 2020-05-01 Hydroxychloroquine Phase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infection Treatment 2 Active Not Recruiting RBR-8h7q82 2020-05-01 Chloroquine Phase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infection Treatment 2 Active Not Recruiting RBR-8h7q82 2020-05-01 Ivermectin Phase II study on chloroquine and hydroxychloroquine in patients with manifestations serious cases of COVID-19 infection Treatment 2 Active Not Recruiting RBR-8h7q82 2020-05-01 Itolizumab A Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications Treatment 2 Active Not Recruiting NCT04475588 2020-04-30 COVID-19 convalescent plasma An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients Basic Science Not Available Active Not Recruiting NCT04471051 2020-04-30 Dornase alfa A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised participants with COVID-19 (The COVASE trial) - Dornase alfa to reduce hyperinflammation in COVID19 - The COVASE trial Treatment 2 Unknown Status EUCTR2020-001937-11-GB 2020-04-30 Remestemcel-L Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome Treatment 3 Active Not Recruiting NCT04371393 2020-04-30 Canakinumab Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID) Treatment 3 Active Not Recruiting NCT04362813 2020-04-30 Honey The Role of Honey and Nigella Sativa in the Management of COVID-19 ; A Randomized Controlled, Open-label, Add-on Trial in Lahore, Pakistan Treatment 3 Active Not Recruiting NCT04347382 2020-04-30 COVID-19 convalescent plasma An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2 Treatment 1 Active Not Recruiting NCT04388527 2020-04-30 Lenzilumab A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia Treatment 3 Active Not Recruiting NCT04351152 2020-04-30 Yohimbine Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI Treatment 1 Completed DRKS00021573 2020-04-30 Midazolam Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI Treatment 1 Completed DRKS00021573 2020-04-30 Pantoprazole Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI Treatment 1 Completed DRKS00021573 2020-04-30 Hydroxychloroquine Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPI Treatment 1 Completed DRKS00021573 2020-04-30 COVID-19 convalescent plasma Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety Treatment Not Available Active Not Recruiting NCT04397523 2020-04-30 COVID-19 convalescent plasma A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity Treatment 3 Active Not Recruiting NCT04361253 2020-04-30 BCG vaccine Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. - BCG-DENMARK-COVID Treatment 3 Active Not Recruiting EUCTR2020-001888-90-DK 2020-04-30 Melphalan Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19 Treatment 2 Active Not Recruiting NCT04380376 2020-04-30 Hydroxychloroquine VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL) Treatment 3 Active Not Recruiting NCT04363203 2020-04-30 Azithromycin VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL) Treatment 3 Active Not Recruiting NCT04363203 2020-04-30 Mycobacterium w. Vaccine A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection Treatment Not Available Active Not Recruiting NCT04347174 2020-04-30 Mycobacterium w. Vaccine A clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infection Treatment Not Available Active Not Recruiting CTRI/2020/04/024846 2020-04-30 Hydroxychloroquine Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada Prevention 3 Active Not Recruiting NCT04374942 2020-04-30 Alunacedase alfa Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 Treatment 2 Active Not Recruiting NCT04335136 2020-04-30 Ruxolitinib Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS) Treatment 2 Active Not Recruiting NCT04374149 2020-04-30 Colchicine Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria. Treatment 3 Active Not Recruiting NCT04350320 2020-04-30 Methylprednisolone EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL - CORTIVID Treatment 3 Unknown Status EUCTR2020-001827-15-ES 2020-04-30 Azithromycin Azithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04363060 2020-04-30 Amoxicillin Azithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04363060 2020-04-30 Clavulanic acid Azithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04363060 2020-04-30 Hydroxychloroquine Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19) Treatment 3 Active Not Recruiting NCT04361461 2020-04-30 Mycobacterium w. Vaccine A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19. Prevention 3 Active Not Recruiting NCT04353518 2020-04-30 Selinexor A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19 Treatment 2 Active Not Recruiting NCT04355676 2020-04-30 Hydroxychloroquine Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death Treatment 1 Active Not Recruiting NCT04323631 2020-04-30 Losartan Aspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trial Treatment 3 Active Not Recruiting PACTR202006473370201 2020-04-30 Acetylsalicylic acid Aspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trial Treatment 3 Active Not Recruiting PACTR202006473370201 2020-04-30 Simvastatin Aspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trial Treatment 3 Active Not Recruiting PACTR202006473370201 2020-04-29 Quercetin Evaluation of the effect of quercetin on the effectiveness of antiviral drug regimen in patients with COVID19 Treatment 3 Active Not Recruiting IRCT20200419047128N2 2020-04-29 Azithromycin Proactive Care of Ambulatory COVID19 Patients : Open-labeled Randomized Trial Treatment 3 Active Not Recruiting NCT04371107 2020-04-29 BNT162b1 SARS-CoV-2 Vaccine A PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS Prevention 2, 3 Active Not Recruiting NCT04368728 2020-04-29 Tozinameran A PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS Prevention 2, 3 Active Not Recruiting NCT04368728 2020-04-29 Remdesivir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-LT 2020-04-29 Hydroxychloroquine An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-LT 2020-04-29 Lopinavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-LT 2020-04-29 Ritonavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-LT 2020-04-29 Chloroquine An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-LT 2020-04-29 Interferon beta-1a An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity Treatment 4 Active Not Recruiting EUCTR2020-001366-11-LT 2020-04-29 Hydroxychloroquine Chloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV) Prevention Not Available Active Not Recruiting NCT04303507 2020-04-29 Chloroquine Chloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV) Prevention Not Available Active Not Recruiting NCT04303507 2020-04-29 Povidone-iodine Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic Prevention 2 Active Not Recruiting NCT04364802 2020-04-29 Azoximer bromide A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19). Treatment 2, 3 Active Not Recruiting NCT04381377 2020-04-29 Ketamine Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 Treatment 2 Active Not Recruiting NCT04365985 2020-04-29 Naltrexone Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 Treatment 2 Active Not Recruiting NCT04365985 2020-04-29 Colchicine Evaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad : A triple-blind randomized placebo controlled clinical trial Treatment 3 Active Not Recruiting IRCT20200408046990N2 2020-04-29 Hydroxychloroquine Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200421047155N1 2020-04-29 Tenofovir Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200421047155N1 2020-04-29 Interferon beta-1b effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital Treatment 2 Recruiting IRCT20200406046968N3 2020-04-29 Hydroxychloroquine Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19 Treatment 1, 2 Active Not Recruiting IRCT20150808023559N20 2020-04-29 Lopinavir Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19 Treatment 1, 2 Active Not Recruiting IRCT20150808023559N20 2020-04-29 Ritonavir Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19 Treatment 1, 2 Active Not Recruiting IRCT20150808023559N20 2020-04-29 Favipiravir Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19 Treatment 1, 2 Active Not Recruiting IRCT20150808023559N20 2020-04-29 Umifenovir Evaluation of the effect of Arbidol drug in the treatment of hospitalized patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20180725040596N2 2020-04-29 Albumin human Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled Trial Treatment 2 Active Not Recruiting NCT04374539 2020-04-29 Human immunoglobulin G Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled Trial Treatment 2 Active Not Recruiting NCT04374539 2020-04-29 Favipiravir A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEER Treatment 3 Active Not Recruiting EUCTR2020-001449-38-GB 2020-04-29 Hydroxychloroquine A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEER Treatment 3 Active Not Recruiting EUCTR2020-001449-38-GB 2020-04-29 Zinc A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEER Treatment 3 Active Not Recruiting EUCTR2020-001449-38-GB 2020-04-29 Azithromycin A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEER Treatment 3 Active Not Recruiting EUCTR2020-001449-38-GB 2020-04-29 Dalteparin Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE Treatment 4 Active Not Recruiting EUCTR2020-001709-21-FR 2020-04-29 Nadroparin Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE Treatment 4 Active Not Recruiting EUCTR2020-001709-21-FR 2020-04-29 Heparin Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE Treatment 4 Active Not Recruiting EUCTR2020-001709-21-FR 2020-04-29 Enoxaparin Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE Treatment 4 Active Not Recruiting EUCTR2020-001709-21-FR 2020-04-29 Tinzaparin Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE Treatment 4 Active Not Recruiting EUCTR2020-001709-21-FR 2020-04-29 Canakinumab Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID). Treatment 3 Active Not Recruiting EUCTR2020-001370-30-DE 2020-04-29 Losartan Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE Treatment 2 Active Not Recruiting EUCTR2020-001766-11-FR 2020-04-29 Spironolactone Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE Treatment 2 Active Not Recruiting EUCTR2020-001766-11-FR 2020-04-29 Remdesivir WHO SOLIDARITY Finland : The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - SOLIDARITY Finland Treatment 3 Active Not Recruiting EUCTR2020-001784-88-FI 2020-04-29 Chlorpromazine Repurposing of Chlorpromazine in Covid-19 Treatment Treatment 3 Active Not Recruiting NCT04366739 2020-04-29 BBIBP-CorV Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above : a randomized, double-blind, placebo parallel-controlled phase I / II clinical trial Treatment 1, 2 Active Not Recruiting ChiCTR2000032459 2020-04-29 Chloroquine Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study Treatment 3 Recruiting ISRCTN10207947 2020-04-29 Hydroxychloroquine Chloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study Treatment 3 Recruiting ISRCTN10207947 2020-04-29 Artesunate Randomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19 Treatment 2 Active Not Recruiting PACTR202006899597082 2020-04-29 Ascorbic acid Randomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19 Treatment 2 Active Not Recruiting PACTR202006899597082 2020-04-29 Tocilizumab Study of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients : a ?crinical trial study Treatment 2 Recruiting IRCT20081027001411N4 2020-04-29 Adalimumab Evaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19 Treatment 3 Recruiting IRCT20171105037262N4 2020-04-29 COVID-19 convalescent plasma A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU) Treatment 2 Active Not Recruiting NCT04547127 2020-04-29 Methylene blue A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU) Treatment 2 Active Not Recruiting NCT04547127 2020-04-28 Dornase alfa Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure Treatment 2 Active Not Recruiting NCT04445285 2020-04-28 Hydroxychloroquine PROTECT : A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). - PROTECT Treatment 2 Unknown Status EUCTR2020-001501-24-IT 2020-04-28 COVID-19 convalescent plasma Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19 Prevention 2 Active Not Recruiting NCT04434131 2020-04-28 Hydroxychloroquine Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study Prevention 3 Active Not Recruiting NCT04349228 2020-04-28 Human immunoglobulin G Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection Treatment 4 Active Not Recruiting NCT04411667 2020-04-28 Zilucoplan ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients Treatment 2 Active Not Recruiting EUCTR2020-001736-95-GB 2020-04-28 Heparin ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients Treatment 2 Active Not Recruiting EUCTR2020-001736-95-GB 2020-04-28 Bemcentinib ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients Treatment 2 Active Not Recruiting EUCTR2020-001736-95-GB 2020-04-28 Acalabrutinib ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients Treatment 2 Active Not Recruiting EUCTR2020-001736-95-GB 2020-04-28 Olitigaltin ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients Treatment 2 Active Not Recruiting EUCTR2020-001736-95-GB 2020-04-28 COVID-19 convalescent plasma Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease Treatment 1 Active Not Recruiting NCT04355897 2020-04-28 Hydroxychloroquine A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Treatment 4 Active Not Recruiting NCT04370782 2020-04-28 Zinc sulfate A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Treatment 4 Active Not Recruiting NCT04370782 2020-04-28 Doxycycline A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Treatment 4 Active Not Recruiting NCT04370782 2020-04-28 Azithromycin A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Treatment 4 Active Not Recruiting NCT04370782 2020-04-28 MultiStem A Phase 2 / 3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19) Treatment 2, 3 Active Not Recruiting NCT04367077 2020-04-28 Anakinra CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 - ANA-COVID-GEAS Treatment 2 Unknown Status EUCTR2020-001825-29-ES 2020-04-28 Canakinumab Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID). Treatment 3 Active Not Recruiting EUCTR2020-001370-30-GB 2020-04-28 Calcifediol Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS) Treatment 2 Active Not Recruiting NCT04366908 2020-04-28 Enoxaparin Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation : a Multicentric Randomized, Open-label Clinical Trial Treatment 3 Active Not Recruiting NCT04345848 2020-04-28 BCG vaccine Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.” COVID-BCG - COVID BCG Treatment 3 Active Not Recruiting EUCTR2020-001678-31-FR 2020-04-28 Enoxaparin Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study - COV-ENOX Treatment 4 Active Not Recruiting EUCTR2020-001823-15-FR 2020-04-28 Atibuclimab Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) Treatment Not Available Active Not Recruiting NCT04346277 2020-04-27 Siltuximab Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID Treatment 2 Unknown Status EUCTR2020-001854-23-IT 2020-04-27 Hydroxychloroquine Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID Treatment 2 Unknown Status EUCTR2020-001854-23-IT 2020-04-27 Tocilizumab Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID Treatment 2 Unknown Status EUCTR2020-001854-23-IT 2020-04-27 Canakinumab Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID Treatment 2 Unknown Status EUCTR2020-001854-23-IT 2020-04-27 Sarilumab Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID Treatment 2 Unknown Status EUCTR2020-001854-23-IT 2020-04-27 Baricitinib Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVID Treatment 2 Unknown Status EUCTR2020-001854-23-IT 2020-04-27 Sarilumab A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia - ESCAPE Treatment 3 Unknown Status EUCTR2020-001390-76-IT 2020-04-27 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 Treatment 1, 2 Active Not Recruiting NCT04366323 2020-04-27 COVID-19 convalescent plasma Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia Treatment 2 Active Not Recruiting NCT04358783 2020-04-27 Anakinra Efficacy and Safety of ANAkinra During Adult " COVID-19 " With Aggravating Respiratory Symptoms : a Multicenter Open-label Controlled Randomized Trial Treatment 3 Active Not Recruiting NCT04364009 2020-04-27 Chloroquine Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients Treatment 4 Completed TCTR20200404004 2020-04-27 Ascorbic acid Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients Treatment 4 Completed TCTR20200404004 2020-04-27 Interferon beta-1a An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting LBCTR2020043495 2020-04-27 Remdesivir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting LBCTR2020043495 2020-04-27 Lopinavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting LBCTR2020043495 2020-04-27 Hydroxychloroquine An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting LBCTR2020043495 2020-04-27 Ritonavir An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting LBCTR2020043495 2020-04-27 Chloroquine An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY Treatment 3 Active Not Recruiting LBCTR2020043495 2020-04-27 Natural Killer Cell Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial Treatment 1, 2 Active Not Recruiting IRCT20200417047113N1 2020-04-27 Human immunoglobulin G "STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19 - GERONIMO19 Treatment 2 Active Not Recruiting EUCTR2020-001768-27-FR 2020-04-27 Azithromycin A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic Prevention 2 Active Not Recruiting NCT04369365 2020-04-27 Hydroxychloroquine Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) Prevention 3 Active Not Recruiting NCT04363450 2020-04-27 COVID-19 convalescent plasma Convalescent Plasma for the Treatment of Moderate-severe COVID-19 : A Proof-of-principle Study Treatment Not Available Active Not Recruiting NCT04365439 2020-04-27 Progesterone A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men Treatment 1 Active Not Recruiting NCT04365127 2020-04-27 Sarilumab Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome Treatment 2 Active Not Recruiting NCT04357860 2020-04-27 Amiodarone Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms Treatment 2, 3 Active Not Recruiting NCT04351763 2020-04-27 Verapamil Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms Treatment 2, 3 Active Not Recruiting NCT04351763 2020-04-27 CIGB-258 peptide Expanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19) Treatment Not Available Completed RPCEC00000321 2020-04-26 Selenium Investigating the effectiveness of selenium on recovery of hospitalized patients with COVID-19 Treatment 3 Recruiting IRCT20190418043307N1 2020-04-26 Enoxaparin Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial) Treatment 3 Active Not Recruiting NCT04401293 2020-04-26 Isoflurane Volatile agents for sedation in patients with COVID-19-associated acute respiratory distress syndrome – a pilot study Treatment Not Available Active Not Recruiting NL8523 2020-04-26 Imatinib Efficacy of Imatinib in mild SARS CoV2 infection : A randomized study Treatment 2 Active Not Recruiting CTRI/2020/04/024806 2020-04-26 Pirfenidone The evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19 Treatment 3 Active Not Recruiting IRCT20200314046764N1 2020-04-26 Colchicine COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study) Treatment 2 Active Not Recruiting NCT04363437 2020-04-26 D-glucose Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19 Treatment 4 Unknown Status EUCTR2020-000705-86-ES 2020-04-26 Omega-3 fatty acids Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19 Treatment 4 Unknown Status EUCTR2020-000705-86-ES 2020-04-26 Amino acids Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19 Treatment 4 Unknown Status EUCTR2020-000705-86-ES 2020-04-26 Tocilizumab CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) Treatment 2 Active Not Recruiting NCT04335071 2020-04-26 COVID-19 convalescent plasma Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan Treatment Not Available Active Not Recruiting NCT04476888 2020-04-25 Ozone Investigation the effects medical Ozone Autohemotherapy on clinical and para clinical features of patients with Covid19 Treatment 2, 3 Recruiting IRCT20190618043923N4 2020-04-25 Zavegepant BHV3500-203 : Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen Treatment 2, 3 Active Not Recruiting NCT04346615 2020-04-25 Angiotensin 1-7 Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19 Treatment Not Available Active Not Recruiting NCT04375124 2020-04-25 Ivermectin â??To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases. A Pilot Study Treatment Not Available Active Not Recruiting CTRI/2020/04/024858 2020-04-25 Hydroxychloroquine PROTECT-Surg Treatment 3 Active Not Recruiting PACTR202004893013257 2020-04-25 Ritonavir PROTECT-Surg Treatment 3 Active Not Recruiting PACTR202004893013257 2020-04-25 Lopinavir PROTECT-Surg Treatment 3 Active Not Recruiting PACTR202004893013257 2020-04-25 Niacin Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical Trial Treatment 2, 3 Recruiting IRCT20200418047122N1 2020-04-25 Apocynin Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical Trial Treatment 2, 3 Recruiting IRCT20200418047122N1 2020-04-25 Ivermectin To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study Treatment Not Available Active Not Recruiting NCT04373824 2020-04-25 Human Umbilical Cord Mesenchymal Stem Cells Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS) Treatment 1, 2 Active Not Recruiting NCT04355728 2020-04-25 Heparin Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS) Treatment 1, 2 Active Not Recruiting NCT04355728 2020-04-25 Ruxolitinib COVID-19 : Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE Study Basic Science Not Available Active Not Recruiting NCT04361903 2020-04-25 Hydroxychloroquine Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative Study Treatment 3 Active Not Recruiting NCT04359953 2020-04-25 Azithromycin Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative Study Treatment 3 Active Not Recruiting NCT04359953 2020-04-25 Telmisartan Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative Study Treatment 3 Active Not Recruiting NCT04359953 2020-04-24 Human Umbilical Cord Mesenchymal Stem Cells A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients Treatment 1 Active Not Recruiting NCT04573270 2020-04-24 Dexamethasone Evolution of the efficacy and safety of Dexamethasone administration in patients with mild to moderate COVID-19 acute respiratory disease syndrome Treatment 2, 3 Active Not Recruiting IRCT20151227025726N17 2020-04-24 Dexmedetomidine Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19 Treatment Not Available Active Not Recruiting NCT04413864 2020-04-24 Clazakizumab A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection Treatment 2 Active Not Recruiting NCT04348500 2020-04-24 VA-MENGOC-BC® Population impact of intervention based on the administration of a single dose of the Outer Membrane Vesicle (OMV) complex contained in VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 (COVID-19) - VME-CORONA Treatment Not Available Completed RPCEC00000314 2020-04-24 Canakinumab Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation Treatment 2 Active Not Recruiting NCT04365153 2020-04-24 Sirolimus Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial) Treatment 2 Active Not Recruiting NCT04341675 2020-04-24 Selinexor A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection - Low Dose Oral Selinexor in Patients with Severe COVID-19 Infection Treatment 2 Active Not Recruiting EUCTR2020-001411-25-GB 2020-04-24 Sirukumab Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease Treatment 2 Active Not Recruiting NCT04380961 2020-04-24 Azithromycin Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study Treatment 3 Active Not Recruiting IRCT20200415047092N1 2020-04-24 Lactobacillus coryniformis K8 Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19 Prevention Not Available Active Not Recruiting NCT04366180 2020-04-24 COVID-19 convalescent plasma A Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized Adults Treatment 3 Active Not Recruiting NCT04362176 2020-04-24 Bevacizumab Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19 Treatment 2 Unknown Status EUCTR2020-001541-39-ES 2020-04-24 Hydroxychloroquine Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled Trial Prevention 3 Active Not Recruiting NCT04352946 2020-04-24 Peginterferon lambda-1a A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19 Treatment 2 Active Not Recruiting NCT04331899 2020-04-24 Alpha-1-proteinase inhibitor A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Treatment 2 Active Not Recruiting EUCTR2020-001391-15-IE 2020-04-24 Colistin A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19) Treatment 0 Active Not Recruiting ChiCTR2000032242 2020-04-23 Sarilumab PILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION - COVID-SARI-001 Treatment 2 Unknown Status EUCTR2020-001745-40-IT 2020-04-23 Favipiravir An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19 Treatment 2, 3 Active Not Recruiting NCT04434248 2020-04-23 AstraZeneca COVID-19 Vaccine A Phase I / II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers Treatment 1, 2 Active Not Recruiting NCT04324606 2020-04-23 COVID-19 convalescent plasma Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II Trial Treatment Not Available Active Not Recruiting NCT04408209 2020-04-23 COVID-19 convalescent plasma Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection Treatment 1, 2 Active Not Recruiting NCT04366245 2020-04-23 Tocilizumab Outcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatment Basic Science Not Available Active Not Recruiting NL8551 2020-04-23 Methylprednisolone Outcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatment Basic Science Not Available Active Not Recruiting NL8551 2020-04-23 Ozone Comparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patients Treatment 2, 3 Active Not Recruiting IRCT20191125045492N2 2020-04-23 Oxygen Comparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patients Treatment 2, 3 Active Not Recruiting IRCT20191125045492N2 2020-04-23 Olokizumab An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19) Treatment 2, 3 Active Not Recruiting NCT04380519 2020-04-23 Hydroxychloroquine PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) - COVIDNA Treatment 3 Unknown Status EUCTR2020-001697-30-ES 2020-04-23 Human Umbilical Cord Mesenchymal Stem Cells Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in patients with acute respiratory distress syndrome secondary to infection by COVID-19 - COVIDMES Treatment 1 Unknown Status EUCTR2020-001505-22-ES 2020-04-23 Albumin human Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVID Treatment 2 Unknown Status EUCTR2020-001722-66-ES 2020-04-23 Human immunoglobulin G Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVID Treatment 2 Unknown Status EUCTR2020-001722-66-ES 2020-04-23 Ritonavir Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized Trial Prevention 3 Active Not Recruiting NCT04364022 2020-04-23 Lopinavir Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized Trial Prevention 3 Active Not Recruiting NCT04364022 2020-04-23 Sevoflurane Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury : a Randomized Controlled Trial Treatment 3 Active Not Recruiting NCT04355962 2020-04-23 Azithromycin Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus Treatment 1 Active Not Recruiting NCT04329572 2020-04-23 Hydroxychloroquine Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus Treatment 1 Active Not Recruiting NCT04329572 2020-04-23 Hydroxychloroquine COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents – a randomized controlled trial - COVID-19 PREVENTION Treatment 3 Active Not Recruiting EUCTR2020-001363-85-DK 2020-04-22 Ruxolitinib Front line treatment with Ruxolitinib in stage II / III Covid-19 patients with defined Hyperinflammation - RuxCoFlam Treatment 2 Active Not Recruiting EUCTR2020-001481-11-DE 2020-04-22 Hydroxychloroquine Hydroxychloroquine for the treatment of mild COVID-19 disease Treatment 2 Active Not Recruiting EUCTR2020-001512-26-DE 2020-04-22 Azithromycin Covid-19 : A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19 DAWN AZITHRO Treatment 2 Active Not Recruiting EUCTR2020-001614-38-BE 2020-04-22 Hydroxychloroquine Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial) Prevention 3 Active Not Recruiting NCT04334148 2020-04-22 Hydroxychloroquine Hydroxychloroquine for the Treatment of Mild COVID-19 Disease Treatment 3 Active Not Recruiting NCT04340544 2020-04-22 COVID-19 convalescent plasma A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. - PLACID Treatment 2 Active Not Recruiting CTRI/2020/04/024775 2020-04-22 Hydroxychloroquine evaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad. Treatment 2, 3 Recruiting IRCT20200325046859N2 2020-04-22 Umifenovir evaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad. Treatment 2, 3 Recruiting IRCT20200325046859N2 2020-04-22 Alteplase A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA) Treatment 2 Active Not Recruiting NCT04356833 2020-04-22 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease Prevention 2 Active Not Recruiting NCT04349631 2020-04-22 Ruxolitinib A Phase-II Clinical Trial for First Line Treatment of Stage II / III Covid-19 Patients to Treat Hyperinflammation Treatment 2 Active Not Recruiting NCT04338958 2020-04-22 Ulinastatin Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19) Treatment 4 Active Not Recruiting ChiCTR2000032135 2020-04-22 Ruxolitinib Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study. - Ruxolitinib Treatment in Patients with Severe COVID-19 Infection.A Danish Safety and Efficacy Study Treatment 2 Active Not Recruiting EUCTR2020-001459-42-DK 2020-04-22 Dapagliflozin An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04350593 2020-04-22 Oseltamivir Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment Treatment 3 Active Not Recruiting NCT04338698 2020-04-22 Hydroxychloroquine Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment Treatment 3 Active Not Recruiting NCT04338698 2020-04-22 Azithromycin Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment Treatment 3 Active Not Recruiting NCT04338698 2020-04-21 Dornase alfa Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS) Treatment 3 Active Not Recruiting NCT04355364 2020-04-21 Hydroxychloroquine Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients Treatment 2, 3 Active Not Recruiting NCT04351516 2020-04-21 Tazobactam Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Piperacillin Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Hydroxychloroquine Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Lopinavir Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Heparin Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Methylprednisolone Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Tocilizumab Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Azithromycin Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Ritonavir Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology Centers Supportive Care Not Available Active Not Recruiting NCT04394182 2020-04-21 Tocilizumab COVID 19 : Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia. Treatment 2 Active Not Recruiting EUCTR2020-001770-30-BE 2020-04-21 VPM1002 A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk Subjects Treatment 3 Active Not Recruiting CTRI/2020/04/024749 2020-04-21 Chloroquine Topical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure rates Treatment 2 Active Not Recruiting CTRI/2020/04/024729 2020-04-21 Tocilizumab The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure Treatment 2, 3 Active Not Recruiting IRCT20200406046968N1 2020-04-21 Budesonide Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia Treatment 4 Active Not Recruiting NCT04355637 2020-04-21 COVID-19 convalescent plasma A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19 Treatment 2 Active Not Recruiting NCT04359810 2020-04-21 Enoxaparin A Randomized Trial of Anticoagulation Strategies in COVID-19 Treatment 3 Active Not Recruiting NCT04359277 2020-04-21 Tocilizumab A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia - TOC-COVID Treatment 2 Active Not Recruiting EUCTR2020-001408-41-DE 2020-04-21 Human interferon beta Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial Treatment 3 Active Not Recruiting NCT04324463 2020-04-21 Acetylsalicylic acid Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial Treatment 3 Active Not Recruiting NCT04324463 2020-04-21 Colchicine Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial Treatment 3 Active Not Recruiting NCT04324463 2020-04-21 Rivaroxaban Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial Treatment 3 Active Not Recruiting NCT04324463 2020-04-21 Azithromycin A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC Treatment 2 Active Not Recruiting EUCTR2020-001327-13-AT 2020-04-21 Chloroquine COVID-19 : addition of azithromycin to chloroquine treatment - CO VOR IT Treatment 4 Active Not Recruiting EUCTR2020-001527-14-NL 2020-04-21 Azithromycin COVID-19 : addition of azithromycin to chloroquine treatment - CO VOR IT Treatment 4 Active Not Recruiting EUCTR2020-001527-14-NL 2020-04-21 Spironolactone The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients Treatment 4 Active Not Recruiting NCT04345887 2020-04-21 Prednisone Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection Treatment 2 Active Not Recruiting NCT04344288 2020-04-21 COVID-19 convalescent plasma Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled Trial. Treatment 2 Completed CTRI/2020/04/024706 2020-04-20 Colchicine COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA - ColCOVID19 Treatment 2 Active Not Recruiting EUCTR2020-001258-23-IT 2020-04-20 Umifenovir Evaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital Complex Treatment 3 Active Not Recruiting IRCT20200523047550N1 2020-04-20 Beractant The effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilation Treatment 3 Recruiting IRCT20091201002804N12 2020-04-20 Remestemcel-L Cell therapy in patients with COVID-19 using mesenchymal stem cells Treatment 1 Recruiting IRCT20190717044241N2 2020-04-20 COVID-19 convalescent plasma Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled Trial Treatment 2 Active Not Recruiting NCT04346446 2020-04-20 Atovaquone Open-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection Treatment 2 Active Not Recruiting NCT04339426 2020-04-20 Azithromycin Open-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection Treatment 2 Active Not Recruiting NCT04339426 2020-04-20 BNT162c2 SARS-CoV-2 Vaccine A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 Treatment 1 Active Not Recruiting EUCTR2020-001038-36-DE 2020-04-20 BNT162a1 SARS-CoV-2 Vaccine A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 Treatment 1 Active Not Recruiting EUCTR2020-001038-36-DE 2020-04-20 Tozinameran A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 Treatment 1 Active Not Recruiting EUCTR2020-001038-36-DE 2020-04-20 BNT162b1 SARS-CoV-2 Vaccine A Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 Treatment 1 Active Not Recruiting EUCTR2020-001038-36-DE 2020-04-20 Cyanocobalamin Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women Basic Science Not Available Active Not Recruiting NCT04407572 2020-04-20 Vitamin D Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women Basic Science Not Available Active Not Recruiting NCT04407572 2020-04-20 Zinc Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women Basic Science Not Available Active Not Recruiting NCT04407572 2020-04-20 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study Treatment 1, 2 Active Not Recruiting NCT04341610 2020-04-20 BCG vaccine Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2 : A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses Prevention 4 Active Not Recruiting NCT04348370 2020-04-20 Anakinra Efficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating respiratory symptoms : a multicenter open-label controlled randomized trial - ANACONDA-COVID-19 Treatment 3 Active Not Recruiting EUCTR2020-001734-36-FR 2020-04-20 Colchicine Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia Treatment 2 Active Not Recruiting NCT04322565 2020-04-20 Folic acid The host Epigenetic methylation repair in COVID-19 using Folic acid : A new suggested prevention and treatment. Treatment 2 Active Not Recruiting PACTR202005599385499 2020-04-20 Hydroxychloroquine A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State. Treatment 3 Active Not Recruiting PACTR202004801273802 2020-04-20 Lopinavir A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State. Treatment 3 Active Not Recruiting PACTR202004801273802 2020-04-20 Chloroquine A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State. Treatment 3 Active Not Recruiting PACTR202004801273802 2020-04-20 Ritonavir A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State. Treatment 3 Active Not Recruiting PACTR202004801273802 2020-04-20 Prednisolone Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19 Treatment 3 Recruiting IRCT20080901001165N52 2020-04-20 Methylprednisolone Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19 Treatment 3 Recruiting IRCT20080901001165N52 2020-04-20 Zinc The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19) Treatment 2, 3 Recruiting IRCT20180425039414N2 2020-04-20 Ascorbic acid Comparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19) Treatment 2, 3 Recruiting IRCT20140305016852N4 2020-04-20 Vitamin D Comparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19) Treatment 2, 3 Recruiting IRCT20140305016852N4 2020-04-20 Pomegranate The effect of pomegranate tea on symptom relief of COVID-19 patients : a double-blind randomized clinical trial study Treatment Not Available Recruiting IRCT20200416047104N1 2020-04-20 Hydroxychloroquine Prevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the community Treatment 3 Active Not Recruiting IRCT20190122042450N4 2020-04-20 Human immunoglobulin G To evaluate the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of COVID-19-induced cytokine storm Treatment 3 Active Not Recruiting IRCT20200317046797N3 2020-04-20 Transcrocetinate Clinical trial of the effect of crocetin in improving the clinical and laboratory symptoms of patients with COVID-19 Treatment 2 Active Not Recruiting IRCT20081019001369N3 2020-04-20 Minocycline Clinical trial of minocycline against COVID-19 Treatment 2 Active Not Recruiting IRCT20081019001369N4 2020-04-20 Hydroxychloroquine Prospective post-exposure hydroxycloroquine prophylaxis for Covid 19 (PROSCLOROCOV 19) Treatment 3 Active Not Recruiting IRCT20130306012728N8 2020-04-20 COVID-19 convalescent plasma Evaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patients Treatment 3 Active Not Recruiting IRCT20151228025732N53 2020-04-20 Licorice Evaluation the effect of aqueous extract of licorice on coronavirus outpatients : A randomized, double-blind, placebo-controlled clinical trial Treatment 2 Active Not Recruiting IRCT20200404046933N1 2020-04-20 Berberine Clinical trial of berberine against COVID-19 Treatment 2 Active Not Recruiting IRCT20081019001369N2 2020-04-20 Naproxen The effect of naproxen on the healing process of patients with COVID-19 Treatment 3 Active Not Recruiting IRCT20200324046850N3 2020-04-20 Calcifediol Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS) Treatment 2 Unknown Status EUCTR2020-001717-20-ES 2020-04-20 Remestemcel-L Phase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia Treatment 1 Unknown Status EUCTR2020-001364-29-ES 2020-04-20 Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins Phase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia Treatment 1 Unknown Status EUCTR2020-001364-29-ES 2020-04-20 Baricitinib Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults Basic Science Not Available Active Not Recruiting NCT04362943 2020-04-20 Anakinra Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults Basic Science Not Available Active Not Recruiting NCT04362943 2020-04-20 Favipiravir Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical Trial Treatment 4 Active Not Recruiting NCT04359615 2020-04-20 Estradiol Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients Treatment 2 Active Not Recruiting NCT04359329 2020-04-20 Azithromycin Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical Trial Treatment 4 Active Not Recruiting NCT04359316 2020-04-20 Melatonin Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts. Prevention 2, 3 Active Not Recruiting NCT04353128 2020-04-20 Azithromycin Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus Treatment 1 Active Not Recruiting NCT04348474 2020-04-20 Hydroxychloroquine Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus Treatment 1 Active Not Recruiting NCT04348474 2020-04-20 Tocilizumab Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19 Treatment 3 Active Not Recruiting NCT04356937 2020-04-20 Favipiravir Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment Treatment 2, 3 Active Not Recruiting NCT04351295 2020-04-20 BCG vaccine Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19 Prevention 3 Active Not Recruiting NCT04350931 2020-04-20 Dexmedetomidine Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection Treatment 4 Active Not Recruiting NCT04350086 2020-04-20 COVID-19 convalescent plasma Plasma Rich Antibodies From Recovered Patients From COVID19 Treatment Not Available Active Not Recruiting NCT04348877 2020-04-20 Ascorbic acid Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCT Prevention 2 Active Not Recruiting NCT04347889 2020-04-20 Hydroxychloroquine Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCT Prevention 2 Active Not Recruiting NCT04347889 2020-04-20 Hydroxychloroquine Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2 Prevention 3 Active Not Recruiting NCT04346329 2020-04-20 Heparin Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial Treatment 2 Active Not Recruiting NCT04344756 2020-04-20 Tinzaparin Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial Treatment 2 Active Not Recruiting NCT04344756 2020-04-20 Human Umbilical Cord Mesenchymal Stem Cells Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Treatment Not Available Active Not Recruiting NCT04273646 2020-04-20 Povidone-iodine Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus. Treatment 0 Active Not Recruiting ACTRN12620000470998 2020-04-20 Ruxolitinib A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia Treatment Not Available Active Not Recruiting NCT04331665 2020-04-20 Isoflurane To Observe Whether Isoflurane Can Treat COVID-19 Patients Basic Science Not Available Active Not Recruiting NCT04492943 2020-04-20 Bromelains The effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patients Treatment 3 Recruiting IRCT20150725023332N3 2020-04-20 Montelukast The effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patients Treatment 3 Recruiting IRCT20150725023332N3 2020-04-20 Ascorbic acid The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19) Treatment 2, 3 Active Not Recruiting IRCT20180425039414N3 2020-04-20 Vitamin E The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19) Treatment 2, 3 Active Not Recruiting IRCT20180425039414N3 2020-04-20 Bromhexine Verification of the efficacy of bromhexine hydrochloride in the prevention of COVID-19 disease Treatment 2 Active Not Recruiting IRCT20200317046797N7 2020-04-19 Ivermectin Evaluation of the effect of oral Ivermectin on the outcome of patients with COVID-19 and compare it with the effect of conucntional therapics in patients admitted to Ziaeian, Baharloo, Imam Khomeini in the spring and summer 2020 Treatment 3 Active Not Recruiting IRCT20180922041089N4 2020-04-19 COVID-19 convalescent plasma Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia : a Prospective Randomized Trial Treatment Not Available Active Not Recruiting NCT04356534 2020-04-19 COVID-19 convalescent plasma Use of convalescent plasma submitted to pathogen inactivation for the treatment of patients with severe COVID-19 Treatment Not Available Recruiting RBR-4vm3yy 2020-04-19 Ascorbic acid The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients Treatment 1 Active Not Recruiting NCT04370288 2020-04-19 Cysteine The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients Treatment 1 Active Not Recruiting NCT04370288 2020-04-19 Methylene blue The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients Treatment 1 Active Not Recruiting NCT04370288 2020-04-19 Hydroxychloroquine Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel. - PrevenCOVID-19 Treatment 3 Unknown Status EUCTR2020-001440-26-ES 2020-04-19 Prednisone OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE Treatment 4 Unknown Status EUCTR2020-001622-64-ES 2020-04-19 Ascorbic acid Study of the effect of Vitamin C on duration of hospital stay in patients with Covid-19 Treatment 2 Active Not Recruiting IRCT20200324046850N5 2020-04-19 Methylene blue Evaluation of the efficacy and safety of methylene blue administration for treatment of COVID-19 patients Treatment 3 Active Not Recruiting IRCT20191228045924N1 2020-04-18 Ivermectin Efficacy of Ivermectin as Add on Therapy in COVID19 Patients : A Pilot Randomized Study Treatment 1 Active Not Recruiting NCT04343092 2020-04-18 Hydroxychloroquine Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection. Treatment 3 Active Not Recruiting EUCTR2020-001536-98-ES 2020-04-18 COVID-19 convalescent plasma A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 Treatment 2 Active Not Recruiting NCT04347681 2020-04-18 Nitric Oxide Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department Treatment 2 Active Not Recruiting NCT04338828 2020-04-18 Chloroquine Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients Treatment 2, 3 Recruiting IRCT20200422047168N1 2020-04-18 Ritonavir Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients Treatment 2, 3 Recruiting IRCT20200422047168N1 2020-04-18 Lopinavir Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients Treatment 2, 3 Recruiting IRCT20200422047168N1 2020-04-18 Tenofovir Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients Treatment 2, 3 Recruiting IRCT20200422047168N1 2020-04-18 Echinacea The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases Treatment 3 Active Not Recruiting IRCT20200415047089N1 2020-04-18 Ginger The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases Treatment 3 Active Not Recruiting IRCT20200415047089N1 2020-04-18 Human immunoglobulin G Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trial Treatment 3 Active Not Recruiting IRCT20200413047056N1 2020-04-18 COVID-19 convalescent plasma Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trial Treatment 3 Active Not Recruiting IRCT20200413047056N1 2020-04-18 Formoterol The efficacy of inhaled formoterol on symptom improvement in covid 19 patients Treatment 3 Recruiting IRCT20170210032478N3 2020-04-18 Ascorbic acid Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ? Treatment 2, 3 Active Not Recruiting IRCT20200411047025N1 2020-04-18 Hydroxychloroquine Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ? Treatment 2, 3 Active Not Recruiting IRCT20200411047025N1 2020-04-18 Atazanavir Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ? Treatment 2, 3 Active Not Recruiting IRCT20200411047025N1 2020-04-18 Ritonavir Evaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ? Treatment 2, 3 Active Not Recruiting IRCT20200411047025N1 2020-04-18 Bromhexine Effect of Bromhexine Hydrochloride on clinical improvement and outcome of COVID-19-induced pneumonia Treatment 3 Active Not Recruiting IRCT20200317046797N4 2020-04-18 Fennel Evaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients : a clinical trial Treatment 3 Recruiting IRCT20200404046935N1 2020-04-18 Colchicine Treatment With COLchicine of Patients Affected by COVID-19 : a Pilot Study Treatment 2 Active Not Recruiting NCT04375202 2020-04-18 Methylprednisolone Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2) : a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial. Treatment 2 Active Not Recruiting NCT04343729 2020-04-18 Sarilumab Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome Treatment 2 Unknown Status EUCTR2020-001531-27-ES 2020-04-18 Antithrombin III human Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19 Treatment 2 Unknown Status EUCTR2020-001659-42-ES 2020-04-18 Favipiravir Efficacy and Safety of Favipiravir in Management of COVID-19 Treatment 3 Active Not Recruiting NCT04349241 2020-04-18 Human interferon beta Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trial Treatment 2, 3 Active Not Recruiting IRCT20120225009124N4 2020-04-18 Human immunoglobulin G Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trial Treatment 2, 3 Active Not Recruiting IRCT20120225009124N4 2020-04-18 Dexamethasone Efficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trial Treatment 2, 3 Active Not Recruiting IRCT20120225009124N4 2020-04-18 Hydroxychloroquine Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workers Treatment Not Available Recruiting IRCT20200414047076N1 2020-04-18 COVID-19 convalescent plasma Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia Treatment 3 Active Not Recruiting NCT04535063 2020-04-17 COVID-19 convalescent plasma CONTAIN COVID-19 : Convalescent Plasma to Limit Coronavirus Associated Complications : a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients Treatment 2 Active Not Recruiting NCT04364737 2020-04-17 Valsartan PRAETORIAN-COVID : A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease Treatment 4 Active Not Recruiting NCT04335786 2020-04-17 Alteplase A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS : The Plasminogen Activator COVID-19 ARDS (PACA) trial - Nebulised rtPA for ARDS due to COVID-19 – The PACA trial Treatment 2 Active Not Recruiting EUCTR2020-001640-26-GB 2020-04-17 Baricitinib Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients Treatment 2 Active Not Recruiting NCT04321993 2020-04-17 Hydrocortisone Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial Treatment 3 Active Not Recruiting NCT04348305 2020-04-17 Selinexor A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection Treatment 2 Active Not Recruiting NCT04349098 2020-04-17 Hydroxychloroquine A Randomized Phase 2 / 3 Trial of Hydroxychloroquine In Covid-19 Kinetics Treatment 2, 3 Active Not Recruiting NCT04353271 2020-04-17 Colchicine The ECLA PHRI COLCOVID Trial Treatment 3 Active Not Recruiting NCT04328480 2020-04-17 Azithromycin A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV Treatment 3 Active Not Recruiting EUCTR2020-001723-13-FR 2020-04-17 Lopinavir A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV Treatment 3 Active Not Recruiting EUCTR2020-001723-13-FR 2020-04-17 Ritonavir A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV Treatment 3 Active Not Recruiting EUCTR2020-001723-13-FR 2020-04-17 Hydroxychloroquine A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOV Treatment 3 Active Not Recruiting EUCTR2020-001723-13-FR 2020-04-17 Nitric Oxide Expanded Access : Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Mild or Moderate Coronavirus Disease (COVID-19) Treatment Not Available Active Not Recruiting NCT04358588 2020-04-17 Favipiravir Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19 Treatment 2 Active Not Recruiting NCT04358549 2020-04-17 Lopinavir COVID-19 Ring-based Prevention Trial With Lopinavir / Ritonavir Prevention 3 Active Not Recruiting NCT04321174 2020-04-17 Ritonavir COVID-19 Ring-based Prevention Trial With Lopinavir / Ritonavir Prevention 3 Active Not Recruiting NCT04321174 2020-04-17 Chloroquine Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial - Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial Other Not Available Active Not Recruiting JPRN-UMIN000040188 2020-04-17 Hydroxychloroquine Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial - Chloroquine and hydroxychloroquine for treatment of COVID-19 : systematic review of randomized and non-randomized controlled trial Other Not Available Active Not Recruiting JPRN-UMIN000040188 2020-04-17 Oxygen Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19) Treatment 0 Active Not Recruiting ChiCTR2000032011 2020-04-16 COVID-19 convalescent plasma Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma Treatment 3 Active Not Recruiting NCT04376034 2020-04-16 Sevoflurane Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection Treatment 4 Active Not Recruiting NCT04359862 2020-04-16 Propofol Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection Treatment 4 Active Not Recruiting NCT04359862 2020-04-16 Hydroxychloroquine Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19 Treatment 3 Active Not Recruiting NCT04420247 2020-04-16 Chloroquine Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19 Treatment 3 Active Not Recruiting NCT04420247 2020-04-16 BCG vaccine Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial Prevention 4 Active Not Recruiting NCT04417335 2020-04-16 Azithromycin Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial Treatment 2, 3 Active Not Recruiting NCT04354428 2020-04-16 Folic acid Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial Treatment 2, 3 Active Not Recruiting NCT04354428 2020-04-16 Ascorbic acid Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial Treatment 2, 3 Active Not Recruiting NCT04354428 2020-04-16 Hydroxychloroquine Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform Trial Treatment 2, 3 Active Not Recruiting NCT04354428 2020-04-16 Chloroquine Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications Treatment 4 Active Not Recruiting NCT04331600 2020-04-16 Cyclosporine Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection Treatment 4 Active Not Recruiting NCT04392531 2020-04-16 BCG vaccine REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL Treatment Not Available Recruiting NL8547 2020-04-16 Ribavirin Evaluation of the Effect of Trifluoperazin in Treatment of Patients with Confirmed 2019 Novel Coronavirus(COVID- 19) : An Open-Label Randomized Clinical Trial Treatment 3 Active Not Recruiting IRCT20200408046992N1 2020-04-16 Azithromycin An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms Treatment 1, 2 Active Not Recruiting NCT04344457 2020-04-16 Hydroxychloroquine An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms Treatment 1, 2 Active Not Recruiting NCT04344457 2020-04-16 Indomethacin An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms Treatment 1, 2 Active Not Recruiting NCT04344457 2020-04-16 Ascorbic acid Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO) : A Phase I / II Safety, Tolerability, and Efficacy Clinical Trial Treatment 1, 2 Active Not Recruiting NCT04357782 2020-04-16 CoronaVac A Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years Prevention 1, 2 Active Not Recruiting NCT04352608 2020-04-16 Clazakizumab A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) Treatment 2, 3 Active Not Recruiting NCT04351724 2020-04-16 Chloroquine A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) Treatment 2, 3 Active Not Recruiting NCT04351724 2020-04-16 Ritonavir A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) Treatment 2, 3 Active Not Recruiting NCT04351724 2020-04-16 Candesartan A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) Treatment 2, 3 Active Not Recruiting NCT04
In response to the COVID-19 pandemic, the DrugBank team has created this information dashboard to provide a comprehensive summary of research in an effort to help interested parties find the information they need quickly and effectively. If you are interested in licensing DrugBank data for commercial use, please contact us.
COVID-19 OUTBREAK SUMMARY: Coronavirus disease 2019 (named COVID-19 on February 11, 2020 by the World Health Organization (WHO) 1,2) was first identified in Wuhan, China near the end of 2019 1. It is caused by the virus known as SARS-CoV-2 (previously called 2019-nCoV). This name was chosen because the virus is related to the coronavirus that caused the SARS outbreak of 2003. The two viruses are different despite their genetic similarity 3. COVID-19 is believed to be less lethal but much more infectious than SARS-CoV 4. Until the recent outbreak, this virus had not been identified in humans 5.
Disclaimer: This dashboard is intended for research purposes only, and is not to be used for self-diagnosis. If you believe you are experiencing symptoms of COVID-19, please reach out to a medical professional. While we do our best to maintain accuracy and provide up-to-date data and information, we do not guarantee that.
COVID-19: Finding the Right Fit
Identifying Potential Treatments Using a Data-Driven Approach
Download the White Paper| Important Information Sources | |
|---|---|
 | WHO COVID-19 Dashboard |
 | Health Canada COVID-19 Dashboard |
 | CDC COVID-19 Dashboard |
| Dataset, Visualization, and Research Tools |
|---|
| COVID-19 Open Research Dataset (CORD-19) |
| COVIDmapper |
| Protein Data Bank COVID-19 Resources |
| DrugBank Datasets |
| IBM Deep Search |